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Abstract
Randomization schemes for two-treatment clinical trials are studied. Theoretical ex-
pressions for the power are derived under both complete randomization and Efron’s bi-
ased coin design for normal and binary responses. The better the scheme is at balancing
the numbers of patients across treatments, the higher the power is. Efron’s biased coin
design is more powerful than complete randomization. Normal approximations to the
powers are obtained. The power of the adjustable biased coin design is also investigated
by simulation.
Covariate-adaptive randomization schemes are analysed when either global or marginal
balance across cells is sought. By considering a fixed-effects linear model for normal
treatment responses with several covariates, an analysis of covariance t test is carried
out. Its power is simulated for global and marginal balance, both in the absence and in
the presence of interactions between the covariates. Global balancing covariate-adaptive
schemes are more efficient when there are interactions between the covariates.
Restricted randomization schemes for more than two treatments are then considered.
Their asymptotic properties are provided. An adjustable biased coin design is intro-
duced for which assignments are based on the imbalance across treatments. The finite-
sample properties of the imbalance under these randomization schemes are studied by
simulation. Assuming normal treatment responses, the power of the test for treatment
differences is also obtained and is highest for the new design.
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Imbalance properties of complete randomization and centre-stratified permuted block
randomization for several treatments are investigated. It is assumed that the patient re-
cruitment process follows a Poisson-gammamodel. When the number of centres is large,
the imbalance for both schemes is approximately multivariate normal. The power of a
test for treatment differences is simulated for normal responses. The loss of power can
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A clinical trial is a combination of studies, experiments and tests performed to test
the efficacy and the safety of some existing or new treatments or drugs on human. A
treatment refers to the method, the therapy or the remedy that is used on a patient for
a disease or injury. A drug refers to the chemical substance intake by humans and it is
used to cure, relieve or prevent diseases. During the trial, we collect data and gather
information about the efficacy and the safety of the treatments and drugs. This is to
identify any positive or adverse effects of the treatments or drugs on patients such that
the most suitable treatments and drugs can be available to patients in the future.
In clinical trials, the patients can be healthy volunteers or patients with specific char-
acteristics. For example, to test the effectiveness of a treatment for a particular disease,
we may have to recruit patients suffering from this disease. In particular, if we need to
recruit patients with several characteristics or we deal with trials for rare diseases, it may
take a very long period to recruit enough patients. The number of patients to be recruited
differs in the different phases of clinical trials.
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There are different types of studies for clinical trials. These include testing the ef-
ficacy and safety of new treatments and drugs on patients, studies of the effectiveness
and safety of existing treatments and drugs and assessing the effectiveness and safety of
different doses of drugs other than the existing dose of a drug. In addition, two or more
treatments or drugs are normally included in a trial.
The cost in completing all phases of a clinical trial is huge. Clinical trials are com-
monly sponsored and carried out by pharmaceutical companies or government-related
organizations. These trials can be carried out in several centres or even in several coun-
tries. We have to ensure the same design and analysis are carried out in different centres
and countries, and data are gathered from all centres and countries for the statistical
analysis.
Pre-clinical studies are also needed to identify the drug for assessment in clinical
trials. Before the trial, potential compounds for drugs have to be tested for several years
and only very few of them can reach the stage to be tested in clinical trials. Clinical trials
are normally classified into four phases. Each phases is usually considered as a separate
clinical trial. It can take years and even decades to complete all four phases of a clinical
trial before new treatments and drugs are available on the market for the general public.
However, sometimes some of these phases are combined. The reasons for combined
phases include making the assessment process quicker for a new treatment or drug to be
available to patients, reducing the costs in carrying out the trials, requiring fewer patients
and reducing the risk to the participants. For example, we often have Phases I and II or
Phases II and III combined.
For Phase I of clinical trials, the main focus is on drug safety. In this stage, studies
and experiments are carried out on around 20-80 patients. The main objective in this
stage is to determine the maximum safe dose, that is, the maximum dose level without
18
causing toxicity. For Phase II, the studies will be carried out on a larger group of pa-
tients of size 100-200. At this stage, further investigation of the effectiveness and safety
of drugs is carried out. This is also a stage to narrow down the number of drugs, by
excluding those over-toxic or inactive drugs and choosing a few of the potential drugs to
proceed to Phase III.
In Phase III, we apply the new drugs or treatments to a larger group of patients.
Further tests will be carried out to confirm the effectiveness and safety of the treatments
and drugs. In here, we may compare the new treatments or drugs to the standard or
existing treatment. Details of different randomization schemes, the treatment assignment
rules to patients, for this phase will be covered in this thesis. This phase is also referred
to as the largest and most extensive study on the new treatments and drugs.
The last phase which is Phase IV is the postmarketing stage where remaining studies
have to be carried out before the drug is approved for marketing. These include studies
on adverse effects and benefits in using this drug.
1.2 Randomization schemes
Randomization refers to the process of randomly allocating patients to one of the
treatments in clinical trials. These randomization schemes can be applied in all phases
of a clinical trial. In this thesis, we will only study the randomization schemes used in
Phase III, where we want to assess the effectiveness of our new treatments or drugs. We
will test for differences in patients’ responses on the treatments. One of the main aims
of randomization schemes is to minimize selection bias.
Selection bias refers to the bias incurred when the experimenter or the investigator
consciously or unconsciously decides which treatment is to be allocated to the next pa-
tient. The assignment process should be unpredictable so that both the investigator and
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the patients will not know in advance the treatment to be allocated next in the trial. The
selection bias is closely related to how likely the next treatment to be allocated to a sub-
ject can be guessed. The more likely that the treatment can be guessed the higher the
selection bias will be. A good randomization scheme should have a low probability of
correctly guessing which treatment is to be allocated to the next patient.
Another aim of randomization schemes is to balance the numbers of patients across
treatments. Statistical power refers to the probability of detecting a genuine treatment
effect in a test for treatment difference. The higher the power of the test under a ran-
domization scheme, the more likely the scheme is to detect a genuine treatment effect.
For example, for statistical analysis of a trial for comparing two treatments, assume the
population variances of the patients’ responses in the two treatment groups are the same.
Then it is optimal when the numbers of patients in the two treatment groups are the same.
In fact, the power of the test is maximized for a balanced trial when the population vari-
ances of the patients’ responses in the two groups are the same (Lachin, 1981).
There are also different types of randomization schemes. The most straightforward
randomization scheme is simple randomization. This is also called repeated simple ran-
dom sampling, simple random sampling or complete randomization. Under this scheme,
patients are randomly allocated to the treatments and it is the best at minimizing the
selection bias.
We also have other types of randomization schemes such as restricted randomization.
One of the main goals of restricted randomization schemes is to balance the numbers of
patients across treatments. Some examples are Efron’s (1971) biased coin design, the
adjustable biased coin design (Baldi Antognini and Giovagnoli, 2004) and permuted
block randomization. Except permuted-block randomization, most of these schemes
have a greater probability of allocating the next patient to a treatment group that has
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fewer patients and vice versa for a treatment group that is overrepresented. The current
numbers of patients on the treatments are therefore an important basis for the treatment
assignment of the next patient under these schemes. For permuted-block randomization,
a fixed block size and an allocation proportion of treatments within blocks are given such
that patients are allocated to treatments within a block randomly.
Covariate-adaptive randomization is also another type of randomization scheme that
will be described in Chapter 3 of this thesis. One of the examples of covariate-adaptive
randomization schemes is the minimization method of Pocock and Simon (1975). Ex-
amples of patients’ covariates or prognostic factors are age, gender, stage of disease and
so on. Under these randomization schemes, we aim to balance the numbers of patients
across treatments for patients classified by their prognostic factors or covariates.
We also have response-adaptive randomization schemes. Under these schemes, pa-
tients’ responses on treatments are recorded and are used for the treatment assignment
of the forthcoming patient. The probability of assigning the next patients to a treatment
that gives better responses will be higher. This is to increase the chance of allocating pa-
tients to treatments that are performing well. Details of response-adaptive randomization
schemes will not be discussed.
1.3 Outline of thesis
The research work presented in this thesis mainly focuses on the comparison of bi-
ased coin designs with other randomization schemes. The biased coin design was devel-
oped by Efron (1971). This is a design for patient allocation to treatments in sequential
clinical trials. Given two treatments, patients have to be allocated one of the two treat-
ments upon their arrival. The biased coin design has a fixed probability greater than a
half to allocate the next patient to a treatment that has been chosen less often. In particu-
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lar, the powers of the test for treatment effect under all these randomization schemes are
of our main concern throughout the thesis. Different assumptions under these random-
ization schemes will be investigated for their impact on the power.
The thesis consists of four main parts. Chapter 2 relates to randomization schemes
with only two treatments. These two treatments are usually referred to as the standard
treatment and the new treatment. A test is carried out to decide whether the new treat-
ment is better than the standard one. The power of the test has been analysed theoreti-
cally and numerical results for the powers have been produced by Chen (2006). Here,
both the theoretical expressions and the numerical results for the power will be given
by assuming normal patient responses with different variances. The cases when these
variances are known or unknown are studied under complete randomization and Efron’s
biased coin design. In Section 2.3, algorithms and numerical results for the power by
simulation under Efron’s biased coin design and the adjustable biased coin design will
be given. The adjustable biased coin design is an extension of Efron’s biased coin de-
sign where at each stage the probability of allocating the next patient to a treatment is a
function instead of a fixed probability. This function depends on the current difference
between the numbers of patients on the two treatments. We call the treatment with fewer
of patients the under-represented treatment. Under the adjustable biased coin design, the
fewer the number of patients on the under-represented treatment, the greater the proba-
bility of assigning the next patient to this treatment. In Section 2.4, the power functions
are analysed under complete randomization and Efron’s biased coin design when the
patients’ responses are binary. Details of the algorithm for the theoretical expression
and the numerical values for the power are given for both designs. In Section 2.5, nu-
merical values for the power using a normal approximation will be presented and hence
compared with the exact powers under complete randomization and Efron’s biased coin
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design.
Chapter 3 covers material on covariate-adaptive randomization schemes. Patient
prognostic factors or covariates such as age and gender will affect the responses of
patients to the treatments. Therefore, it is sensible to study the treatment effect in a
group of patients with the same or similar prognostic profiles. The covariate-adaptive
randomization schemes refer to randomization schemes that apply to patients grouped
by covariates. Such schemes are studied by Shao, Yu and Zhong (2010) when there is
a single covariate and two treatments under comparison. One of the main aims of these
covariate-adaptive randomization schemes is to balance the number of patients with the
same prognostic profile. Here, three covariate-adaptive randomization schemes are stud-
ied when either global or marginal balance is sought. By considering a fixed-effects
model for normal treatment responses when there are several covariates, an analysis of
covariance t test is carried out. Numerical values for the power are simulated for the
three randomization schemes for both global and marginal balance when there is an in-
teraction between the covariates. It is shown that the covariate-adaptive adjustable biased
coin design produces the highest power among the three. In addition, the power gain un-
der global balance is higher than under marginal balance when there is an interaction
between the covariates.
Chapter 4 gives results for different biased coin designs when there are more than
two treatments. In this chapter, the assignment rules for more than two treatments under
complete randomization and different biased coin designs will be demonstrated. A new
class of assignment rules will be given such that for each treatment the probability of
assigning the next patient to this treatment depends on the current value of the imbal-
ance in this treatment. The asymptotic properties of complete randomization and these
biased coin designs will be stated. This is followed by simulation results for the imbal-
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ances across treatments, which confirms the theoretical asymptotic properties under all
these schemes. Assuming patients’ responses to be normally distributed and given the
numbers of patients on the treatments, the analysis of variance F test is then used to test
whether there are any treatment differences.
Chapter 5 is about the imbalance properties of complete randomization and permuted
block randomization in clinical trials for several treatments. The number of patients to
be recruited in different centres can be described by a patient recruitment process. The
model is a Poisson process with arrival rate from a gamma distribution (Anisimov and
Fedorov, 2007) such that the number of patients to be recruited in each centre has a
beta-binomial distribution. Details about this model will be given in Section 5.3. We
then have the imbalances defined for each treatment within centres and for all centres,
and hence the column vector for the overall imbalance. In addition, for both of these
randomization schemes, analytical results for the imbalances are investigated assuming
that the number of patients to be recruited in different centres is fixed or when the pa-
tient recruitment process follows a Poisson-gamma model. When the number of centres
involved in a trial is large, the overall imbalance for both schemes is approximately a
multivariate normal. The accuracy of the approximations is assessed by simulation. The
variances of the imbalance in a particular treatment within a centre are then compared
under these two randomization schemes when the number of patients to be recruited in
each centre is fixed or random. A test is then suggested for testing if there is at least
one treatment difference when we compare each of the new treatments with the control
treatment. By considering different simulated scenarios under centre-stratified permuted
block randomization, the sample sizes are found in a balanced trial when a particular
level of the power is achieved. We use the same sample sizes to study the impact on the
power in the imbalanced case for each of the scenarios.
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Chapter 6 draws conclusions and gives an indication of possible future work.
Supplementary information for Chapters 2-5 is given in three appendices.
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Chapter 2
Restricted randomization schemes for
two treatments
In this chapter, we will consider clinical trials where only two treatments are in-
volved. Several randomization schemes will be covered and studied in detail with differ-
ent assumptions. Consider a sequential clinical trial where patients arrive one by one and
have to be assigned immediately to either of the two treatments. At each stage for each
newly arrived patient, the assignments to be made under these randomization schemes
are based on the current allocation status, that is, the current number of patients on each
of the two treatments. One group of patients will receive the standard treatment and we
call this the control group. The other group will receive the new treatment and is called
the treatment group. For simplicity, treatment 1 will represent the standard treatment
and treatment 2 will represent the new treatment.
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2.1 Treatment assignment rules under different random-
ization schemes
2.1.1 Complete randomization/ Repeated simple random sampling
The assignment rules under complete randomization (CR) are very straightforward.
Upon arrival, each patient is equally likely to be assigned to one of the two treatments.
That is, both treatments 1 and 2 have the same probability of 1/2 of being allocated the
next patient. The probabilities of assignment for different patients are independent. This
scheme achieves a high level of randomness in the assignment which means that the
treatment to be assigned to the next patient is less likely to be predicted. In other words,
the probability of correctly guessing the next treatment assignment for each newly ar-
rived patient is low and hence the sequence of treatment allocations is less obvious.
Furthermore, the selection bias discussed in Blackwell and Hodges (1957) and Efron
(1971) which refers to the bias incurred when the experimenter’s decision to allocate the
subject to a treatment for which the experimenter thinks it will be the most suitable for
the subject, is relatively low under complete randomization. In addition, the selection
bias of the design defined in Baldi Antognini and Giovagnoli (2004) as the expected
proportion of correct guesses equals 1/2 under complete randomization for any sample
size. Due to the randomness in the assignment of this design, the imbalances across the
treatments produced under this scheme is very high compared to other designs.
2.1.2 Efron’s biased coin design
In Efron (1971), the biased coin design BCD(p) was introduced and described as
follows: in an experiment with two treatments, each patient arrives sequentially and
has to be assigned immediately to one of the treatments. Based on the number of pa-
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tients currently on each of the treatments, the biased coin design assigns the next patient
to a treatment that has been chosen less often previously with probability p such that
p > 1/2. When patients arrive sequentially, the assignment rule is to balance the num-
ber of patients on the treatments. It aims to achieve some randomness when assigning
each patient to a treatment, which reduces any selection bias in the assignment of patients
to treatments. In addition, this design also aims to maintain a balance in the number of
patients on the two treatments. A balanced trial minimizes the variance of the test statis-
tic and hence increases the power of the test when the variances for patients’ responses
are equal for the two groups.
2.1.3 The adjustable biased coin design
A new design called the adjustable biased coin design (ABCD) introduced by Baldi
Antognini and Giovagnoli (2004) is an extension of Efron’s biased coin design. This is
also a design which aims to eliminate selection bias and maintain a balance in the number
of patients in the treatment groups. Efron’s biased coin design is similar to the adjustable
biased coin design for which assignment of patients to treatment groups depends solely
on the current number of patients in the two groups and biases the allocation towards the
under-represented treatment. The only difference between them is their probability of
selecting an under-represented treatment. The ABCD is a class of biased coin designs
for which the probability of selecting a treatment at stage n is a decreasing function of
the current difference between the numbers of patients on this treatment and the other
treatment. Let n1 and n2 be the numbers of patients on treatment 1 and 2, respectively.
Let δn = 1 if the nth patient is allocated to treatment 1 and δn = −1 otherwise. Let
p(n1, n2) be the conditional probability that the next patient is allocated to treatment 1
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so that
p(n1, n2) = P (δn+1 = 1|n, D˜n),
where D˜n =
∑n
i=1 δi = n1 − n2.
Let F (.) be a function F : Z→ [0, 1] for Z the set of integers such that
1. F (x) is decreasing ;
2. F (−x) = 1− F (x).
Then F is the class of non-constant functions satisfying 1. and 2. above. Let
p(n1, n2) = F (n1 − n2),
so that p(n1, n2) = 1/2 if n1 = n2. The ABCD is generated by the function F (.) in F .




|x|a+1 if x ≤ −1,
1
2
if x = 0,
1
|x|a+1 if x ≥ 1,
(2.1)
where a ∈ R+ is a design parameter.
The ABCD generated by the above expression is abbreviated by ABCD(Fa). This
class of functions Fa(.) will be our main focus for studying the properties of the ad-
justable biased coin design. When a = 0, it becomes complete randomization and as
a → ∞, the design becomes deterministic. Note that F (.) is the general form of the
function that generates the ABCD and Fa(.) is the particular class of functions that we
are interested in. Therefore, by comparing F (.) and Fa(.) for (2.1), we see that the
unknown variable x is x = n1 − n2. In general, Fa(.) is the probability of allocating
the next patient to treatment 1 and this function depends on a chosen value of a and x
which is the difference between the numbers of patients on treatment 1 and treatment 2
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at different stages. Hence, the probability of allocating the next patient to treatment 2 is
1− Fa(x).
2.1.4 Wei’s class of biased coin designs
Wei (1978) developed a new class of biased coin designs called the adaptive biased
coin designs which are defined as follows.
Let D˜n = n1 − n2 be the difference in the numbers of patients on treatments 1 and 2
after n assignments. Under this class of designs, the probability of assigning the (n+1)th
patient to treatment 1 is a decreasing function of D˜n/n, denoted by p(D˜n/n). Similarly,
the probability of assigning the (n + 1)th patient to treatment 2 is denoted by q(D˜n/n),
where p(D˜n/n) + q(D˜n/n) = 1. The function p(x) is chosen to be symmetric such that
p(x) = q(−x) for x ∈ [−1, 1]. In Wei (1978), the special case p(x) = (1 − x)/2 is




for the probability of assigning the (n+ 1)th patient to treatment 1.
2.1.5 Smith’s class of designs
In Smith (1984), the decreasing function p(D˜n/n) from Wei’s class of designs is
studied. Assuming this function is differentiable at zero, a class of designs is suggested
such that the probability of assigning treatment 1 to the (n + 1)th patient is p(x) =







where ρ = −2p′(0) and p′(0) is the first derivative of the function p at 0. When ρ = 0,
this class of designs reduces to complete randomization.
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2.1.6 The D- and DA-optimum biased coin designs
In Atkinson (1982), the theory of optimum design is used to obtain the probabilities
of assigning the next patient to a treatment for the biased coin design. The D- and
DA-optimum biased coin designs are discussed. Consider a linear model for treatment
responses E(Y) = xTβ for which the responses on the two treatments are independent
observations with the same variance σ2. The covariance matrix of the least squares
estimator of β is
Var(βˆ) = σ2(XTX)−1.
The fitted value at x is denoted by yˆ(x) = βˆ
T
x and the variance of the fitted value
at x is Var{yˆ(x)} = σ2xT (XTX)−1x. In the context of optimum experimental design,
it is suggested that we can represent the n patient design by a measure ξn. After n
assignments, the information matrix of the design ξn is denoted byM(ξn) = n−1(XTX),
whereXTX is a p× p matrix. In addition, the standardized variance at x is given by




The D-optimum criterion is used when all the parameters in β are of interest in the
study. The main purpose of the D-optimality criterion is to minimizes the generalized
variance of these parameters’ estimators. In other words, this maximizes the determinant
ofM(ξn).
However, if the contrasts between the treatment effects are of interest, the DA-
optimality criterion is more appropriate to use for treatment allocations. The contrasts
are the components of the vector ATβ where A is a p × s matrix for the contrasts
with rank s < p. The covariance matrix of the least squares estimator AT βˆ is pro-
portional to ATM−1(ξn)A. The DA-optimality criterion maximizes the determinant of
{ATM−1(ξn)A}−1. The standardized variance under the DA-optimality criterion is de-
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noted by
dA(x, ξn) = x
TM−1(ξn)A{ATM−1(ξn)A}−1ATM−1(ξn)x.




as the probability of allocating the next patient to treatment j for j = 1, 2.
The special case for which the model for treatment responses is E(Y ) = βj for
j = 1, 2 is used with two treatments and no prognostic factors involved. The contrast
β1 − β2 is of interest and AT = (1,−1) is the matrix of contrasts. The rank of this
matrix is 1. After n assignments, there are n1 patients on treatment 1 and n2 patients
on treatment 2. The covariance matrix of the least squares estimator in this case is
σ2diag(1/n1, 1/n2) andM(ξn) = diag(n1/n, n2/n).
The standardized variance for theD-optimality criterion is d(j, ξn) = n/nj for treat-
ment j = 1, 2. For the biased coin assignment rule, the probabilities of allocating the
next patient to treatments 1 and 2 are p1 = n2/n and p2 = n1/n , respectively.
For the DA-optimality criterion, the standardized variance is dA(1, ξn) = n2/n1 for
treatment 1 and dA(2, ξn) = n1/n2 for treatment 2. Here, the probabilities of allocating












Under both the D- and the DA-optimality criteria, the probabilities of treatment al-
location are special cases of Smith’s class of designs. When ρ = 1 in p(x) or p(n1, n2),
this probability is the same as the p1 in Atkinson’s design for theD-optimality criterion.
Similarly, q(x) and p2 are the same. When ρ = 2, p(x) is the same as p1 in Atkinson’s
design, and also q(x) is the same as p2, for the DA-optimality criterion.
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2.1.7 Asymptotic properties of the treatment assignment designs
Complete randomization
For complete randomization, the number of patients on treatment 1, n1, has a bino-
mial distribution with parameters n and 1/2. Hence, the variance of n1 is n/4. By the
















in distribution as n→∞. All of the above is also true for n2 for the number of patients
on treatment 2 under complete randomization.
Efron’s biased coin design
In Hu, Zhang and He (2009), for a two-treatment trial, the asymptotic variance of
n1/
√
n for the efficient randomized-adaptive designs (ERADE) attains the Crame´r-Rao
lower bound. Efron’s biased coin design is a special case of ERADE with the target
allocation ξ = 1/2 on each treatment. As ξ is a constant under Efron’s biased coin de-
sign, the Crame´r-Rao lower bound is zero. Hence, under Efron’s biased coin design, the
asymptotic variance of n1/
√












The adjustable biased coin design
The function F : Z→ [0, 1], with Z the set of integers, is decreasing and symmetric.
The probability of assigning the (n+1)th patient to treatment 1 is Fa(x), where x = D˜n.
In Baldi Antognini and Giovagnoli (2004) and Baldi Antognini (2008), it is shown that
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n1/n→ 1/2 and D˜n/
√











Wei’s, Smith’s and Atkinson’s classes of designs
It is shown inWei (1978) that if p(x) is differentiable at x = 0, n−1/2D˜n converges to
a normal distribution with mean 0 and variance 1/{1− 4p′(0)}. By rearranging terms as
n→∞, √n(n1/n− 1/2) will converge to a normal distribution. Here, E(n−1/2D˜n) =
E{√n(n1/n−1/2)} = 0 andVar(n−1/2D˜n) = 4Var{
√















in distribution as n→∞.
In Smith (1984), the particular class of designs with
p(x) =
(1− x)ρ
(1 + x)ρ + (1− x)ρ
is considered with ρ = −2p′(0). Since p(x) is differentiable at x = 0, n−1/2D˜n for
this particular class of designs has the above asymptotic properties. Note that, we have















in distribution as n→∞.
In addition, Atkinson’s class of D- and DA-optimum biased coin designs are two
































in distribution as n→∞ under the DA-optimum biased coin design.
From all of the above, we can see that Efron’s biased coin design and the adjustable
biased coin are less variable asymptotically in balancing the numbers of patients on two
treatments. For both Efron’s biased coin design and the adjustable biased coin design,
√
n (n1/n− 1/2) converges to zero instead of a normal distribution.
In Baldi Antognini and Giovagnoli (2004), the plots of the asymptotic values of
the expected absolute differences D˜n and D˜n/n suggest that the adjustable biased coin
design converges to balance faster than Wei’s class of designs when a = 2ρ for a =
1, 2, 4 and is preferable to Efron’s biased coin design with p = 2/3 for n > 10. In
addition, in terms of the asymptotic predictability, the adjustable biased coin design
generated by (2.1) for any choice of a is preferable to Efron’s biased coin design with
p = 2/3 in balancing the numbers of patients on the two treatments.
2.2 Theoretical analysis of the power with normal re-
sponses for complete randomization and Efron’s bi-
ased coin design
2.2.1 Background
In Chen (2006), the power of two designs for detecting treatment effects is inves-
tigated. The power is treated as the conditional probability of correctly detecting a
treatment effect given a particular status of the treatment allocation. The powers of
the complete randomization and the biased coin design with a deterministic value of p
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are investigated and compared. Of course, if p = 1/2, the BCD(p) is just complete ran-
domization. One of the treatment groups is defined to be the control group and the other
the treatment group.
Firstly, it is assumed that there are n patients at the end of the trial with n2 of them in
the treatment group and n1 of them in the control group, so that n = n2 + n1. Secondly,
let the control responses X1, ..., Xn1 be independent and normally distributed with un-
known mean µ1, and similarly let the treatment responses Y1, .., Yn2 be independent and
normally distributed with unknown mean µ2. The control responses are independent of
the treatment responses. In addition, the control responses and treatment responses are
assumed to have a common variance σ2.
The null hypothesis H0 : µ1 = µ2 is tested against H1 : µ2 > µ1. With the variances
assumed to be the same for the treatment and control responses, the situations of known
and unknown variances are investigated. Expressions are derived for the conditional and
unconditional powers of the two designs in both cases. The total number of patients n
is assumed to be 20. Therefore, the absolute difference in the numbers of patients on
the control group and treatment group are all even numbers from 0 to 20. In particular,
four tables of numerical values for the powers are provided. In addition, the author has
included the powers of the biased coin design with different values of p. The conclusion
is that in both the known variance and the unknown variance cases, the biased coin design
is uniformly more powerful than complete randomization and the power increases when
the value of p in the biased coin design increases.
In what follows, extended work on the power based on Chen (2006) paper will be
presented. The theoretical analysis and numerical values produced for the powers under
complete randomization and the Efron’s biased coin design will be given both when
the variances of the responses are known and different and when the variances of the
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responses are unknown and different.
2.2.2 Exact power with known and different variances
Let σ1 and σ2 be the standard deviations for the control and treatment groups, re-
spectively. Further, let X¯n1 and Y¯n2 be the mean responses for the control and treatment
groups, respectively. Then, for known variances, we carry out a z-test on the treatment
responses. Let zα be the number that satisfies 1− Φ(zα) = α where Φ is the cumulative
distribution function of the standard normal distribution.

















Then the power of this test given a particular allocation status is the probability of re-
jecting H0 for H1 given a particular allocation status of n1 and n2. It is equal to
βZ,α(µ2 − µ1, σ1, σ2|n1, n2) = Φ(δ − zα).
By, multiplying the conditional power by the probability of a particular allocation status
and then summing over allocation status, the unconditional power of the test can be
obtained.
We need to know the probability mass function of the allocation status. Under com-
plete randomization, each of the patients is equally likely to be assigned to the treatment









So the power of the α-level z-test under the complete randomization is
βZ,α,CR(µ2 − µ1, σ1, σ2) =
∑
n1+n2=n










For the biased coin design, there is a probability p > 1/2 of allocating the next
patient to the treatment that has been chosen less often. Under this design, the probability
of obtaining a particular allocation status n1 an n2 depends on the absolute difference
in the numbers of patients on the treatment and control groups. Full details about the
allocation status under the biased coin design are given in Chen (1999). The key points
are as follows. Let Dn be the absolute difference in the numbers of patients on the two
treatments up to time n, so that Dn = |n1 − n2|. This Dn forms a Markov chain with
period 2 on the state space {0, 1, 2, ...} with P (n)l,m = P (Dn = m|D0 = l) as its n-
step transition probabilities for l,m, n ≥ 0. These probabilities yield the probability of
obtaining a particular allocation status under the biased coin design. Note that
• P (1)0,1 = P (Dn+1 = 1|Dn = 0) = 1 for any n ∈ Z and n ≥ 0.
• P (1)k,k+1 = P (Dn+1 = k + 1|Dn = k) = 1− p = q for q < 1/2 and k ≥ 1.
• P (1)k,k−1 = P (Dn+1 = k − 1|Dn = k) = p for k ≥ 1.
• for i 6= j, i, j ≥ 0 and |i− j| 6= 1, P (1)i,j = P (Dn+1 = i|Dn = j) = 0.
From Karlin and McGregor (1957), a formula for the n-step transition probabilities is
P
(n)
l,m = P (Dn = m|D0 = l)











































P (Dn = |n1 − n2||D0 = 0) if n1 6= n2.
So the unconditional power under Efron’s biased coin design is













One of the main aims of the above two designs is to achieve a balance in the numbers
of patients on the two treatments. However, since the variances of the patients’ responses
in the two treatment groups are not the same, the power of the test is not maximized when
the numbers of patients in the two treatment groups are the same. This means that the
optimal allocation for maximum power is not n1 = n2. Neyman allocation gives the
optimal allocation ratio for the numbers of patients on treatments 1 and 2. This ratio is
determined by the values for the variances of the patients’ responses in the two treatment




for treatment 1 and 1−ρ1 for treatment 2. We can use this ratio to determine the optimal
numbers of patients in the two treatment groups. The probability of obtaining a particular
allocation status under Neyman optimal allocation (NOA) will be determined by this
ratio.
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We consider both the deterministic and the random cases under Neyman alloca-
tion. In the deterministic case, the probability of obtaining a particular allocation status
(n1, n2) under Neyman allocation is
PNOA(D){(n1, n2)} =

1 if n1 = round(nρ1) and n2 = round{n(1− ρ1)},
0 otherwise,
where the notation round(x) denotes rounding the value of x to the nearest integer.
The above probability mass function is an indicator function and can also be written as
1NOA(D){(n1, n2)}. So the power of the α-level z-test under Neyman allocation in the
deterministic case is
βZ,α,NOA(D)(µ2 − µ1, σ1, σ2) =
∑
n1+n2=n




Φ(δ − zα)1NOA(D){(n1, n2)}.
Next, we study the random case under Neyman allocation. Here, each patient has a
probability ρ1 of being allocated to treatment 1 and a probability 1−ρ1 of being allocated
to treatment 2. Therefore, n1 ∼ Bin(n, ρ1) and n2 ∼ Bin(n, 1− ρ1). The probability of






ρn11 (1− ρ1)n2 .
So the unconditional power in the random case for Neyman allocation is
βZ,α,NOA(R)(µ2 − µ1, σ1, σ2) =
∑
n1+n2=n









ρn11 (1− ρ1)n2 .
The new numerical results for the powers under complete randomization and the
biased coin design will be shown in the following three tables when we aim to balance
the numbers of patients on the two treatments. In addition, results for the power for
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Neyman allocation are given for comparison. We took n = 20, d¯ = µ2 − µ1 and
α = 0.05. Different values of p are considered. The greater the value of p in the BCD(p),
the more deterministic the design. Different values for the treatment difference d¯ have
also been considered. Three sets of values for σ21 and σ
2
2 are studied.
Table 2.1: Powers of CR, BCD(p), NOA(D) and NOA(R) with σ21 = 0.5, σ
2
2 = 1, n = 20
and α = 0.05
d¯ = 0 d¯ = 0.5 d¯ = 1 d¯ = 1.5 d¯ = 2
CR(p=1/2) 0.05 0.3504 0.8074 0.9816 0.9993
BCD(p=7/12) 0.05 0.3567 0.8178 0.9849 0.9997
BCD(p=8/12) 0.05 0.3595 0.8223 0.9862 0.9997
BCD(P=9/12) 0.05 0.3607 0.8241 0.9867 0.9998
BCD(p=10/12) 0.05 0.3612 0.8249 0.9869 0.9998
BCD(p=11/12) 0.05 0.3615 0.8253 0.9870 0.9998
BCD(p=1) 0.05 0.3617 0.8257 0.9871 0.9998
NOA(D) 0.05 0.3686 0.8349 0.9888 0.9998
NOA(R) 0.05 0.3560 0.8163 0.9841 0.9995
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Table 2.2: Powers of CR, BCD(p), NOA(D) and NOA(R) with σ21 = 1, σ
2
2 = 2, n = 20
and α = 0.05
d¯ = 0 d¯ = 0.5 d¯ = 1 d¯ = 1.5 d¯ = 2
CR(p=1/2) 0.05 0.2257 0.5543 0.8458 0.9701
BCD(p=7/12) 0.05 0.2292 0.5641 0.8557 0.9746
BCD(p=8/12) 0.05 0.2308 0.5684 0.8598 0.9764
BCD(P=9/12) 0.05 0.2315 0.5702 0.8615 0.9771
BCD(p=10/12) 0.05 0.2318 0.5710 0.8623 0.9774
BCD(p=11/12) 0.05 0.2320 0.5715 0.8627 0.9775
BCD(p=1) 0.05 0.2321 0.5718 0.8630 0.9776
NOA(D) 0.05 0.2361 0.5819 0.8713 0.9802
NOA(R) 0.05 0.2289 0.5629 0.8541 0.9737
Table 2.3: Powers of CR, BCD(p), NOA(D) and NOA(R) with σ21 = 0.5, σ
2
2 = 2, n = 20
and α = 0.05
d¯ = 0 d¯ = 0.5 d¯ = 1 d¯ = 1.5 d¯ = 2
CR(p=1/2) 0.05 0.2537 0.6231 0.8975 0.9851
BCD(p=7/12) 0.05 0.2570 0.6318 0.9060 0.9885
BCD(p=8/12) 0.05 0.2584 0.6357 0.9096 0.9899
BCD(P=9/12) 0.05 0.2590 0.6374 0.9111 0.9904
BCD(p=10/12) 0.05 0.2593 0.6381 0.9117 0.9906
BCD(p=11/12) 0.05 0.2594 0.6385 0.9121 0.9907
BCD(p=1) 0.05 0.2595 0.6388 0.9123 0.9907
NOA(D) 0.05 0.2771 0.6780 0.9352 0.9949
NOA(R) 0.05 0.2679 0.6568 0.9215 0.9915
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The first column of each table gives the probabilities of rejecting the null hypothesis
H0 when H0 is true. We can see that these values obtained from our equations match
with the assumed significance level of the test α = 0.05. From the tables, we can
also conclude that the biased coin design is uniformly more powerful than complete
randomization for the case where the control and treatment responses have different
but known variances. The power function increases as the p in the biased coin design
increases from 7/12 to 11/12 as well.
For Neyman allocation, the powers obtained are higher in the deterministic case than
in the random case for the same value of d¯. Furthermore, these powers in the determin-
istic case are higher than their corresponding powers under complete randomization and
the biased coin design for all values of p. Consider the case when σ21 = 0.5 and σ
2
2 = 2.
The sum of the variances of the patients’ responses on the two treatments is the largest
in this case. The powers obtained here for Neyman allocation in the random case are
higher than their corresponding powers under complete randomization and the biased
coin design for all values of p. However, for the other two cases, the powers for Neyman
allocation in the random case are higher than the corresponding powers under complete
randomization but are lower than those for the biased coin design for all values of p.
2.2.3 Exact power with unknown and different variances
Welch’s (1938) approximate t-test is often used when the variances of the treatment
and control responses are unknown and different. The degrees of freedom are chosen
so that the test statistic under the null hypothesis has approximately a t distribution.
Let again X¯n1 and Y¯n2 be the mean responses for the control and treatment groups,
respectively. Further, let s22 and s
2
1 be the sample variances for the treatment and control
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We reject H0 if and only if T > tν,α, where tν,α is the right-tailed α-level critical
value of the t-test with degrees of freedom ν. UnderH1 : µ2 > µ1, the test statistic T has
approximately a non-central t distribution with ν degrees of freedom and non-centrality
parameter δ in (2.2). When the variances of the control and treatment responses are
unknown and different, the power of this test given a particular allocation status is the
probability of rejecting H0 given a particular allocation status n1 and n2. It is equal to
βT,α(µ2 − µ1, σ1, σ2, s1, s2|n1, n2) = 1− Tν,δ(tν,α), (2.4)
where Tν,δ is the cumulative distribution function of the non-central t distribution with ν
degrees of freedom and noncentrality parameter δ. By multiplying the conditional power
by the probability of a particular allocation status and summing over allocation status the
unconditional power of the test can be obtained.
Now, we know the probability mass function of the allocation status n1 and n2 under
complete randomization from (2.3). Therefore, the power of the test under complete
randomization is









For the biased coin design, the probability of obtaining a particular allocation status
n1 and n2 depends on the absolute difference Dn in the numbers of patients on the two
treatments up to time n. This Dn forms a Markov chain on the state space {0, 1, 2, ...}
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with P (n)l,m = P (Dn = m|D0 = l) as its n-step transition probabilities for l,m, n ≥ 0
given in (2.4). So the power of the test is









The above two expressions give the powers of complete randomization and the biased
coin design when the variances of the control and treatment responses are different and
unknown. These are both expressed in terms of the means of the control and treatment
responses, the standard deviations of the control and treatment responses, and the sample
standard deviations of the control and treatment responses; which are the parameters
µ1, µ2, σ1 and σ2, and the variables s1 and s2, respectively. The sample variances s21 and
s22 are two random variables which take any non-negative values.
In order to produce numerical results for the powers of these two designs, the con-
ditional power is needed where neither of the variables s1 and s2 are involved. This can
be obtained by integrating the product of the conditional power and the joint probability
density function of s1 and s2, with respect to s1 and s2. The powers of the two designs
are then calculated by multiplying this new conditional power by the probability mass
function of the allocation status and summing. The original conditional power of the test
when the variances of the treatment and control responses are different and unknown is
given in (2.4), where both Tν,δ and ν involve the variables s1 and s2. Let f(s21, s22|n1, n2)
be the joint probability density function of s21 and s
2
2 given the allocation status (n1, n2).
Then the new conditional power is












{1− Tν,δ(tν,α)}f(s22, s21|n1, n2) ds21ds22.
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We know, (n1−1)s21/σ21 ∼ χ2n1−1 and that (n2−1)s22/σ22 ∼ χ2n2−1. Let y1 = s21, y2 =
s22, x1 = (n1 − 1)s21/σ21 and x2 = (n2 − 1)s22/σ22 . Then the probability density functions




























for x2 > 0, where Γ is the gamma function. By the method of change of variables, the
probability density function of y1 is
f(y1|n1) =
∣∣∣∣dx1dy1

























and similarly for the probability density function of y2. So the probability density func-







































The treatment responses are independent and normally distributed with mean µ2 and
variance σ22 , the control responses are independent and normally distributed with mean
µ1 and variance σ21 , and the control responses are independent of the treatment responses.
Therefore, the random variables s21 and s
2
2 are also independent. The joint probability
density function of s21 and s
2




2|n1, n2) = f(s21|n1)f(s22|n2). (2.6)
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Finally, the power of complete randomization when the variances of the treatment
and control responses are unknown and different is
βT,α,CR(µ2 − µ1, σ1, σ2) =
∑
n1+n2=n






Similarly, the power of the biased coin design is









We assume that the total number of patients in the trial is 20, so that n = 20. There
are in total 21 combinations of values for n1 and n2 which give n = n1+n2 = 20. There
are two special cases for which a specific joint probability density function for s21 and s
2
2
is used instead of (2.6).
• When n1 = 0, then n = n2 = 20. All the patients are allocated to the treatment
group and no patient is in the control group, which means there will be no sample
variance for the control responses and hence no probability density function for s21.
The joint probability density function of s21 and s
2
2 is just the probability density




2|n1, n2) = f(s22|n2). Similarly, when n2 = 0,
n = n1 = 20 and there is no sample variance for the treatment group. The joint
probability density function of s21 and s
2




2|n1, n2) = f(s21|n1).
• When n1 = 1, then n2 = n− n1 = 19. Only one patient is allocated to the control
group. As there is only one patient in the control group, the sample variance of
the control responses will be s21 = 0. Then, from (2.5), f(s
2
1|n1) = 0 and the
joint probability density function is f(s21, s
2
2|n1, n2) = 0. Similarly, when n2 = 1,
the sample variance of the treatment responses is s22 = 0, and hence the joint
probability density function is f(s21, s
2
2|n1, n2) = 0.
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The new numerical values for the powers of complete randomization and the biased
coin design are presented in the following three tables.
Table 2.4: Powers of CR and BCD(p) with σ21 = 0.5, σ
2
2 = 1, n = 20 and α = 0.05
d¯ = 0 d¯ = 0.5 d¯ = 1 d¯ = 1.5 d¯ = 2
CR(p=1/2) 0.05 0.3270 0.7683 0.9686 0.9975
BCD(p=7/12) 0.05 0.3345 0.7830 0.9756 0.9990
BCD(p=8/12) 0.05 0.3379 0.7893 0.9781 0.9993
BCD(P=9/12) 0.05 0.3393 0.7918 0.9790 0.9994
BCD(p=10/12) 0.05 0.3400 0.7929 0.9794 0.9994
BCD(p=11/12) 0.05 0.3403 0.7935 0.9796 0.9995
BCD(p=1) 0.05 0.3406 0.7939 0.9797 0.9995
Table 2.5: Powers of CR and BCD(p) with σ21 = 1, σ
2
2 = 2, n = 20 and α = 0.05
d¯ = 0 d¯ = 0.5 d¯ = 1 d¯ = 1.5 d¯ = 2
CR(p=1/2) 0.05 0.2124 0.5177 0.8090 0.9530
BCD(p=7/12) 0.05 0.2166 0.5299 0.8233 0.9615
BCD(p=8/12) 0.05 0.2185 0.5354 0.8293 0.9648
BCD(P=9/12) 0.05 0.2193 0.5376 0.8318 0.9660
BCD(p=10/12) 0.05 0.2197 0.5386 0.8328 0.9665
BCD(p=11/12) 0.05 0.2199 0.5392 0.8334 0.9668
BCD(p=1) 0.05 0.2200 0.5396 0.8338 0.9670
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Table 2.6: Powers of CR and BCD(p) with σ21 = 0.5, σ
2
2 = 2,n = 20 and α = 0.05
d¯ = 0 d¯ = 0.5 d¯ = 1 d¯ = 1.5 d¯ = 2
CR(p=1/2) 0.05 0.2367 0.5797 0.8618 0.9717
BCD(p=7/12) 0.05 0.2404 0.5906 0.8745 0.9791
BCD(p=8/12) 0.05 0.2420 0.5954 0.8800 0.9819
BCD(P=9/12) 0.05 0.2427 0.5974 0.8822 0.9829
BCD(p=10/12) 0.05 0.2430 0.5983 0.8832 0.9833
BCD(p=11/12) 0.05 0.2432 0.5988 0.8837 0.9836
BCD(p=1) 0.05 0.2433 0.5991 0.8841 0.9837
The first column of each table shows the significance level of the test, which gave the
assumed significance level α = 0.05. From the tables, we can see that the biased coin
design is uniformly more powerful than complete randomization for the case where the
control and treatment responses have different and unknown variances. Also, the power
function increases as the p in the biased coin design increases. The power is smaller in
the case when the assumed variances of the control and treatment responses are σ21 = 1
and σ22 = 2 than in the case when the assumed variances are σ
2
1 = 0.5 and σ
2
2 = 1. The
sum of the variances is smaller in the latter case and leads to a higher power. Therefore,
when the variances of the treatment and control responses are unknown and different,
the power increases when the sum of the two variances is smaller.
By comparing the powers of complete randomization and Efron’s biased coin design
above to the corresponding powers when the variances of the treatment and control re-
sponses are known and different, the powers here are slightly less. This is due to the
t-test being only approximate and the variances of the patients’ responses on the two
treatments being unknown. There is some variation in the values of the powers of the
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two designs due to the approximation. The first column in the table has values which
give the assumed significance level α = 0.05.
2.3 Simulation of power under Efron’s biased coin de-
sign and the adjustable biased coin design with nor-
mal responses
In this section, the powers under Efron’s biased coin design and the adjustable bi-
ased coin design will be studied by simulation. Baldi Antognini (2008) considered the
known variance case for the ABCD and investigated the power function of the z-test.
He then describes the Markovian properties of the BCD. A theoretical analysis is given
of the power by comparing the adjustable biased coin design with Efron’s (1971) BCD
and Wei’s (1978) adaptive biased coin design. Theoretically, the adjustable biased coin
design is shown to give a uniformly more powerful z-test than the other two designs.
Consider an experiment with n = 20 patients. Each of them arrive sequentially and
have to be assigned to one of the treatments immediately. Both the biased coin design
and the adjustable biased coin design have a probability which biases the allocation
of a patient in favour of an under-represented treatment. The biased coin design has
a fixed probability p > 1/2 of allocating a patient to an under-represented treatment.
The adjustable biased coin design has a probability Fa(x) of allocating a patient to a
treatment. This probability varies with the numbers of patients currently in the two
groups, unlike the p in Efron’s biased coin design.
The powers of Efron’s biased coin design and the adjustable biased coin design were
produced by simulations in R. Patients arrive one by one and are assigned to one of
the treatments immediately. The assignment rule is as follows. Firstly, we randomly
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generate a number from a uniform distribution U [0, 1]. When the first patient arrives, we
have a probability of 1/2 of assigning this patient to either of the treatments. The rules
for the biased coin design and the adjustable biased coin design will be applied from the
second patient onwards. For the biased coin design with fixed p > 1/2, if the random
number is less than or equal to p, then we will assign the patient to the under-represented
treatment group, and otherwise to the other group. If the random number generated is
less than or equal to the value Fa(x), we will allocate the patient to the control group,
and otherwise to the treatment group. The difference in the numbers of patients on the
two treatments is calculated after each patient is allocated to a treatment.
Twenty random numbers are generated in R to represent twenty patients and to al-
locate them to one of the treatments according to the biased coin rule. This is repeated
for the adjustable biased coin design. These twenty assignments are considered to be
one trial. The patients are assumed to have normal responses. At the end of a trial, the
numbers of patients in the control and treatment groups, n1 and n2, will be known. With
chosen values for the means and variances, we simulate values from a normal distribu-
tion to represent the patients’ responses. Thus, we simulate n1 values from a normal
distribution with mean µ1 and variance σ21 and n2 values from a normal distribution with
mean µ2 and variance σ22 . The averages of the responses for the control and treatment
groups, X¯n1 and Y¯n2 , respectively, can be calculated from the simulated responses. Then






















when the variances for the control and treatment groups are different, that is σ21 6= σ22.
The significance level is assumed to be α = 0.05. We reject H0 if Z > zα.
The above is repeated 10,000 times with Efron’s biased coin design and the ad-
justable biased coin design for different values for the means and variances. The number
of tests with H0 being rejected is counted for the two designs. The proportion of tests
for which H0 is rejected is the estimated power. Simulation results for the estimated
powers of Efron’s biased coin design and the adjustable biased coin design are shown in
the following four tables. Again let d¯ = µ2−µ1. Different values for d¯ are used to study
the power of the two designs.
Table 2.7: Powers of BCD(p) and ABCD with σ2 = 1, n = 20 and α = 0.05
d¯ = 0 d¯ = 0.5 d¯ = 1 d¯ = 1.5 d¯ = 2
BCD(p=7/12) 0.050 0.300 0.714 0.952 0.998
BCD(p=8/12) 0.051 0.297 0.720 0.953 0.998
BCD(p=9/12) 0.051 0.297 0.728 0.954 0.997
BCD(p=10/12) 0.047 0.298 0.733 0.958 0.997
BCD(p=11/12) 0.052 0.302 0.721 0.957 0.998
ABCD(a=1) 0.047 0.292 0.723 0.954 0.998
ABCD(a=2) 0.050 0.295 0.729 0.955 0.998
ABCD(a=4) 0.048 0.304 0.720 0.959 0.997
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Table 2.8: Powers of BCD(p) and ABCD with σ21 = 0.5, σ
2
2 = 1, n = 20 and α = 0.05
d¯ = 0 d¯ = 0.5 d¯ = 1 d¯ = 1.5 d¯ = 2
BCD(p=7/12) 0.050 0.354 0.811 0.984 1
BCD(p=8/12) 0.050 0.358 0.821 0.986 1
BCD(p=9/12) 0.049 0.359 0.827 0.987 1
BCD(p=10/12) 0.052 0.356 0.830 0.986 1
BCD(p=11/12) 0.045 0.359 0.833 0.987 1
ABCD(a=1) 0.050 0.357 0.818 0.986 1
ABCD(a=2) 0.051 0.369 0.826 0.988 1
ABCD(a=4) 0.046 0.368 0.825 0.987 1
Table 2.9: Powers of BCD(p) and ABCD with σ21 = 1, σ
2
2 = 2, n = 20 and α = 0.05
d¯ = 0 d¯ = 0.5 d¯ = 1 d¯ = 1.5 d¯ = 2
BCD(p=7/12) 0.052 0.225 0.568 0.849 0.975
BCD(p=8/12) 0.048 0.233 0.564 0.853 0.975
BCD(p=9/12) 0.050 0.240 0.567 0.859 0.979
BCD(p=10/12) 0.048 0.232 0.575 0.859 0.978
BCD(p=11/12) 0.049 0.234 0.571 0.865 0.977
ABCD(a=1) 0.050 0.238 0.581 0.867 0.980
ABCD(a=2) 0.048 0.232 0.579 0.866 0.980
ABCD(a=4) 0.051 0.228 0.573 0.869 0.980
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Table 2.10: Powers of BCD(p) and ABCD with σ21 = 0.5, σ
2
2 = 2, n = 20 and α = 0.05
d¯ = 0 d¯ = 0.5 d¯ = 1 d¯ = 1.5 d¯ = 2
BCD(p=7/12) 0.051 0.257 0.638 0.907 0.989
BCD(p=8/12) 0.047 0.249 0.646 0.910 0.991
BCD(p=9/12) 0.048 0.267 0.637 0.909 0.990
BCD(p=10/12) 0.049 0.259 0.639 0.914 0.991
BCD(p=11/12) 0.045 0.260 0.635 0.911 0.990
ABCD(a=1) 0.049 0.255 0.651 0.911 0.990
ABCD(a=2) 0.056 0.256 0.638 0.914 0.992
ABCD(a=4) 0.052 0.260 0.641 0.912 0.990
For both designs, the power increases when d¯ increases. In addition, a larger value
is obtained for the power when the sum of the variances is smaller. However, the trend
in the power of the biased coin design when p increases is not obvious. Therefore, no
conclusion can be drawn about the power of the biased coin design when p increases
from the simulations. Similarly, no obvious pattern can be seen in the powers of the
adjustable biased coin design when a increases. Hence, we cannot draw any conclusions
about the power of the ABCD when a increases.
Theoretically, the adjustable biased coin design has been shown by Baldi Antognini
(2008) to be uniformly more powerful than Efron’s biased coin design. Here, we have
tried to quantify the increase in power by simulation. The numerical values for the pow-
ers give no evidence that the adjustable biased coin design is uniformly more powerful
than Efron’s biased coin design. We have also simulated the trial 100,000 times and one
million times and no significant increase in the power was shown by using the adjustable
biased coin design. Therefore, from the values that have been obtained, we cannot con-
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clude that the adjustable biased coin design is uniformly more powerful than Efron’s
biased coin design. Further theoretical work may be possible to study the degree of
increase in power for the adjustable biased coin design over Efron’s biased coin design.
2.4 Power under complete randomization and Efron’s
biased coin design with binary responses
Previously, we assumed that the treatment and control groups have normal responses.
In this section, the situation when binary responses are available is considered. There-
fore, each patient has a response which follows a Bernoulli distribution. Let Xi for
i = 1, ..., n1 represent the response of the ith patient in the control group and let Yj for
j = 1, ..., n2 represent the response of the jth patient in the treatment group such that
Xi =






1 if the jth patient in the treatment group survives,
0 otherwise.
Let P (Xi = 1) = p1 be the probability that a patient survives in the control group and let
P (Yj = 1) = p2 be the probability that a patient survives and is in the treatment group.
By assumption, the random variables X1, X2, ..., Xn1 are independent and identi-
cally distributed and the random variables of Y1, Y2, ..., Yn2 are independent and identi-
cally distributed. The control and treatment responses are also independent. Let X =∑n1
i=1Xi and Y =
∑n2
j=1 Yj . Then, given n1 and n2, we have X|n1 ∼ Bin(n1, p1) and
Y |n2 ∼ Bin(n2, p2). The conditional probability mass functions of these two random
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variables are













Since the control and treatment responses are independent, the joint conditional proba-
bility mass function of the numbers of patients who survive in the control and treatment
groups is just the product of their individual conditional probability mass functions given
by












We are interested in whether there is a treatment effect. Here, p1 and p2 are the two
parameters of interest. A difference in these two parameters will indicate a treatment
effect in the case of binary responses. We want to testH0 : p1 = p2 againstH1 : p2 > p1.
We reject H0 if Y −X > d for some positive integer d.
Numerical values for the powers of complete randomization and the biased coin
design with binary responses will be produced. The conditional power, which is the
probability of correctly detecting a treatment effect given a particular allocation status,
is needed first. This is the same as the probability of rejecting H0 given a particular
allocation status, P (Y −X = y − x > d|n1, n2), for a chosen critical value d ∈ Z+.
In order to obtain the probability mass function of Y −X , we use the joint conditional
probability mass function of X and Y and a change of variables. Let A = X + Y and
B = Y −X . Then we have to obtain the joint conditional probability mass function ofA
and B denoted by g(a, b|n1, n2). Then we can sum over all values of a in g(a, b|n1, n2).
The resulting expression is the conditional probability mass function g(b|n1, n2) which
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is also the conditional probability mass function of Y −X given n1 and n2. Finally, by
choosing a critical value d, the probability P (Y −X = y− x > d|n1, n2) can be found.
By a change of variables, the joint conditional probability mass function g(a, b|n1, n2)
is


































We have to sum over all values of a in g(a, b|n1, n2) to obtain the conditional probability
mass function of B. Therefore, the range for a has to be known. We know that x can
take any integer value between 0 and n1. Similarly, y can take any integer value between
0 and n2. From x = (a − b)/2, we know that a is an integer that lies between b and
2n1 + b inclusively. Similarly, from y = (a + b)/2, a is an integer that lies between −b
and 2n2 − b inclusively. So we have four conditions for the range of a: a ≥ b, a ≥ −b,
a ≤ 2n1 + b and a ≤ 2n2 − b. By drawing the four lines a = b, a = −b, a = 2n1 + b
and a = 2n2 − b on a graph, we can identify the values for a and b that satisfies these
conditions. The values for a and b are the discrete points inside the shaded area. Three
graphs are given to show the shaded area of interest, when n1 > n2, when n1 = n2 and
when n1 < n2. The red, blue, yellow and green lines represent the lines with equations
a = b, a = −b, a = 2n1 + b and a = 2n2 − b, respectively.
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Figure 2.1: Values of a and b when n1 > n2










Figure 2.2: Values of a and b when n1 = n2









Figure 2.3: Values of a and b when n1 < n2










The first two conditions a ≥ b and a ≥ −b imply that a is greater than or equal to
|b| and the last two conditions a ≤ 2n1 + b and a ≤ 2n2 − b imply that a is less than or
equal to n− |b+n1−n2|.We know that all values for a depend on the current value for
b. Consider all values for a when b is fixed. Then, we have a = b + 2x, so that a takes
values in steps of two and a = {|b|, |b| + 2, ..., n − |b + n1 − n2|}. Therefore, we sum
over a in steps of two for each value for b in the conditional power.
The conditional power P (Y −X = b > d|n1, n2) = P (Y −X = y− x > d|n1, n2)
























































This is the power given the allocation status n1 and n2.
The unconditional power can be obtained by multiplying the conditional power by






































and the power of the biased coin design is

























































We now consider the power when the significance level is fixed. Numerical values
for the power are given for complete randomization and Efron’s biased coin design in
the following two tables. The first column of each table shows the significance level. By
choosing the appropriate critical value d in each case, we want to fix the value for the
significance level to be around 0.05. The critical value d is chosen so that this is less than
or equal to 0.05. Here, d may not be the same for different designs as the probability
distribution of the allocation status is different, since Efron’s biased coin design is better
than complete randomization in terms of balancing the numbers of patients on the two
treatment groups.
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Table 2.11: The power of CR and BCD with µ = p2 − p1 and n = 20
µ = 0 µ = 0.2 µ = 0.4 µ = 0.6 µ = 0.8
CR(p=1/2) d=6 0.0430 0.1313 0.3134 0.5745 0.8320
BCD(p=7/12) d=5 0.0464 0.1708 0.4279 0.7492 0.9547
BCD(p=8/12) d=5 0.0320 0.1478 0.4221 0.7762 0.9750
BCD(p=9/12) d=5 0.0259 0.1366 0.4192 0.7900 0.9829
BCD(p=10/12) d=5 0.0232 0.1311 0.4178 0.7970 0.9861
BCD(p=11/12) d=5 0.0217 0.1279 0.4170 0.8012 0.9877
Table 2.12: The power of CR and BCD with µ = p2 − p1 and n = 50
µ = 0 µ = 0.2 µ = 0.4 µ = 0.6 µ = 0.8
CR(p=1/2) d=9 0.0443 0.2403 0.6249 0.9234 0.9970
BCD(p=7/12) d=7 0.0513 0.3523 0.8281 0.9916 1
BCD(p=8/12) d=7 0.0385 0.3417 0.8483 0.9960 1
BCD(p=9/12) d=7 0.0489 0.3898 0.8820 0.9980 1
BCD(p=10/12) d=7 0.0337 0.3370 0.8570 0.9972 1
BCD(p=11/12) d=7 0.0330 0.3362 0.8584 0.9974 1
From the above tables, we can see that the biased coin design performs much better
than complete randomization in terms of power for each value of µ = p2 − p1. We took
five values of p1 from 0.5 to 0.1 in steps of 0.1 and p2 takes five values from 0.5 to 0.9
in steps of 0.1. In Table 2.11, for µ = 0.6 and µ = 0.8, we can also see that the power
of the biased coin design increases when p increases. Similar conclusions hold when the
number of patients is n = 50 in Table 2.12. An increase in the number of patients in the
trial gives a larger value for the power in each case.
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2.5 Normal approximation for the power under com-
plete randomization and Efron’s biased coin design
In this section, we assume that patients’ responses in the two treatment groups are
normally distributed. We study the numerical values for the power obtained using a
normal approximation for complete randomization and Efron’s biased coin design, and
compare these with the exact values. The exact values were obtained by Chen (2006)
when the variances are the same, in Section 2.2.2 when the variances are known and
different, and in Section 2.2.3 when the variances are unknown and different.
In Shao, Yu and Zhong (2010), normal approximations to the power are given under
different randomization schemes. The responses of patients in the two treatment groups
are assumed to be normally distributed. We wish to test H0 : µ1 = µ2 against H1 : µ2 >







The sample variances for the standard and new treatments are denoted by s21 and s
2
2,
respectively. We will replace s21 and s
2





variances are known. Given a significance level of α, we reject H0 if T > cα, where cα
is the critical value of a Student’s t-distribution or the standard normal distribution when
the variances of the patients’ responses are unknown or known, respectively.
When the variances of the responses in the two treatment groups are the same, we
have σ21 = σ
2
2 = σ
2. Then we have,
lim
n→∞
P (T > cα) = Φ(−cα).
The unconditional power underH1 for the two sample t-test under complete randomiza-
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tion and the biased coin design is given by









This represents the normal approximation to the power. The following three tables give
the exact power and the normal approximation to the power for complete randomization
and Efron’s biased coin design. In the calculations, we took σ2 = 1.
Table 2.13: Exact powers of CR and BCD(p) with normal approximation when n = 20,
α = 0.05, σ = 1 and known
d¯ = 0 d¯ = 0.5 d¯ = 1 d¯ = 1.5 d¯ = 2
CR(p=1/2) 0.05 0.2893 0.7024 0.9461 0.9960
BCD(p=7/12) 0.05 0.2947 0.7139 0.9522 0.9971
BCD(p=8/12) 0.05 0.2972 0.7190 0.9546 0.9975
BCD(p=9/12) 0.05 0.2983 0.7211 0.9555 0.9976
BCD(p=10/12) 0.05 0.2987 0.7220 0.9560 0.9976
BCD(p=11/12) 0.05 0.2990 0.7225 0.9562 0.9976
N.Approx 0.05 0.2992 0.7228 0.9563 0.9977
We can see that the normal approximation to the power is slightly higher than the ex-
act values obtained under complete randomization and Efron’s biased coin design when
the variances of the responses are the same and known. The differences in the exact and
approximate powers under complete randomization are no more than about 2%, while
those in the powers under Efron’s biased coin design are no more than about 1%. As the
exact power is higher for the biased coin design than for complete randomization, the
over-approximation is less serious for the biased coin design than for complete random-
ization.
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Table 2.14: Exact powers of CR and BCD(p) with normal approximation when n = 20,
α = 0.05, σ = 0.5 and unknown
d¯ = 0 d¯ = 0.5 d¯ = 1 d¯ = 1.5 d¯ = 2
CR(p=1/2) 0.05 0.6732 0.9937 1 1
BCD(p=7/12) 0.05 0.6847 0.9952 1 1
BCD(p=8/12) 0.05 0.6897 0.9957 1 1
BCD(p=9/12) 0.05 0.6918 0.9959 1 1
BCD(p=10/12) 0.05 0.6927 0.9959 1 1
BCD(p=11/12) 0.05 0.6932 0.9960 1 1
N.Approx. 0.05 0.7228 0.9977 1 1
Table 2.15: Exact powers of CR and BCD(p) with normal approximation when n = 20,
α = 0.05, σ = 2 and unknown
d¯ = 0 d¯ = 0.5 d¯ = 1 d¯ = 1.5 d¯ = 2
CR(p=1/2) 0.05 0.1313 0.2755 0.4709 0.6732
BCD(p=7/12) 0.05 0.1329 0.2806 0.4802 0.6847
BCD(p=8/12) 0.05 0.1337 0.2829 0.4843 0.6897
BCD(p=9/12) 0.05 0.1340 0.2839 0.4861 0.6918
BCD(p=10/12) 0.05 0.1341 0.2844 0.4868 0.6927
BCD(p=11/12) 0.05 0.1342 0.2846 0.4873 0.6932
N.Approx 0.05 0.1388 0.2992 0.5128 0.7228
In the case of unknown and equal variances, the normal approximation to the power
again gives larger values for the power under both schemes than the exact calculations.
The over-approximation is also more serious for complete randomization than for the
biased coin design. However, the differences in the exact and approximate values are
64
greater than those when the variances are the same and known.
When the variances of the responses are different, the unconditional power under the
two designs for the two sample t-test is











The next two tables present the exact power and the normal approximation to the power
for the two designs.
Table 2.16: Exact powers of CR and BCD(p) with normal approximation when n = 20,
α = 0.05, σ21 = 0.5, σ
2
2 = 2 and known
d¯ = 0 d¯ = 0.5 d¯ = 1 d¯ = 1.5 d¯ = 2
CR(p=1/2) 0.05 0.2537 0.6231 0.8975 0.9851
BCD(p=7/12) 0.05 0.2570 0.6318 0.9060 0.9885
BCD(p=8/12) 0.05 0.2584 0.6357 0.9096 0.9899
BCD(P=9/12) 0.05 0.2590 0.6374 0.9111 0.9904
BCD(p=10/12) 0.05 0.2593 0.6381 0.9117 0.9906
BCD(p=11/12) 0.05 0.2594 0.6385 0.9121 0.9907
BCD(p=1) 0.05 0.2595 0.6388 0.9123 0.9907
N.Approx 0.05 0.2595 0.6388 0.9123 0.9907
For known and different variances, the normal approximation to the power gives the
most accurate approximation compared to the previous cases. The normal approximation
to the power gives the same results as to the biased coin design when p = 1. There is
still an over-approximation to the power under the two schemes. The differences in the
exact and approximate values are no more than 1% for all d¯ and p 6= 1 under the biased
coin design. The normal approximation to the power also works better for the biased
coin design than for complete randomization.
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Table 2.17: Exact powers of CR and BCD(p) with normal approximation when n = 20,
α = 0.05, σ21 = 0.5, σ
2
2 = 1 and unknown
d¯ = 0 d¯ = 0.5 d¯ = 1 d¯ = 1.5 d¯ = 2
CR(p=1/2) 0.0500 0.3270 0.7683 0.9686 0.9975
BCD(p=7/12) 0.0500 0.3345 0.7830 0.9756 0.9990
BCD(p=8/12) 0.0500 0.3379 0.7893 0.9781 0.9993
BCD(p=9/12) 0.0500 0.3393 0.7918 0.9790 0.9994
BCD(p=10/12) 0.0500 0.3400 0.7929 0.9794 0.9994
BCD(p=11/12) 0.0500 0.3403 0.7935 0.9796 0.9995
BCD(p=1) 0.0500 0.3406 0.7939 0.9797 0.9995
N.Approx 0.05 0.3617 0.8257 0.9871 0.9998
When the variances of the responses are unknown and different, the exact power is
obtained for Welch’s approximate t-test. The normal approximation to the power again
gives larger values for the power than the exact calculations under the two schemes. The
differences in the exact and approximate values are no more than 4% for the biased coin
design.
The asymptotic expression given for the normal approximation to the power are the
same under complete randomization and the biased coin design. The values obtained
for the power by the normal approximation are therefore the same under complete ran-
domization and the biased coin design. For each case, the numerical values for the
power given by the normal approximation are higher than the exact values. There is an
over-estimation to the power. The problem of over approximation is more serious for
complete randomization than for the biased coin design.
In the planning stage of a clinical trial, we have to estimate the number of patients
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that are needed to achieve a certain power for a given treatment difference. The prob-
lem of over approximation to the power will lead the planning team to recruit too few
patients. By knowing the degree of over-approximation can help the planners to adjust
their sample size estimate accordingly.
2.6 Conclusions
It is clear that complete randomization gives the lowest power among the designs
both when patients’ responses are binary and normally distributed. Complete random-
ization schemes are less likely to detect a genuine treatment difference than the other
designs. Efron’s biased coin design is basically as good as the adjustable biased coin
design in terms of balancing the numbers of patients on two treatments.
In this chapter, we have described the simplest case in clinical trials. Restricted
randomization schemes are considered where patient assignment only depends on the
current numbers of patients on the two treatments. In the next chapter, we will study
schemes where covariate information will be used for treatment assignment. In other
words, we study covariate-adaptive randomization schemes in two-treatment trials. In






Consider a clinical trial in which there are two treatments under comparison. Patients
arrive sequentially and have to be assigned to one of the treatments immediately. A ran-
domization scheme can be used for treatment assignment to ensure that there are similar
numbers of patients in the two treatment groups and to maintain some randomness in the
assignment for valid statistical inference. These randomization schemes have their own
assignment rules for which the assignments are made based on the current numbers of
patients on the treatments.
In addition, some of the patients’ prognostic factors like their age, gender, current
health condition and so on will have an influential effect on their responses to different
treatments. Therefore, it is sensible to include these prognostic factors as covariates both
in the randomization stage and in the analysis stage. When the randomization schemes
are applied to patients classified by their prognostic factors, we call these covariate-
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adaptive randomization schemes. These schemes ensure that patients with the same
prognostic profile are balanced across the treatment groups. One of the most well-known
covariate adaptive randomization processes is the minimization procedure developed by
Pocock and Simon (1975) and described as follows. We first identify patients’ prognos-
tic profiles by classifying them into different levels within each of the covariates. Let
the total number of treatments involved beK. Then we calculate the imbalance between
the treatments at different levels of the prognostic factors if the next patient is assigned
to treatment j for j = 1, .., K. If some of the levels of the covariates are more impor-
tant, more weight will be put on these. The overall imbalance is calculated from the
imbalances of each level of the covariates. The next assignment will be made to the
treatment which gives the minimum overall imbalance. Covariate-adaptive randomiza-
tion schemes are also studied by Shao, Yu and Zhong (2010) when there is only one
covariate and K = 2. Here, the covariate is considered to be a random variable.
In this chapter, we will investigate different covariate-adaptive randomization schemes
when K = 2. In Section 3.2, the linear models for patients’ responses is introduced
when there are several covariates. We will only consider a fixed- effects model. Under
any covariate-adaptive randomization scheme, we can achieve either global or marginal
balance in the numbers of patients in the two treatment groups. Their properties are
investigated for two covariates by Baldi Antognini and Zagoraiou (2011). In Section
3.3, global and marginal balance will be described for two or more covariates. The pa-
tient assignment rules will be introduced in Section 3.4 for covariate-adaptive simple
random sampling, the covariate-adaptive biased coin design and the covariate-adaptive
adjustable biased coin design for both global and marginal balance. In Section 3.5, an
analysis of covariance t test on the treatment difference under the above three randomiza-
tion schemes will be described. In Shao, Yu and Zhong (2010), an analytical approach is
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given to obtain expressions for normal approximations to the power under different ran-
domization schemes for a single covariate. In Section 3.6, we assess the accuracy of the
normal approximation to the power for different scenarios. The corresponding expres-
sion for the normal approximation will also be given when there are p ≥ 2 covariates.
Numerical values for the power of the analysis of covariance t test will be simulated in
Section 3.7. The values will be simulated for different scenarios under the three random-
ization schemes for both global and marginal balance. Finally, we draw conclusions in
Section 3.8.
3.2 Models for covariate-adaptive randomization
Consider a trial with two treatments and n patients in total. Treatment 1 represents
the standard treatment and treatment 2 represents the new treatment. We call the group
of patients that receive treatment 1 the control group and the group of patients receiving
treatment 2 the treatment group. Let n1 and n2 be the numbers of patients in the control
and treatment groups, respectively. The response of the ith patient on treatment j is Yij
for i = 1, .., n and j = 1 if the ith patient is allocated to treatment 1 or j = 2 if the ith
patient is allocated to treatment 2. Let Ii be the indicator variables such that
Ii =

0 if the ith patient is allocated to treatment 1,
1 if the ith patient is allocated to treatment 2
(3.1)
for i = 1, ..., n. The response of patient i can be represented as
Yi = IiYi2 + (1− Ii)Yi1.
3.2.1 Linear model for patients’ responses
We are interested in the model for the Yij . Let Zik be the kth covariate used in the
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randomization process for the ith patient and let the total number of covariates used be
p. Then our model for patients’ responses may be written in matrix form as
Y =Wµ+ Zβ + ². (3.2)
Here, Y is the n× 1 column vector which contains all the responses Yij for i = 1, ..., n
and j = 1 or 2 such that
Y =
(
Y11, Y21, ..., Yn11, Y(n1+1)2, Y(n1+2)2, ..., Yn2
)T
.
The column vectors µ and β represent the parameters in the model. Let µ1 and µ2 be
the mean responses for treatment 1 and 2, respectively. Then µ is 2 × 1 column vector
with components µ1 and µ2 − µ1. The ith patient will take µ1 in the model when the
subject is allocated to treatment 1 and µ2 when the subject is allocated to treatment 2.
Furthermore, W is an n × 2 matrix with ones in the first column and the values of Ii in
the second column.
The matrix Z contains the values of the covariates used in the randomization and
their interactions. More specifically, it includes all values of the p covariates Zik for
i = 1, ..., n and k = 1, ..., p, together with any interaction terms between them. These















terms. Therefore, Z is a n× q matrix, where p ≤ q.
These covariates are either qualitative or quantitative variables. Quantitative vari-
ables refer to variables with numerical values. They can be discrete or continuous. Ex-
amples of quantitative covariates are the height and weight of a patient, the amount of
alcohol intake per day, the number of packs of cigarettes smoked and so on. The first ex-
ample is a continuous quantitative variable and the last is a discrete quantitative variable.
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Qualitative variables refer to variables that cannot be measured in terms of numbers and
are classified into different categories. These variables can be further divided into two
categories which are categorical and ordinal. For ordinal variables, the categories are
ordered. For example, the current health condition of a patient can be classified into cat-
egories in terms of status with levels such as ’very bad’, ’normal’,’very good’ and so on.
Categorical covariates have no sense of ordering. Gender is an example of categorical
covariates for which has the levels ’male’ or female’.
We transform all the quantitative and qualitative covariates into factors variables as
follows. Consider the covariate Zik which represents the prognostic profile for the kth
covariate of the ith patient. This particular covariate is divided into lk levels, where lk
represents the total number of levels for the kth covariate and k = 1, ..., p. These total
numbers of levels for different covariates may be the same.
In the case where the covariates are quantitative, we have to define ranges for each
of the levels within each covariate. For a particular covariate k, it will be classified as
being in a particular level if its values lie within the range of that level. We allocate an
integer value to each level of the covariate. For example, the covariate for age will take
the value −1 if the age of a patient is between 0 − 20, 0 for ages between 21 to 40 and
so on. Another covariate, the height of a patient may take value −1 if their height is less
than or equal to 100 cm, 0 for height above 100 cm and less than or equal to 120 cm and
so on.
When the covariates are qualitative and ordinal, a value will be assigned to each of the
levels of the covariates. For example, the health condition of a patient is represented by a
value of −2 for ’very bad’ condition and 2 for ’very good’ condition. For qualitative and
categorical covariates, we will also assign a value to each of the categories of a covariate.
For example, we take −1 for a female patient and 1 for a male patient.
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The values of all of the levels for each covariate add up to zero. This is to ensure that
an effect of one level can be compensated for by inverse effects of all the other levels.
Therefore, these values are used for the values of the covariates Zik for i = 1, .., n and
k = 1, ..., p in the model.
The q× 1 column vector β contains the regression parameters for the covariates and
is
β = (β1, β2, ..., βp, βp+1, ..., βq)
T .
Here, there are in total p covariates used in the randomization and β1 to βp are the
regression parameters for each of the covariates. The rest of the components in β from
βp+1 onwards are the regression parameters for the interactions between the covariates.
Finally, ² is the n× 1 column vector for the random errors ²ij such that
² =
(
²11, ..., ²n11, ²(n1+1)2, ..., ²n2
)T
,
where the ²ij for i = 1, ..., n and j = 1 or 2 are independent and identically distributed
with mean 0 and variance σ2² . These random errors ²ij are independent of all of the
covariates Zik. The model can be considered as either a fixed-effects or a random-effects
model.
3.2.2 Background
In Shao, Yu and Zhong (2010), the model for treatment responses is written in the
form
Yij = µj + bZi + ²ij.
The above equation is a special case of (3.2). Here, Yij and ²ij for i = 1, .., n and j = 1
or 2 are the components of the vectorsY and ², respectively. Also,
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In this model, only one covariate is considered and hence there are no interaction
terms. This covariate is assumed to be a univariate covariate with finite second order
moment. The covariate Zi here is the same as Zik in (3.2) with k = p = 1. So Zi1 can
be written as Zi in this case. This means that Z = (Z1, Z2, ..., Zn)T . In addition, the
column vector β in (3.2) which contains all the regression parameters for the covariates
and their interactions is now just b.
In Shao, Yu and Zhong (2010), the covariates Zi used in the randomization are ran-
dom variables. In fact, (Yi1, Yi2, Zi) for i = 1, ..., n are assumed to be independent
random variables from some distribution. The random variables Zi are independent and
identically distributed and can be from a discrete or continuous distribution. The random
variables ²ij are independent of the Zi.
When Zi is discrete, there will be a list of possible values for Zi. These Zi take
any values in this list. If Zi is continuous, then we have to define a discrete function of
Zi, denoted by D(Zi). Under any covariate-adaptive randomization scheme, when Zi
is discrete, we will apply its assignment rule for each value of Zi. When Zi is continu-
ous, we will apply the assignment rules to patients in each of the categories defined by
D(Zi). Our aim is to achieve balance between the two treatment groups for each of the
prognostic factors.
3.2.3 Fixed-effects model
Consider now (3.2) as a fixed-effects model. The parameters in β for the covariates
Zik and in µ are some fixed quantities. These parameters are called the fixed-effect
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coefficients in the model. Under the fixed-effects model, the covariates Zik that we use
are also fixed quantities with integer values instead of random variables that takes value
from some distribution. Under this model, all levels of each covariate are used. We will
not randomly choose samples of levels for each covariate. All of the patients’ responses
have the same variance.
3.3 Global balance and marginal balance
3.3.1 Background
One of the main aims of randomization schemes is to balance the numbers of patients
across treatment groups. When a patient arrives at a clinical centre, we have to assign
this patient to one of the treatments immediately. Therefore, for a covariate-adaptive
randomization scheme, one of its aims is to ensure a balance in the numbers of patients in
the two treatment groups when patients are classified by their prognostic factors. When
there are two or more covariates, either global or marginal balance can be sought under
different covariate-adaptive randomization schemes. Global and marginal balancing are
only used when the fixed-effects model is considered for patients’ responses. There
are in total p covariates to consider. Each of the covariates is classified into different
levels. Let the total number of levels for the kth covariate be lk for k = 1, ..., p. Let L
sk
k
represents level sk of the kth covariate for k = 1, ..., p and sk = 1, ..., lk. For a particular




k . The values of
lk for k = 1, ..., p can be the same or different.
3.3.2 Global balance
Global balance is where balance is achieved in the numbers of patients on the two
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treatments for all combinations of the levels of the covariates. There are a total of l1 ×
l2 × . . .× lp possible combinations for all levels of the covariates. We will refer to each
of the combinations as one of the l1 × l2 × . . . × lp cells for the covariates. When a
patient arrives, the subject’s prognostic profile will be recorded. We will know which
cell the patient falls into. The assignment rule for a particular randomization scheme
will be applied within that cell. We normally use the same randomization scheme for
all cells. We may also use different randomization schemes in all or some of the cells.
It will depend on how important it is to balance the numbers of patients between two
treatments in a particular cell. Global balance therefore balances the numbers of patient
in each of the cells {(L11, L12, ..., L1p), (L21, L12, ..., L1p), ..., (Ll11 , Ll22 , ..., Llpp )}.
Wewill letDm(Ls11 , L
s2
2 , ..., L
sp
p ) be the difference between the number of patients on
treatment 1 and the number of patients on treatment 2 up to themth assignment based on
all patients with the prognostic profile {(Ls11 , Ls22 , ..., Lspp )}. This Dm(Ls11 , Ls22 , ..., Lspp )
is used for the treatment assignment of the next patient in global balance for covariate-
adaptive randomization schemes. Given the sign of thisDm, we know the under-represented
treatment for this particular prognostic profile afterm assignments have been made.
3.3.3 Marginal balance
Marginal balance is another way to balance the numbers of patients between two
treatment groups. Here, we consider the difference in the numbers of patients on two
treatments marginally for the levels of the covariates. When a patient arrives, its prog-
nostic profile is noted and we know the levels of each of the p covariates for this patient.
Let the prognostic profile of the next patient be (Ls11 , L
s2
2 , ..., L
sp
p ). Assume that m as-
signments have been made prior to this patient, let Dm(Ls11 ) be the difference between
the number of patients on treatment 1 and the number on treatment 2 based on all pa-
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tients with level s1 of the first covariate, and similarly define Dm(Ls22 ), ..., Dm(L
sp
p ).
These quantities measure the marginal imbalance at the individual levels of the p co-
variates for the next patient. Let D¯m denote the overall imbalance used under covariate-
adaptive randomization for the treatment assignment of the next patient based on the first
m assignments in the marginal approach. This imbalance is a linear combination of the
marginal imbalances at the individual levels of the p covariates and is defined as
D¯m = c1Dm(L
s1
1 ) + c2Dm(L
s2
2 ) + ...+ cpDm(L
sp
p ),
where ck for k = 1, ..., p are any real numbers which represent the weights chosen to
reflect the relative importance of the covariates. The overall imbalance D¯m is calculated
at each stage m and the sign of D¯m will be noted. Hence, at each stage, the under-
represented treatment will be known.
3.4 Assignment rules for covariate-adaptive randomiza-
tion schemes
The treatment assignment rules are now described for covariate-adaptive simple ran-
dom sampling, the covariate-adaptive biased coin design and the covariate-adaptive ad-
justable biased coin design which achieve either global or marginal balance when pa-
tients are classified by their prognostic factors.
Under covariate-adaptive simple random sampling for global balance, the next pa-
tient has a probability of 1/2 of being allocated to either of the treatments in the appro-
priate cell for all values of Dm(Ls11 , L
s2
2 , ..., L
sp
p ). For marginal balance, the probability
of allocating the next patient to either of the treatments is 1/2 for all values of D¯m.
Next, the covariate-adaptive biased coin design is introduced. This is a design that
applies Efron’s (1971) biased coin design in the randomization process to patients grouped
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by their prognostic profiles. Under the covariate-adaptive biased coin design, given the
prognostic profile (Ls11 , ..., L
sp
p ) of the next patient, for global balance there is a fixed
probability p > 1/2 of allocating the next patient to a treatment that has been chosen
less often. Thus, we have
P (Im = 1) =

p if Dm−1(Ls11 , L
s2
2 , ..., L
sp
p ) > 0,
1/2 if Dm−1(Ls11 , L
s2
2 , ..., L
sp
p ) = 0,
1− p if Dm−1(Ls11 , Ls22 , ..., Lspp ) < 0
as the probability of assigning the next patient to treatment 2. As p→ 1, the assignments
tend to be more deterministic. For marginal balance, the allocation rule is similar but the
difference Dm−1(Ls11 , ..., L
sp
p ) is replaced by D¯m−1 such that
P (Im = 1) =

p if D¯m−1 > 0,
1/2 if D¯m−1 = 0,
1− p if D¯m−1 < 0.
Note that, for both global and marginal balance, when p = 1/2, the covariate-adaptive
biased coin design reduces to covariate-adaptive simple random sampling.
The last covariate-adaptive randomization scheme to be introduced is the covariate-
adaptive adjustable biased coin design. This design was developed by Baldi Antognini
and Giovagnoli (2004). It is an extension of Efron’s biased coin design in which the
probability of assigning the next patient to a treatment depends on a decreasing and
symmetric function F (.) of the difference in the numbers of patients in the two treat-
ment groups. For the covariate-adaptive adjustable biased coin design, given that the
prognostic profile of the next patient is (Ls11 , L
s2
2 , ..., L
sp
p ), the probability of assigning
this patient to treatment 1 is F as1,s2,...,sp(.), where a is a design parameter. For global
balance afterm assignments, let x = Dm(Ls11 , ..., L
sp
p ). Then the probability or function
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to assign the next patient to treatment 1 given the prognostic profile is F as1,...,sp(x) and




|x|a+1 if x ≤ −1,
1/2 if x = 0,
1
|x|a+1 if x ≥ 1,
(3.5)
where a ≥ 0. As a → 0, the design reduces to covariate-adaptive simple random
sampling, whereas the design becomes more deterministic as a → ∞. Similarly, for
marginal balance under the covariate-adaptive adjustable biased coin design, the prob-
ability of assigning the next patient to treatment 1 given the same prognostic profile as
above is F as1,...,sp(x) in (3.5) with x = D¯m.
3.5 Analysis of covariance for fixed-effects model
After the treatment assignments have been made, the patients’ responses in the two
treatment groups will be studied under these covariate-adaptive randomization schemes.
We are now interested in whether there is a genuine treatment difference between the
two treatment groups.
Under the fixed-effects model, the covariates Zik used take integer values and all
levels within any of the covariates are considered. In what follows, assume that the total
number of levels of each of the covariates is the same, so that l1 = l2 = ... = lp. We
also assume that the values of all the levels of the covariates add up to zero. Finally, the
patients’ responses in the two treatment groups can be obtained from (3.2)
To test whether the population means are different, that is, there is a treatment effect,
a two-sample t-test will be carried out. An analysis of covariance on the responses of the
patients is considered. For each patient, the effect of the covariate will be removed from
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the patients’ responses to obtain the adjusted responses. The sample mean and variance
of the adjusted responses will give estimated values for µj for j = 1, 2.
Let Rij be the adjusted response of the ith patient allocated to treatment j for i =
1, ..., n and j = 1 or 2. LetR represent the n×1 column vector of the adjusted responses
Rij given by
R = (R11, R21, ..., Rn11, Rn1+12, ..., Rn2)
T ,
where
R = Y − Zβ.
Each of the matrices R, Z and Y can be split into two sub-matrices. We have R =
(R1,R2)
T as an n× 1 column vector such that R1 is the n1 × 1 vector for the adjusted
responses Ri1 for the patients on treatment 1 andR2 is the n2× 1 vector for the adjusted
responses Ri2 for the patients on treatment 2. Similarly, Y = (Y1,Y2)T is an n × 1
column vector with Y1 as an n1 × 1 column vector for the responses Yi1 on treatment
1 and Y2 is an n2 × 1 column vector for the responses Yi2 on treatment 2. Finally,
Z = (Z1,Z2)
T is an n×q matrix such thatZ1 represents the n1×q matrix with the values
of the covariates and their interaction terms for those patients allocated to treatment 1 and
Z2 is an n2 × q matrix which contains the values of the covariates and their interaction
terms for the patients allocated to treatment 2.
Let the sample means of the adjusted responses for treatments 1 and 2 bem1 andm2,




















Given α as the significance level of the test, H0 is rejected if |TC | > tn−2−q,α/2. Under
H0, the test statistic TC has a Student’s t-distribution with n− 2− q degrees of freedom.
Next, we have to find an estimate for the variance of µˆ2− µˆ1 for the test statistic. Us-
ing Hinkelmann and Kempthorne (2008) and (3.2), the estimation is as follows. Matrices
W and Z are of full rank, 2 and q, respectively, so that (WTW)−1 exists.
Model (3.2) reduces to Y = Wµ∗ + ²∗ if no covariates are included, where µ∗
represents the 2×1 column vector of population means and ²∗ is the n×1 column vector
of error terms in this model. The least squares estimator of µ∗ in this model is µ̂∗ =
(WTW)−1WTY. Now let PW be the projection matrix or the orthogonal projection on
W such that PW = W(WTW)−1WT . Also, let RW = In −W(WTW)−1WT =
In − PW , where In is the n × n identity matrix, be the orthogonal projection on the
orthogonal complement ofW. Then, Y = PWY + RWY, where PWY and RWY are
orthogonal, so that (RWY)T (PWY) = 0.
The least squares estimator of β
β̂ = (ZTRWZ)
−1ZTRWY
and the estimator of µ in (3.2) is
µ̂ = µ̂∗ − (WTW)−1WTZβ̂.
The error sum of squares is obtained as
SSE = YTY − µ̂∗TWTY − β̂TZTRWY.
An unbiased estimator of the variance of the random error is then the mean square error
given by
σˆ2² = SSE/(n− 2− q).
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Since, µ̂∗ and β̂ are uncorrelated, the variance of the estimator ofµ can be calculated
as
Var(µ̂) = Var(µ̂∗) + (WTW)−1WTZVar(β̂)[(WTW)−1WTZ]T
= [(WTW)−1 + (WTW)−1WTZ(ZTRWZ)−1ZTW(WTW)−1]σ2² ,
which can be estimated by
V̂ar(µ̂) = [(WTW)−1 + (WTW)−1WTZ(ZTRWZ)−1ZTW(WTW)−1]σˆ2²
An estimator of the variance of any linear combination of the µˆj for j = 1, 2 can be
calculated from the variance of µ̂. Let a be a 2 × 1 column vector such that it contains
the coefficients of the linear combination of the µˆj , j = 1, 2. Then the linear combination
of the µj can be written as aT µ̂. Therefore, an estimator of the variance of this linear
combination of the µj is
̂Var(aT µ̂) = σˆ2²aT [(WTW)−1 + (WTW)−1WTZ(ZTRWZ)−1ZTW(WTW)−1]a.
(3.6)
This can be used to obtain an estimator of the variance of the difference between the
mean responses of the two treatment groups.
3.6 Normal approximation for power when the covari-
ates are random variables
3.6.1 Background
Consider a clinical trial where patients are classified into different groups according
to their prognostic profiles. The patients are allocated to one of the treatments by a
covariate-adaptive randomization scheme. In Shao, Yu and Zhong (2010), the covariates
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used in the randomization Zi for i = 1, ..., n are random variables. The responses of
patients in the two treatment groups are compared by carrying out a two sample t-test to
see whether there is a difference between the two treatment groups. The null hypothesis







where Y¯2 and Y¯1 are the sample mean on treatments 2 and 1, respectively. With a signif-
icance level α, the null hypothesis is rejected if |Ts| > cα, where cα is the critical value
of a Student’s t-distribution or the standard normal distribution.
Let Y = {Yij, i = 1, .., n, j = 1 or 2} and I = {Ii, i = 1, ..., n}, and let Z =
{D(Zi), i = 1, .., n}. Further, let ∆i = Zi − E{Zi|D(Zi)} and ∆i = 0 if Zi = D(Zi).
Then, the difference in the sample means was calculated as




{b(2Ii − 1)∆i + Ii²i2 − (1− Ii)²i1}+ op(n−1/2)
conditionally on Z = {D(Zi), i = 1, .., n}, where (∆i, ²i1, ²i2) are conditionally inde-
pendent of I given Z .
The asymptotic mean and variance of Y¯2−Y¯1 were shown to be µ2−µ1 and 4(b2σ2∆+
σ2² )/n, where σ
2
∆ = Var(∆i). It was also shown that
(Y¯2 − Y¯1)− (µ2 − µ1)
2τ∆/n1/2
→ N(0, 1)
in distribution as n→∞, where τ 2∆ = b2σ2∆ + σ2² , conditionally on Z .




















z = Var(Zi) conditionally on Z. Under H0, we have
lim
n→∞
P (|Ts| > cα) = 2Φ(−cατz/τ∆).
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Consider three randomization methods: simple randomization, biased coin random-
ization and covariate-adaptive biased coin randomization. Then, the unconditional power
under H1 for the two-sample t-test under simple randomization and the biased coin
method is given by

















The power under covariate-adaptive biased coin randomization is given by




















Consider a trial in which there is only one covariate. Assume that patients’ responses
follow a fixed-effects model of the form (3.2). Here, Z is an n × 1 column vector
containing the values for Zi for i = 1, ..., n.
Two-sample t test
Consider a two sample t test and assume that the Zi for all i = 1, ..., n are discrete
uniform random variables. We will study the power of this test under the covariate-
adaptive biased coin design with null hypothesis H0 : µ2 − µ1 = 0 and alternative
hypothesisH1 : µ2 − µ1 > 0. Since we assume that treatment 1 is the control treatment,
we are interested in whether the new treatment which is treatment 2 is better than the
standard or the control treatment. Therefore, the alternative hypothesis for this test is
one-sided.
Simulation is carried out to study the numerical values for the power of the two
sample t test under the covariate-adaptive biased coin design for different scenarios and
to compare these with the numerical values obtained using a normal approximation.
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When the Zi are discrete uniformly distributed with possible values 1, ..., K, each value
has probability 1/K. We will consider the values K = 2, 4, 8 such that they divide the
real line into K categories with equal probabilities. The parameter b in the model is
assumed to be 0.75 and the significance level is α = 0.05. We have n = 100 and the
random error term ²ij is generated from a normal distribution with mean 0 and σ² =
0.5, 1, 2. The probability p used in the covariate-adaptive biased coin design is 2/3.
We first want to obtain the numerical values for the power using a normal approxi-
mation. For the above one-sided test, we have










as the normal approximation. When Zi is discrete, ∆i is by definition 0. It follows that
Var(∆i) = σ
2




² . The covariate Zi is discrete uniformly distributed with
variance σ2z = (K
2−1)/12 forK = 2, 4, 8 and τ 2z = b2(K2−1)/12+σ2² . The following
table gives numerical values for the power for various choices of d¯ = µ2 − µ1.
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Table 3.1: Power by simulation and normal approximation when Zi are discrete uni-
formly distributed
d¯ 0 0.25 0.5 0.75 1 1.25 1.5
Simulation
K σ²
2 0.5 0.023 0.661 0.998 1 1 1 1
1 0.039 0.297 0.795 0.974 0.999 1 1
2 0.043 0.144 0.336 0.568 0.787 0.921 0.979
4 0.5 0.004 0.269 0.924 1 1 1 1
1 0.022 0.198 0.626 0.931 0.996 1 1
2 0.038 0.126 0.296 0.537 0.760 0.906 0.975
8 0.5 0.003 0.048 0.317 0.773 0.974 0.999 1
1 0.008 0.066 0.273 0.624 0.890 0.982 0.999
2 0.024 0.083 0.196 0.384 0.614 0.796 0.922
Normal Approximation
K σ²
2 0.5 0.020 0.672 0.998 1 1 1 1
1 0.040 0.306 0.771 0.977 0.999 1 1
2 0.047 0.147 0.336 0.580 0.796 0.927 0.981
4 0.5 0.001 0.238 0.963 1 1 1 1
1 0.016 0.185 0.638 0.946 0.998 1 1
2 0.037 0.123 0.297 0.536 0.763 0.910 0.975
8 0.5 0 0 0.187 0.947 1 1 1
1 0.001 0.022 0.221 0.684 0.958 0.999 1
2 0.015 0.061 0.179 0.385 0.630 0.831 0.943
86
The numerical values in the first column represent the significance level of the test
for each scenario. Clearly, the values obtained by simulation and by the normal ap-
proximation are less than 0.05. In a two-sample t test, the significance level obtained is
conservative under the covariate-adaptive biased coin design, as explained by Shao, Yu
and Zhong (2010). As Var(Y¯2 − Y¯1) is less variable than Var(Y¯2) + Var(Y¯1), there is a
negative correlation between Y¯1 and Y¯2. The unbiased estimator of Var(Y¯2) + Var(Y¯1),
s21/n1 + s
2
2/n2, is the denominator in the test statistic and gives a smaller value for the
test statistic. Hence, the test is less likely to reject H0 and produces a smaller value
for the significance level. This explains why the numerical results obtained here are
conservative.
For each K, the significance level increases when σ² increases. When K is larger,
the power for the same values for d¯ and σ² decreases. The power tends to 1more quickly
when σ² is smaller. For large values of d¯, it is clear that the power obtained from the
normal approximation is larger than the simulated value.
Analysis of covariance t test
An analysis of covariance t test can also be carried out on the treatment difference.
This is a two-sample t test when the effect of the covariates is removed from the patients’
responses. In Shao, Yu and Zhong (2010), the normal approximation to the power by
analysis of covariance is given by

















where TC is the test statistic for the analysis of covariance t test. Here, we consider
a one-sided t test with null hypothesis H0 : µ2 − µ1 = 0 and alternative hypothesis
H1 : µ2 − µ1 > 0. The normal approximation to the power is










Therefore, the power obtained from the normal approximation is not affected by the
distribution of Zi.
Now consider the general case where we have p covariates. Let Zik have mean 0 and
variance σ2zk for k = 1, ..., p. Then using the same notation as in Section 3.5, µ
∗ is the
vector of population means in the model without covariates and µ̂∗ = (WTW)−1WTY.
The variance of µ̂∗ then becomes
Var(µ̂∗) = (WTW)−1WTVar(Y)W(WTW)−1
= (WTW)−1WT{βTVar(Z)βIn +Var(²)}W(WTW)−1,
whereVar(Y) is the n×n covariance matrix for the column vector of patients’ responses
and In is the n×n identity matrix. As patients’ responses are independent, the covariance
of Yij and Yi′j for i, i′ = 1, ..., n and i 6= i′ is zero. The covariance matrix ofY will have
the variance of Yij for i = 1, ..., n as the ith diagonal element and zeros elsewhere.
Similarly, Var(Z) is the covariance matrix of Z. As the Zik are independent and
identically distributed for each k = 1, ..., p with mean 0 and variance σ2zk , Var(Z) is a
p × p covariance matrix with σ2zk as the kth diagonal element and zeros elsewhere. In






Finally, as ²ij for i = 1, ..., n are independent and identically distributed random errors
with mean 0 and variance σ2² , Var(²), the covariance matrix of ² is an n× n matrix with
diagonal entries σ2² and zeros elsewhere.
So
Var(Y) = (βTVar(Z)β + σ2² )In.
Therefore,
Var(µ̂∗) = (βTVar(Z)β + σ2² )(W
TW)−1.
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Now, consider the variance of Zβ̂. Then we have
Var(Zβ̂) = E[(Zβ̂)(Zβ̂)T ]− E(Zβ̂)E(Zβ̂)T
= E[Zβ̂β̂
T
ZT ]− E(Zβ̂)E(Zβ̂)T .




= E(Z){E(β̂T β̂)− E(β̂)TE(β̂)}E(Z)T
= E(Z)Var(β̂)E(Z)T .
We are interested in obtaining an estimate of the variance of µ̂. Since µ̂∗ and β̂ are
uncorrelated, the variance of µ̂ can be written as
Var(µ̂) = Var(µ̂∗) + (WTW)−1WTVar(Zβ̂)W(WTW)−1
= (βTVar(Z)β + σ2² )(W
TW)−1
+ (WTW)−1W{E(Z)Var(β̂)E(Z)T}W(WTW)−1.
The estimate of the variance of µ̂ becomes
V̂ar(µ̂) = (β̂
T
V̂ar(Z)β̂ + σˆ2² )(W
TW)−1
+ (WTW)−1W{E(Z)V̂ar(β̂)E(Z)T}W(WTW)−1,
where σˆ²2 is defined earlier as the error mean square, V̂ar(Z) is the estimator of the
covariance matrix of Z and V̂ar(β̂) is the estimator of the covariance matrix of the least
square estimator β. Let a be the column vector of contrasts of the population means.
Then we have
̂Var(aT µ̂) = aT [(β̂
T




In the simulations, we assume there is only one covariate. The matrix Z in (3.2)
is just an n × 1 column vector and all of the Zi for i = 1, ..., n take values from one
distribution. Here, E(Z) = 0 and Var(Z) = σ2z . So Var(Zβ̂) = 0. In addition, the
vector β will only contain a single scalar and is denoted by b. Then we have




The least squares estimator of b will also become a scalar and is denoted as βˆ. We have




where σˆ2z is the estimator of the variance of Z and the sample variance of Z is used. Let
aT = (0, 1), as we want to study whether treatment 2 is better than treatment 1. We have
to estimate the variance of µˆ2 − µˆ1, which can be expressed as




TW)−1 (0, 1)T .
The numerical values for the power obtained from analysis of covariance using sim-
ulation and the normal approximation are given below. The values for α, β, n,K and σ²
are the same as for the two-sample t test.
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Table 3.2: Power by simulation and normal approximation for analysis of covariance t
test
d¯ 0 0.25 0.5 0.75 1 1.25 1.5
Simulation
K σ²
2 0.5 0.048 0.795 1 1 1 1 1
1 0.054 0.345 0.801 0.981 0.999 1 1
2 0.057 0.153 0.341 0.594 0.795 0.926 0.982
4 0.5 0.044 0.802 1 1 1 1 1
1 0.050 0.341 0.800 0.983 0.999 1 1
2 0.049 0.147 0.345 0.586 0.799 0.927 0.980
8 0.5 0.051 0.800 1 1 1 1 1
1 0.054 0.346 0.798 0.980 0.999 1 1
2 0.049 0.166 0.335 0.589 0.799 0.923 0.980
Normal Approximation
All K σ²
0.5 0.05 0.804 1 1 1 1 1
1 0.05 0.347 0.804 0.982 1 1 1
2 0.05 0.154 0.347 0.591 0.804 0.931 0.982
The numerical values for the power obtained using a normal approximation are usu-
ally larger than the simulated values. However, the significance level of the test is close
to 0.05 for each scenario.
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3.6.3 More than one covariate
The theoretical calculations for the normal approximations to the power in Shao,
Yu, Zhong (2010) were considered when a single univariate covariate is involved in
the randomization process. However, in real trials, more than one prognostic factor or a
combination of several prognostic factors will affect the responses of patients to different
treatments. We now consider the case where more than one univariate covariate is used
in the randomization process.
Let p be the number of covariates used. Here, the covariates Zik for i = 1, ..., n
and k = 1, ..., p are assumed to be random variables. In Shao, Yu and Zhong (2010), a
first-order linear model for the patients’ responses Yij was constructed for a univariate
covariate. We extend the analysis to a second-order linear model for patients’ responses
where there is more than one univariate covariate.
The model for patients’ responses is written as













where µj is the mean response on treatment j for j = 1, 2 and Zik is the kth covariate for
the ith patient. There are p first-order terms. Next, we have two types of second-order
terms in the model. The first type is the squared term in the covariate Zik and there are
p of them. The second type is the interaction term between two different covariates and
there are p× (p− 1) of these. Finally, ²ij is the random error term.
In (3.2), Yij and ²ij are the components of the column vectorsY and ², respectively.
The column vector µ will be the same as in (3.3) and the matrixW will be of the same
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form as in (3.4). The matrix Z can be written as
Z =






Z1p . . . Zn1p Z(n1+1)p . . . Znp
Z211 . . . Z
2
n11







Z21p . . . Z
2
n1p
Z2(n1+1)p . . . Z
2
np
Z11Z12 . . . Zn11Zn12 Z(n1+1)1Z(n1+1)2 . . . Zn1Zn2





















∆ik∆im = ZikZim − E{ZikZim|D(Zik)},
where D(Zik) is the discrete function of Zik if Zik is continuous. Then the covariate-
adaptive biased coin design applies Efron’s biased coin assignment rule within each
category defined byD(Zik). In this case, Z is defined as Z = {D(Zik), i = 1, ..., n, k =
1, ..., p}, so that when Zik = D(Zik), ∆ik = 0.
The same test will be carried out of H0 : µ2 − µ1 = 0 against H1 : µ2 − µ1 > 0.
Here, we want to test if treatment 2 is better than treatment 1. We have the same test
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statistic Ts as in (3.7) and H0 will be rejected if Ts > cα, for cα defined as earlier. The
sample means of the responses on the two treatments Y¯1 and Y¯2 are needed for the test
statistic. We may write

























































{Ii²i1 − (1− Ii)²i0}+ op(n−1/2),
The asymptotic mean of Y¯2 − Y¯1 is calculated by taking the expectation of Y¯2 − Y¯1
conditionally on Z and is equal to µ2 − µ1.
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This is the form 4τ ∗2∆ /n, where τ
∗2
∆ is known from above. We also have
(Y¯2 − Y¯1)− (µ2 − µ1)
2τ ∗∆/n1/2
→ N(0, 1)







































































































































Again, as compared with τ 2z , τ
∗2
z is more complicated.
The normal approximation to the power when there are p covariates can be obtained
as in (3.8) for simple random sampling and the biased coin design and as in (3.9) for





3.7 Simulation for global and marginal balance
3.7.1 Algorithms for global balance
In this section, we look at different covariate-adaptive randomization schemes when
global and marginal balancing are sought in the numbers of patients on the two treat-
ments by simulation.
The model for patients’ responses to be considered here is the fixed-effects model.
Assume that the covariates Zik are fixed and take integer values. For the kth covariate
for k = 1, .., p, the values for all levels of this covariate will add up to zero. We assume
that the number of levels for each covariate is the same.
Assume that two covariates or prognostic factors are considered to be of particular
importance in affecting patients’ responses to the treatments. Let Zi1 and Zi2 denote the
first and second covariates. The numbers of levels for these are denoted by l1 and l2,
respectively, where l1 = l2.
We consider two scenarios where both of the covariates either have two or three
levels. For example, for three-level covariates, that is, l1 = l2 = 3, we denote the
levels by a1, a2 and a3 for the first covariate and b1, b2 and b3 for the second covariate.
Global balancing balances the numbers of patients at each of the combinations of the
levels of the covariates. There will be in total nine possible combinations of the levels of
the two covariates. Patients will be classified into nine cells or strata according to their
prognostic profiles. The nine combinations for the two covariates are
{(a1, b1), (a1, b2), (a1, b3), (a2, b1), (a2, b2), (a2, b3), (a3, b1), (a3, b2), (a3, b3)}.
In other words, global balancing balances the numbers of patients in the two treatment
groups in each of the nine cells.
In the simulations, we generate two random numbers from a uniform distribution
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between 0 and 1 for each patient. The first number will represent the level of the first co-
variate and the second number the level of the second covariate for this patient. Suppose
that we consider covariates with two levels. Then, if the first random number is greater
than or equal to 0 and less than or equal to 0.5, then this patient belongs to level a1 of
the first covariate. If the first random number is greater than 0.5 and less than or equal to
1, then this patient belongs to level a2 of the first covariate. For a three-level covariate,
if the first random number has value greater than or equal to 0 and less than or equal to
1/3, then this patient belongs to level a1 of the first covariate. If the first random number
has value greater than 1/3 and less than or equal to 2/3, then this patient belongs to level
a2 of the first covariate. Finally, if the first random number is greater than 2/3 and less
than or equal to 1, this patient belongs to level a3 of the first covariate. Similarly, this
applies to the second random number for the second covariate at two or three levels. By
making use of the random numbers, each patient is equally likely to fall into one of two
or three levels for both covariates. Therefore, we can obtain a prognostic profile for each
patient by simulation.
We consider three covariate-adaptive randomization schemes, which are covariate-
adaptive simple random sampling, covariate-adaptive biased coin randomization and
covariate-adaptive adjustable biased coin randomization. The covariate-adaptive ran-
domization schemes are applied to each of the nine cells. At each stage, when a pa-
tient arrives, the patient is classified into one of the nine cells according to the patient’s
prognostic characteristics. Within this cell, the current imbalance in the numbers of pa-
tients on the two treatments will be noted and this patient will be allocated to the under-
represented treatment with a probability p. Under covariate simple random sampling p
is fixed and equals 1/2. For the covariate-adaptive biased coin design, p is also fixed
and takes value greater than a half to allocate the patient to the treatment that has been
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chosen less often. Here, we only consider the same p for all cells under the covariate-
adaptive biased coin design. Under the covariate-adaptive adjustable biased coin design,
this probability p varies with the current imbalance and equals F a(x) defined in Chapter
2 with some chosen design parameter a. Thus, we assume that a is the same for all cells
and for all stages. At the same stage, F a(x) may be different in different cells as x the
difference in the numbers of patients on treatments 1 and 2 may be different in different
cells.
In the simulations for global balance, given the prognostic profile of a patient, we
know which of the cells the patient belongs to. A third random number is generated
for this patient. This random number is generated from a uniform distribution between
0 and 1 and will be used for treatment assignment. For this particular cell, we have to
identify the current numbers of patients on the two treatments. Under covariate-adaptive
simple random sampling in global balance, if the third random number has value greater
than or equal to zero and less than 0.5, this patient will be allocated to treatment 1. If the
third random number has value greater than or equal to 0.5 and less than or equal to 1,
then this patient will be allocated to treatment 2.
Under the covariate-adaptive biased coin design for global balance, we take different
values for p in the simulations. Given the prognostic profile of the next patient, we will
just look at the current numbers of patients on the two treatments in this particular cell. If
the third random number has value greater than or equal to 0 and less than p, this patient
will be allocated to the treatment that has fewer patients. If the third random number
has value greater than or equal to p and less than or equal to 1, then this patient will
be allocated to the treatment that has more patients. If the numbers of patients on the
two treatments are the same, then the covariate-adaptive biased coin assignment process
will reduce to the covariate-adaptive simple random sampling assignment process with
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p = 1/2.
Under the covariate-adaptive adjustable biased coin design for global balance, given
the prognostic profile of the next patient, we have to calculate the difference in the num-
bers of patients on treatments 1 and 2 in this particular cell. This difference is denoted
by x in the function F as1,s2(x) for the probability of allocating this patient to treatment 1
given the prognostic profile as (s1, s2). If the third random number for this patient has
value greater than or equal to zero and less than F as1,s2(x), this patient will be allocated
to treatment 1. If the third random number has value greater than or equal to F as1,s2(x)
and less than or equal to 1, this patient will be allocated to treatment 2.
3.7.2 Algorithms for marginal balance
Marginal balancing balances the numbers of patients on the two treatments marginally
for each level of the covariates. For example, suppose that the two covariates have three
levels. Denote the three levels of the two covariates by a1, a2 and a3 and b1, b2 and b3.
We aim to balance the numbers of patients on the two treatments at each level of the
covariates. In other words, we balance across the levels {a1, a2, a3} of the first covariate
and balance across the levels {b1, b2, b3} of the second covariate. The patient’s prog-
nostic profile is recorded upon arrival at a clinical centre and classifies the patient into
one of the three levels of both covariates. Suppose that we have made m assignments
so far and the prognostic profile of this next patient is level a1 for the first covariate and
level b1 for the second covariate. First, we have to calculate the current imbalance in the
numbers of patients on treatments 1 and 2 at level a1 for the first covariate for all levels
of the second covariate, that is, Dm(a1). We then calculate the imbalance at level b1 for
the second covariate for all levels of the first covariate, Dm(b1).
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From Section 3.3, the overall imbalance afterm assignments is
D¯m = c1Dm(a1) + c2Dm(b1),
where c1 and c2 are integers representing the weights given to Dm(a1) and Dm(b1),
respectively. This overall imbalance is used for treatment assignments in marginal bal-
ance. More specifically, we either consider the overall imbalance as D¯m = Dm(ai), for
i = 1, .., 3, so that c1 = 1 and c2 = 0, or D¯m = Dm(bi) for i = 1, .., 3, so that c1 = 0
and c2 = 1. In other words, we only consider the levels of one of the covariates.
In the simulations for marginal balance, the prognostic profile of a patient is created
in exactly the same way as in the global balancing case. By using the two random
numbers generated from a uniform distribution between 0 and 1, we can identify the
levels of the two covariates for each patient. For the (m + 1)th patient, we can then
calculate the overall imbalance D¯m. Similar to global balancing, based on the sign of
the overall imbalance D¯m = Dm(a1) or D¯m = Dm(b1), we will know the current under-
represented treatment. A third random number is generated for each patient from a
uniform distribution between 0 and 1 for treatment assignment.
Under covariate-adaptive simple random sampling for marginal balance, the sign of
D¯m is ignored for treatment assignment. The assignment is made to treatment 1 if the
third random number for this patient has value greater than or equal to 0 and less than
0.5. Similarly, assignment is made to treatment 2 if the third random number has value
greater than or equal to 0.5 and less than or equal to 1.
Under the covariate-adaptive biased coin design, we will have a probability p > 1/2
of allocating the next patient to the treatment that has been chosen less often. As we
know the sign of D¯m, we know which is the under-represented treatment. If the third
random number for this patient has value greater than or equal to zero and less than p,
we will allocate this patient to the treatment that has fewer patients based on D¯m. If the
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third random number has values greater than or equal to p and less than or equal to 1,
then this patient will be allocated to the treatment that has more patients.
Finally, under the covariate-adaptive adjustable biased coin design for marginal bal-
ance, the next patient is allocated to treatment 1 with probability F a(x) where x = D¯m.
If the third random number for this patient has value greater than or equal to zero and
less than F a(x), treatment 1 will be allocated to this patient. If the third random number
has value greater than or equal to F a(x) and less than or equal to 1, then this patient is
allocated to treatment 2.
3.7.3 Model and test for treatment difference
In the simulations, interactions can either be present or absent between the covariates.
In both situations, we study the simulated power of the covariate-adaptive randomiza-
tion schemes for global and marginal balance. Two different models for the patients’
responses will be considered. Let Yij be the response of the ith patient on treatment j.
Then the model used for two covariates with no interaction is
Yij = µ1 + (µ2 − µ1)Ii + β1Zi1 + β2Zi2 + ²ij
and
Yij = µ1 + (µ2 − µ1)Ii + β1Zi1 + β2Zi2 + β3(Zi1 ∗ Zi2) + ²ij
when there is an interaction between the covariates.
We have Ii as defined in (3.1) for i = 1, ..., n, and β1 and β2 are the unknown
parameters for the first and second covariates Zi1 and Zi2, respectively. As the levels for
a covariate add up to zero, for two-level covariates we have either 1 or −1 for the values
of Zi1 and Zi2; and −1, 0 or 1 for the values of Zi1 and Zi2 when these two covariates
have three levels. The term Zi1 ∗ Zi2 denotes the interaction term for the two covariates
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and is the product of the two values from the first and the second covariate. Therefore,
for two-level covariates, the interaction term will take values of 1 or−1, and similarly for
three-level covariates, the interaction term will take values of −1, 0 or 1. The parameter
for the interaction term in this model is β3.
We can express the above two models in matrix form as in (3.2). The patients’
responses Yij and the random error terms ²ij are represented by the vectors Y and ²,
respectively. The matrixW here is exactly the same as in (3.2). This is an n× 2 matrix
with all ones in the first column and the values for Ii in the second column. The column
vector µ is also the same as in (3.2).
Next we have β = (β1, β2)
T when there is no interaction between the two covariates
and β = (β1, β2, β3)
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We construct a test of H0 : µ2 − µ1 = 0 against H1 : µ2 − µ1 > 0. The same
procedure will be applied as in Section 3.5. An analysis of covariance t test is used and
the power is simulated for the three covariate-adaptive randomization schemes under
global and marginal balance, when there are two or three levels for the covariates and
when interactions between the two covariates are either present or absent. This test has
a Student’s t distribution under H0 with n− 2− q degrees of freedom.
3.7.4 Power under global and marginal balance
We now study the numerical values for the power obtained using the above test by
simulation under the covariate-adaptive simple random sampling, the covariate-adaptive
biased coin design and the covariate-adaptive adjustable biased coin design. Let the total
number of patients in a trial be n. We will study two scenarios: n = 100 and n = 200.
Let β1 = 1, β2 = 0.75 and β3 = 3. For all i = 1, ..., n and j = 1, 2, when n = 100, the
random error term ²ij is generated from a standard normal distribution, whereas, when
n = 200, ²ij is generated from a normal distribution with mean 0 and standard deviation
1.5. Let the significance level of the test be α = 0.05.
We reject H0 when the test statistic is greater than some critical value from a Stu-
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dent’s t distribution. When n = 100, we have 95 degrees of freedom when there are
interactions and 96 degrees of freedom when there are no interactions. Similarly, when
n = 200, we have 195 and 196 degrees of freedom, respectively.
The adjusted means m1 and m2 described in Section 3.5 for treatments 1 and 2, re-
spectively, are calculated as the estimators of the population means µ1 and µ2. These
two adjusted means are needed in the numerator of the test statistic TC . To obtain the
estimator of the variance of µˆ2 − µˆ1 in the denominator of the test statistic, recall from
Section 3.5 that we need to use (3.6). Here, a is a column vector containing the coeffi-
cients in the linear combination of µ. In this case, we have µ2 − µ1 = (0, 1)µ. From
the above, we know that aT = (0, 1). Therefore, we have ̂Var(µˆ2 − µˆ1), which is the
estimator of the variance of µˆ2 − µˆ1 with aT = (0, 1) in (3.6).
We simulate each such trial 10, 000 times and record the number of times that H0 is
rejected. The proportion of rejections is calculated and represents the simulated power
of the test. The simulated power will be studied for different values of d¯ and different
values of the design parameters in the biased coin designs.
In what follows, we abbreviated covariate-adaptive simple random sampling, the
covariate-adaptive biased coin design and the covariate-adaptive adjustable biased coin
design by CSRS, CBCD and CABCD. The following four tables give values for the sim-
ulated power under global and marginal balance for three-level and two-level covariates
with interactions.
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Table 3.3: Powers of CSRS, CBCD and CABCD with interactions between the three-
level covariates when n = 100 and α = 0.05
Schemes d¯ = 0 d¯ = 0.25 d¯ = 0.5 d¯ = 0.75 d¯ = 1 d¯ = 1.25
Global Balance
CSRS(p=1/2) 0.053 0.329 0.782 0.977 0.999 1
CBCD(p=8/12) 0.053 0.349 0.795 0.981 1 1
CBCD(p=9/12) 0.051 0.337 0.795 0.979 0.999 1
CBCD(p=10/12) 0.049 0.339 0.802 0.981 1 1
CBCD(p=11/12) 0.050 0.338 0.801 0.983 1 1
CABCD(a=1) 0.049 0.335 0.795 0.981 0.999 1
CABCD(a=2) 0.050 0.344 0.795 0.979 1 1
CABCD(a=4) 0.050 0.342 0.797 0.980 1 1
Marginal Balance
CSRS(p=1/2) 0.050 0.341 0.791 0.978 1 1
CBCD(p=8/12) 0.048 0.335 0.788 0.979 1 1
CBCD(p=9/12) 0.047 0.337 0.784 0.979 0.999 1
CBCD(p=10/12) 0.049 0.346 0.790 0.978 0.999 1
CBCD(p=11/12) 0.054 0.345 0.797 0.978 1 1
CABCD(a=1) 0.052 0.334 0.785 0.976 1 1
CABCD(a=2) 0.050 0.350 0.792 0.979 0.999 1
CABCD(a=4) 0.050 0.332 0.790 0.980 0.999 1
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Table 3.4: Powers of CSRS, CBCD and CABCD with interactions between the three-
level covariates when n = 200 and α = 0.05
Schemes d¯ = 0 d¯ = 0.25 d¯ = 0.5 d¯ = 0.75 d¯ = 1 d¯ = 1.25
Global Balance
CSRS(p=1/2) 0.048 0.317 0.753 0.966 0.999 1
CBCD(p=8/12) 0.050 0.315 0.760 0.971 0.999 1
CBCD(p=9/12) 0.047 0.319 0.754 0.970 0.999 1
CBCD(p=10/12) 0.050 0.316 0.754 0.969 0.999 1
CBCD(p=11/12) 0.050 0.317 0.767 0.970 0.999 1
CABCD(a=1) 0.053 0.322 0.757 0.965 0.999 1
CABCD(a=2) 0.048 0.315 0.766 0.968 0.999 1
CABCD(a=4) 0.054 0.320 0.757 0.971 0.998 1
Marginal Balance
CSRS(p=1/2) 0.052 0.328 0.754 0.969 0.998 1
CBCD(p=8/12) 0.051 0.316 0.755 0.968 0.999 1
CBCD(p=9/12) 0.048 0.312 0.761 0.971 0.998 1
CBCD(p=10/12) 0.049 0.317 0.760 0.969 0.999 1
CBCD(p=11/12) 0.048 0.321 0.753 0.969 0.998 1
CABCD(a=1) 0.052 0.320 0.758 0.969 0.999 1
CABCD(a=2) 0.049 0.323 0.754 0.967 0.999 1
CABCD(a=4) 0.052 0.311 0.749 0.969 0.999 1
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Table 3.5: Powers of CSRS, CBCD and CABCDwith interactions between the two-level
covariates when n = 100 and α = 0.05
Schemes d¯ = 0 d¯ = 0.25 d¯ = 0.5 d¯ = 0.75 d¯ = 1 d¯ = 1.25
Global Balance
CSRS(p=1/2) 0.048 0.336 0.785 0.979 1 1
CBCD(p=8/12) 0.050 0.342 0.795 0.979 1 1
CBCD(p=9/12) 0.049 0.343 0.802 0.982 1 1
CBCD(p=10/12) 0.051 0.347 0.794 0.983 1 1
CBCD(p=11/12) 0.052 0.343 0.800 0.979 0.999 1
CABCD(a=1) 0.052 0.345 0.800 0.981 1 1
CABCD(a=2) 0.048 0.333 0.796 0.978 1 1
CABCD(a=4) 0.053 0.344 0.789 0.983 0.999 1
Marginal Balance
CSRS(p=1/2) 0.048 0.336 0.790 0.982 0.999 1
CBCD(p=8/12) 0.049 0.340 0.791 0.977 0.999 1
CBCD(p=9/12) 0.053 0.347 0.790 0.979 1 1
CBCD(p=10/12) 0.048 0.336 0.791 0.981 0.999 1
CBCD(p=11/12) 0.045 0.349 0.787 0.979 1 1
CABCD(a=1) 0.047 0.350 0.794 0.982 1 1
CABCD(a=2) 0.049 0.341 0.796 0.981 1 1
CABCD(a=4) 0.052 0.345 0.793 0.978 1 1
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Table 3.6: Powers of CSRS, CBCD and CABCDwith interactions between the two-level
covariates when n = 200 and α = 0.05
Schemes d¯ = 0 d¯ = 0.25 d¯ = 0.5 d¯ = 0.75 d¯ = 1 d¯ = 1.25
Global Balance
CSRS(p=1/2) 0.050 0.317 0.756 0.971 0.999 1
CBCD(p=8/12) 0.047 0.318 0.760 0.971 0.998 1
CBCD(p=9/12) 0.050 0.316 0.759 0.969 0.999 1
CBCD(p=10/12) 0.051 0.325 0.762 0.967 0.999 1
CBCD(p=11/12) 0.051 0.308 0.762 0.969 0.999 1
CABCD(a=1) 0.054 0.320 0.764 0.972 0.999 1
CABCD(a=2) 0.051 0.321 0.758 0.971 0.999 1
CABCD(a=4) 0.051 0.321 0.759 0.973 0.999 1
Marginal Balance
CSRS(p=1/2) 0.054 0.316 0.753 0.968 0.999 1
CBCD(p=8/12) 0.049 0.324 0.756 0.969 0.999 1
CBCD(p=9/12) 0.050 0.317 0.763 0.966 0.999 1
CBCD(p=10/12) 0.050 0.317 0.754 0.969 0.999 1
CBCD(p=11/12) 0.049 0.314 0.751 0.967 0.999 1
CABCD(a=1) 0.051 0.323 0.755 0.970 0.998 1
CABCD(a=2) 0.049 0.315 0.768 0.969 0.999 1
CABCD(a=4) 0.050 0.312 0.756 0.969 0.999 1
The first column in the tables shows the actual significance level of the test in each
scenario. Due to the variation in the simulations, we obtain values close to 0.05 but not
exactly this value. The power increases when d¯ increases. For the CBCD and CABCD,
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the power also increases when the design becomes more deterministic, that is, when p in
the CBCD and a in the CABCD increase. For a fixed sample size, we can see from the
tables that the power is highest for the CABCD and lowest for CSRS. This means that
the former design will require fewer patients than the other two to achieve the same level
of power.
Obviously, the simulated power under covariate-adaptive simple random sampling
gives the lowest power among all schemes. The standard error of the values in the
second column is
√
0.3× 0.7/10, 000 ≈ 0.004. For example, for 3-level covariates and
n = 100, the value of the power for CSRS under global balance is 0.329 and is 0.349 for
the CBCD with p = 8/12. The difference between the two powers is 0.02, which is more
than three standard errors. In addition, under marginal balance, the increase in the power
is around one to two standard errors. We can see that the increase in the power is greater
under global balance than marginal balance. These conclusions are also generally true
for other values of d¯ and when n = 200. Furthermore, the same conclusions apply when
there are only two levels for the covariates.
The results show a genuine increase in the power when using the covariate-adaptive
biased coin design instead of covariate-adaptive simple random sampling. In other
words, the covariate-adaptive biased coin design achieves a more balanced trial than
covariate-adaptive simple random sampling when patients are classified according to
their prognostic profiles. In addition, both covariate-adaptive designs gain more power
when we consider global balance instead of marginal balance when there are interactions
between the covariates.
In the situation without covariates, the adjustable biased coin design has been proved
theoretically to give a more balanced trial than Efron’s biased coin design. We will
first discuss the difference in the simulated powers for the covariate-adaptive adjustable
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biased coin design and the covariate-adaptive biased coin design when there is an inter-
action between the covariates. As p in the covariate-adaptive biased coin design and a
in the covariate-adaptive adjustable biased coin design increase, theoretically both of the
designs will become more deterministic in treatment allocation and hence increase the
power. From the values of the simulated power obtained, for both two-level and three-
level covariates and when n = 100 or n = 200, under the CABCD, the increase in the
power when a increases is not very obvious. It shows around one to two standard errors
of variation with different values of a in the above four tables for global and marginal
balance. The tables also suggested that the power under the CBCD shows no obvious
increase when p increases. For both global and marginal balance, the variation in the
power is less than two standard errors.
We can see that, when there is an interaction between the covariates, there is no dif-
ference in the powers between global and marginal balance for covariate-adaptive simple
random sampling. However, global balance gives around 1% more power than marginal
balance under the covariate-adaptive biased coin design and the covariate-adaptive ad-
justable biased coin design. This means that, under these two covariate-adaptive ran-
domization schemes, global balance is more efficient at detecting a genuine treatment
difference than marginal balance.
However, by comparing the powers obtained under global balance for two-level and
three-level covariates, there is no obvious difference in their values for the same value
of d¯ under the three covariate-adaptive randomization schemes. Therefore, we cannot
conclude in the case where there are interactions between covariates whether two-level
or three-level covariates give a higher power under global balance. This conclusion holds
for marginal balance as well.
Next, the simulated power will be shown in the following four tables for the covariate-
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adaptive randomization schemes when there are no interactions between the two covari-
ates under global and marginal balance.
Table 3.7: Powers of CSRS, CBCD and CABCD with no interactions between the three-
level covariates when n = 100 and α = 0.05
Schemes d¯ = 0 d¯ = 0.25 d¯ = 0.5 d¯ = 0.75 d¯ = 1 d¯ = 1.25
Global Balance
CSRS(p=1/2) 0.049 0.331 0.789 0.977 1 1
CBCD(p=8/12) 0.050 0.336 0.795 0.978 1 1
CBCD(p=9/12) 0.047 0.343 0.799 0.981 1 1
CBCD(p=10/12) 0.049 0.346 0.797 0.982 0.999 1
CBCD(p=11/12) 0.046 0.342 0.792 0.981 1 1
CABCD(a=1) 0.049 0.348 0.794 0.980 0.999 1
CABCD(a=2) 0.049 0.343 0.797 0.978 0.999 1
CABCD(a=4) 0.053 0.338 0.799 0.979 0.999 1
Marginal Balance
CSRS(p=1/2) 0.047 0.333 0.789 0.978 0.999 1
CBCD(p=8/12) 0.048 0.334 0.789 0.979 1 1
CBCD(p=9/12) 0.048 0.344 0.798 0.980 1 1
CBCD(p=10/12) 0.052 0.339 0.794 0.977 1 1
CBCD(p=11/12) 0.049 0.337 0.798 0.979 0.999 1
CABCD(a=1) 0.051 0.338 0.792 0.980 0.999 1
CABCD(a=2) 0.051 0.353 0.795 0.977 1 1
CABCD(a=4) 0.051 0.335 0.795 0.979 0.999 1
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Table 3.8: Powers of CSRS, CBCD and CABCD with no interactions between the three-
level covariates when n = 200 and α = 0.05
Schemes d¯ = 0 d¯ = 0.25 d¯ = 0.5 d¯ = 0.75 d¯ = 1 d¯ = 1.25
Global Balance
CSRS(p=1/2) 0.048 0.320 0.752 0.970 0.999 1
CBCD(p=8/12) 0.049 0.314 0.764 0.967 0.999 1
CBCD(p=9/12) 0.046 0.315 0.763 0.971 0.998 1
CBCD(p=10/12) 0.056 0.327 0.763 0.971 0.999 1
CBCD(p=11/12) 0.051 0.311 0.767 0.972 0.999 1
CABCD(a=1) 0.049 0.323 0.758 0.968 0.999 1
CABCD(a=2) 0.053 0.326 0.757 0.972 0.999 1
CABCD(a=4) 0.051 0.318 0.760 0.970 0.999 1
Marginal Balance
CSRS(p=1/2) 0.050 0.314 0.748 0.965 0.999 1
CBCD(p=8/12) 0.056 0.316 0.751 0.967 0.999 1
CBCD(p=9/12) 0.049 0.312 0.755 0.968 0.998 1
CBCD(p=10/12) 0.049 0.317 0.760 0.969 0.999 1
CBCD(p=11/12) 0.043 0.318 0.766 0.970 0.999 1
CABCD(a=1) 0.047 0.314 0.761 0.971 0.999 1
CABCD(a=2) 0.053 0.323 0.752 0.971 0.998 1
CABCD(a=4) 0.049 0.322 0.750 0.968 0.998 1
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Table 3.9: Powers of CSRS, CBCD and CABCD with no interaction between the two-
level covariates when n = 100 and α = 0.05
Schemes d¯ = 0 d¯ = 0.25 d¯ = 0.5 d¯ = 0.75 d¯ = 1 d¯ = 1.25
Global Balance
CSRS(p=1/2) 0.051 0.335 0.794 0.975 0.999 1
CBCD(p=8/12) 0.051 0.333 0.803 0.983 1 1
CBCD(p=9/12) 0.050 0.352 0.798 0.981 1 1
CBCD(p=10/12) 0.052 0.343 0.796 0.981 0.999 1
CBCD(p=11/12) 0.049 0.343 0.801 0.982 1 1
CABCD(a=1) 0.049 0.339 0.790 0.979 0.999 1
CABCD(a=2) 0.049 0.345 0.797 0.981 1 1
CABCD(a=4) 0.053 0.345 0.794 0.981 1 1
Marginal Balance
CSRS(p=1/2) 0.049 0.333 0.789 0.979 1 1
CBCD(p=8/12) 0.048 0.348 0.789 0.982 0.999 1
CBCD(p=9/12) 0.051 0.338 0.795 0.982 0.999 1
CBCD(p=10/12) 0.047 0.343 0.792 0.981 1 1
CBCD(p=11/12) 0.050 0.346 0.800 0.980 0.999 1
CABCD(a=1) 0.047 0.346 0.796 0.980 0.999 1
CABCD(a=2) 0.056 0.333 0.802 0.980 0.999 1
CABCD(a=4) 0.055 0.346 0.798 0.982 0.999 1
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Table 3.10: Powers of CSRS, CBCD and CABCD with no interaction between the two-
level covariates when n = 200 and α = 0.05
Schemes d¯ = 0 d¯ = 0.25 d¯ = 0.5 d¯ = 0.75 d¯ = 1 d¯ = 1.25
Global Balance
CSRS(p=1/2) 0.052 0.325 0.752 0.967 0.999 1
CBCD(p=8/12) 0.051 0.316 0.763 0.969 0.999 1
CBCD(p=9/12) 0.051 0.321 0.755 0.965 0.999 1
CBCD(p=10/12) 0.049 0.325 0.761 0.969 0.999 1
CBCD(p=11/12) 0.049 0.327 0.753 0.970 0.999 1
CABCD(a=1) 0.050 0.315 0.759 0.970 0.999 1
CABCD(a=2) 0.050 0.309 0.757 0.967 0.999 1
CABCD(a=4) 0.050 0.321 0.756 0.971 0.999 1
Marginal Balance
CSRS(p=1/2) 0.047 0.319 0.753 0.967 0.998 1
CBCD(p=8/12) 0.051 0.314 0.756 0.967 0.999 1
CBCD(p=9/12) 0.046 0.310 0.760 0.967 0.999 1
CBCD(p=10/12) 0.055 0.313 0.761 0.968 0.999 1
CBCD(p=11/12) 0.051 0.324 0.754 0.970 0.999 1
CABCD(a=1) 0.054 0.321 0.757 0.968 0.999 1
CABCD(a=2) 0.052 0.317 0.749 0.967 0.999 1
CABCD(a=4) 0.049 0.323 0.759 0.971 0.999 1
When there is no interaction between the two covariates, the powers are similar for
global and marginal balance under all three covariate-adaptive randomization schemes.
Covariate-adaptive simple random sampling again gives the lowest power for each value
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of d¯. We cannot conclude whether global balance or marginal balance is better when
there is no interaction between the covariates. In this case, we can say that global balance
is as good as marginal balance when there is no interaction between the covariates. In
addition, under each of the covariate-adaptive randomization schemes, it is not clear
whether two-level or three-level covariates give a higher power under global or marginal
balance.
3.8 Conclusions
Covariate-adaptive randomization schemes provide methods for patient allocation
when we want to study treatment effects in patients classified by prognostic factors. This
is to ensure that we have the same numbers of patients in the two treatment groups for
each combination of the covariates’ profiles. One of the main aims of covariate-adaptive
randomization schemes is to balance the numbers of patients on the two treatments with
patients classified by their prognostic factors. Under any such scheme, we can further
achieve global or marginal balance. When there are two covariates, the simulated power
obtained under global balance is higher than that under marginal balance when there
are interactions between the covariates. The powers obtained are similar for global and
marginal balance when there are no interactions between the covariates.
Numerical values for the power using a normal approximation are also given under
covariate-adaptive simple random sampling and the biased coin design when a single
covariate is uniformly distributed. It is shown that these values for the power over-
approximate the actual value for the power in both cases. This will cause the planner
for the trial to prepare less resources than are needed to achieve a particular level of
power for the study. For example, we can estimate the sample size needed to achieve a
certain level of power by the normal approximation method. However, in reality, under
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both randomization schemes, this sample size will give a power too low. The theoret-
ical properties and the expression for the normal approximation to the power when we
consider more than one covariate are also provided.
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Chapter 4
Randomization schemes with more
than two treatments
In the previous two chapters, we studied different randomization schemes and their
power properties when two treatments are compared in a clinical trial. It is sometimes
more efficient to compare several treatments in the same trial for ease of comparison and
to identify their effects. In this chapter, we consider different randomization schemes
when there are more than two treatments.
4.1 Introduction
Most of the randomization schemes that we have studied and which are considered
in the literature are based on trials with two treatments. Here, assume that patients enter
a clinical trial sequentially and have to be assigned immediately to one of K > 2 treat-
ments. Assume also that the variances of the patients’ responses on different treatments
are the same. It will be most efficient to have a balanced trial. These randomization
schemes will have to maintain a balance in the numbers of patients across the K treat-
ments and preserve randomness in the allocation. The assignment rules for these ran-
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domization schemes can be based on different criteria. One of the most commonly used
criteria is the number of patients currently on each of the treatments. For each new pa-
tient, the probabilities of assigning this patient to each of the K treatments are obtained
by incorporating this information into the calculations. The probabilities obtained may
be all different or some of them may be the same. The larger the probability for a given
treatment, the more likely the next patient will be allocated to that particular treatment.
In most cases, the goal is to obtain a larger probability of assigning the next patient to an
under-represented treatment. Another criterion used for treatment assignment is the im-
balance across treatments. The imbalance is defined in the two-treatment case as simply
the difference in the numbers of patients on the two treatments. In the case of more than
two treatments, the imbalance at each stage for each treatment has to be defined.
In Section 4.2, different randomization schemes for more than two treatments will be
introduced. Their probabilities of assigning the next patient to the different treatments
will also be given. In addition, a new class of designs called the adjustable biased coin
design will be proposed such that each assignment is made based on all of the current
imbalances at each stage. The values for these imbalances are incorporated into the prob-
abilities of assignment to all K treatments at each stage. Section 4.3 will be concerned
with comparing the covariances of the numbers of patients on different treatments un-
der complete randomization and the biased coin design. In Section 4.4, the asymptotic
properties of the randomization schemes will be described. This is followed by simula-
tions of the imbalances under different randomization schemes in Section 4.5, where the
finite-sample behaviour of the imbalances under different randomization schemes will
be demonstrated. In Section 4.6, numerical values for the power of an F test are given
by simulation for different randomization schemes. Finally, conclusions will be drawn
in Section 4.7. Note that, similar to previous chapters, treatment 1 is always the standard
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treatment. The patients that are allocated to this treatment group form the control group.
4.2 Classes of treatment assignment rules
4.2.1 Complete randomization
Under complete randomization, each patients is equally likely to be assigned to one
of theK treatments. In other words, the probability of allocating treatment j to a patient
for each j = 1, ..., K is 1/K. These probabilities remain the same for all stages. This
design ignores the current numbers of patients on the treatments at each stage. Complete
randomization gives the highest level of randomness in assignment among all schemes
and selection bias is a minimum. Selection bias refers to the bias where the experi-
menter’s decision depends on the suitability of a subject, and is discussed by Blackwell
and Hodges (1957) and Efron (1971). However, complete randomization is more likely
to produce severe imbalances in the numbers of patients across the treatments.
4.2.2 Permuted-block randomization
Permuted-block randomization is another example of a randomization scheme for
several treatments. The block length and the proportion of patients allocated to a partic-
ular treatment within a block are pre-specified. The sequence of treatments is randomly
permuted within a block. By combining the sequences for all blocks, a complete se-
quence for the treatment assignments is formed. Each patient arrives in a trial and is
allocated to a treatment following this sequence. Under permuted-block randomization,
an equal proportion of patients is usually allocated to each treatment in order to balance
the numbers of patients across the treatment groups. In addition, the block size or the
length of the block K1 can be chosen to be a multiple of the number of treatments in
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the trial so as to obtain a balance across the treatment groups for every K1 patients in
the trial. Permuted-block randomization is very efficient at maintaining a balance in the
numbers of patients across the treatment groups. However, the assignments are very
deterministic and the selection bias for this design is very high.
In this chapter, we will not consider permuted-block randomization. In practice, a
clinical trial can be carried out in different centres. The assignment rules for different
centres may be the same or different. When a patient arrives at a particular centre,
the assignment rules for this particular centre will be applied. This is called a centre-
stratified randomization scheme and centre-stratified permuted-block randomization will
be discussed in the next chapter.
4.2.3 Efron’s biased coin design
The biased coin design introduced by Efron (1971) gives a compromise between
randomness and maintaining balance in the treatment allocation. Under the biased coin
design for two-treatment trials, we have a fixed probability p > 1/2 of allocating the next
patient to a treatment that has been chosen less often and 1− p otherwise. This idea can
be extended to the case of more than two treatments. The aim is to balance the proportion
of patients on each of the treatments. We have a fixed probability p > 1/K of allocating
the next patient to the treatment that has the least number of patients. Furthermore, the
probability of allocating the next patient to one of the other treatments is (1−p)/(K−1).
If we have more than one treatment that has the least number of patients, the following
can be applied. Let n∗ be the number of treatments that have the least number of patients.
Then, for a chosen probability p > 1/K, we have p/n∗ as the probability of assigning
the next patient to one of the n∗ treatments and (1 − p)/(K − n∗) as the probability of
allocating the next patient to one of the other treatments.
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4.2.4 Optimum biased coin design
In Atkinson (1982, 2004), the ideas of D- and DA-optimality are used to obtain the
probabilities in the biased coin design for allocating the next patient to one of the K
treatments. The linear model E(y) = xTβ is for the responses of the patients, which
are independent and have variance σ2. The variance of the least square estimates of β
is Var(βˆ) = σ2(XTX)−1, where the p × p information matrix XTX is assumed to be
of full rank from n observations. In the construction of optimum experimental designs,
let the measure be ξn for an n-point design over the design region X. The information
matrix for this design isM(ξn) = n−1(XTX). The fitted value is yˆ(x) = βˆTx at x with
variance Var{yˆ(x)} = σ2xT (XTX)−1x. The scaled variance of the predicted responses
is Var{yˆ(x)}/σ2. The standardized variance is obtained by scaling the variance by σ2
and the number of observations, so that it is given by




To achieveD-optimality, the determinant ofM(ξn) is maximized and this minimizes the
variances of the estimates of the parameters. For an n-point design, the (n + 1)st point
is added where d(x, ξn) is a maximum.
If all of the parameters in the model are of interest, the D-optimal criterion will be
appropriate. Alternatively, if the contrasts between the treatment effects are of interest,
the DA-optimal criterion can be used. For most of this chapter, the DA-optimal crite-
rion will be appropriate to use instead of the D-optimal criterion. The contrasts are s
linear combinations. These are the components of the vectorATβ, whereA is an p× s
matrix with rank s < p. The least squares estimate of the contrast vector will be de-
noted byAT βˆ. The covariance matrix ofAT βˆ is proportional toATM−1(ξn)A and the
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standardized variance is given by
dA(x, ξn) = x
TM−1(ξn)A{ATM−1(ξn)A}−1ATM−1(ξn)x.
Sequential DA -optimum designs are generated one point at a time by adding an obser-
vation at x where dA(x, ξn) is a maximum.
In a clinical trial with K > 2 treatments, we will study the design region X which
consists ofK points. Here, we replace d(x, ξn) and dA(x, ξn)with d(j, ξn) and dA(j, ξn),
respectively. The sequential construction of theD- or theDA- optimum designs allocates
the (n+1)st patient to the treatment such that its respective standardized variance d(j, ξn)
or dA(j, ξn) is maximized.










for theDA-optimal biased coin design. Assume that the s = (K− 1)-dimensional space
of the contrasts is orthogonal to the overall mean for which the matrix AT is arbitrary.
Then the standardized variance can be written as
dA(j, ξn) = (n− nj)/nj = rj − 1,
where rj = n/nj is the reciprocal of the proportion of patients on treatment j. Under
the DA-optimality criterion, the probability of allocating treatment j for j = 1, ..., K to






4.2.5 Wei’s class of biased coin designs
A class of treatment assignment rules was suggested byWei (1978) for more than two
treatments. Suppose that, in a clinical trial after n assignments, there are nj,n patients
on treatment j for j = 1, ..., K such that
∑K
j=1 nj,n = n. Let p be the K × 1 vector
p = (p1, p2, ..., pK)
T ,where pj is the probability of allocating treatment j to the (n+1)st
patient. Then the vector p is a function of the vector (n1,n/n, n2,n/n, ..., nK,n/n)
T and
has the following properties.
1. The vector p is a function from Ω to Ω where
Ω =
{







2. If yi < yj , then pi ≥ pj and, if yi = yj , then pi = pj for i 6= j and i, j = 1, ..., K.
3. We have pj (y1, ..., yj−1, 1/K, yj+1, ..., yK) = 1/K for all yi such that i 6= j and
i = 1, ..., K. In addition,
∑
i6=j yi = 1− 1/K.
4. Finally, pj(y) is continuous at the point (1/K, ..., 1/K)
T for j = 1, ..., K.
The numbers of patients on the treatments after n assignments are represented by the
vector Dn = (n1,n, n2,n, ..., nK,n)
T . This vector forms a Markov chain with transition
probabilities
pj (Dn/n) = P
{
Dn+1 = (n1,n, ..., nK,n)
T + ej|Dn = (n1,n, ..., nK,n)T
}
,
where ej is a K × 1 vector which contains 1 in its jth component and zeros elsewhere
for j = 1, ..., K. Wei (1978) proves that E(nj,n) = n/K and E[pj(Dn/n)] = 1/K,
and also that Dn/n → (1/K, ..., 1/K)T in probability as n → ∞. It is also shown by
induction that the variance of the number of patients on treatment j after n assignments
under this class of treatment assignment rules is smaller than the corresponding variance
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under complete randomization. In the next section, these results will be extended to the
covariance of the numbers of patients on any two treatments.
4.2.6 Smith’s extension of Wei’s class of biased coin designs
Wei’s class of treatment assignment rules was extended by Smith (1984). A new
procedure was proposed by generalizing Wei’s procedure to achieve a limiting design
measure (ξ1, ..., ξK) for ξj ≥ 0, j = 1, ..., K and
∑K
j=1 ξj = 1. Here, we want the
limiting proportion of patients allocated to treatment j to be ξj . In this case, all ξj for
j = 1, .., K are known at the start of the trial. The vector p has to satisfy two properties.
1. The vector p is twice continuously differentiable on Ω.
2. If yj ≥ ξj , then pj(y) ≤ ξj .
The main result is given as the following theorem. Let ρ be the parameter which is
the sum of all the limiting proportions of patients allocated to the treatments such that
ρ =
∑K
j=1 ξj . Further, let δj,n be 1 if the nth patient is allocated to treatment j and 0
otherwise. Then we have the approximation
Cov(nj,l, nm,n) ≈

(1 + 2ρ)−1l1+ρn−ρ(ξj − ξ2j ), j = m,
−(1 + 2ρ)−1l1+ρn−ρξjξm, j 6= m,
for l ≤ n as l→∞ with the joint distributions asymptotically normal and
Cov(δj,l, δm,n) ≈

ξj − ξ2j , l = n, j = m,
−ξjξm, l = n, j 6= m,
−ρ(1 + ρ)(1 + 2ρ)−1lρn−1−ρ(ξj − ξ2j ), l 6= n, j = m,
ρ(1 + ρ)(1 + 2ρ)−1lρn−1−ρξjξm, l 6= n, j 6= m.
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The above two approximations for the covariances are very useful in obtaining the
asymptotic form of the covariance matrix underWei’s class of biased coin designs. These
will be given explicitly in Section 4.4.
4.2.7 The adjustable biased coin design
The idea of the biased coin assignment rule can be extended to situations where
more than two treatments are used in a trial. The simplest case was given for Efron’s
biased coin assignment rule in Section 4.2.3. This assignment rule only depends on the
number of patients on each treatment at each stage. The probabilities are fixed and do
not take into account the numbers of patients on all treatments at different stages and
the degree of imbalance at different stages. A new class of treatment assignment rules
is now suggested. Here, the probability of assigning the next patient to treatment j is
calculated by taking into account the imbalances on all treatments.
The imbalance on treatment j at stage n is defined by
∆j,n = nj,n − n
K
.
At each stage n, the imbalance shows the difference between the number of patients on
treatment j and the average number of patients per treatment. When the imbalance is
zero, this implies that we have an average number of patients on treatment j at stage n
and that there is no imbalance. A negative imbalance shows that treatment j is under-
represented with fewer patients than the average at stage n and vice versa for a positive
imbalance. The sum of these imbalances at any stage n is 0, that is,
∑K
j=1∆j,n = 0.
Let Fj(z) be a function of the current imbalance on treatment j. This function will be
different according to the sign of the current imbalance. Define this function as Fj : R→
[0, 1], where R is the set of real numbers. Then the function depends on the value z ∈
∆j,n for any treatment j after n assignments. For a particular stage n and treatment j, the
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imbalance is zero when the number of patients on treatment j equals the average number
of patients per treatment. So, at stage n+ 1, we define Fj(z) = 1/K. If the value of the
imbalance is negative, which means that treatment j is under-represented, we will need
more patients on this treatment to achieve a balanced trial. Therefore, for the (n + 1)st
assignment, we should have Fj(z) > 1/K. Similarly, for a positive imbalance, there
are more patients on treatment j than on average, and we should have Fj(z) < 1/K.
The values for Fj(z) take into account the degree of imbalance on treatment j at stage
n. The function Fj(z) is not symmetric and is decreasing. More specifically, after n




|z|+K , z > 0,
1
K
, z = 0,
|z|+1
|z|+K , z < 0,
where z ∈ ∆j,n.








j=1 pj = 1. As Fj(z) depends on the imbalance on treatment j, the probability
pj of the next patient being allocated to treatment j depends on Fi(z) for all treatments
i = 1, ..., K and is therefore obtained from the imbalances on all treatments from the
previous stage. We call this class of designs the adjustable biased coin design.
Remark For the above design, assume that K = 2. Then the probability pj for
j = 1, 2 of assigning the next patient to treatment j becomes pj = Fj(z), as the denom-
inator in (4.1) is
∑2
i=1 Fi(z) = 1. It is clear that this does not give the same results as
the adjustable biased coin design for two treatments proposed by Baldi Antognini and
Giovagnoli (2004). Recall from Chapter 2 that pj = Fa(x) for this design. For K = 2,
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the value z in Fj(z) is the difference between the number of patients on treatment j for
j = 1, 2 and the average number of patients on each treatment up to n assignments. This
z can be any real number. However, the value x in Fa(x) is the difference between the
number of patients on treatment 1 and the number of patients on treatment 2. The values
for x can only be integers and this is the imbalance defined by Baldi Antognini and Gio-
vagnoli (2004) for their adjustable biased coin design. This means that the imbalances
for the two designs are different.
4.3 Comparison of the covariances under complete ran-
domization and Wei’s class of biased coin designs
In this section, we will compare the covariances of the numbers of patients on any
two treatments for complete randomization and Wei’s class of biased coin designs. We
want to show by induction that the covariances under complete randomization are at
least as large as those under Wei’s class of biased coin designs.
Let Sn = (L1,n, ..., LK,n)
T be theK × 1 vector, where Lj,n is the number of patients
on treatment j after n assignments under complete randomization. It is clear that Sn
has a multinomial distribution with parameters n and p. Under complete randomization,
each patient is equally likely to be assigned to one of the K treatments. The probability
pj of assigning treatment j to the next patient will be 1/K for j = 1, ..., K. So the
covariance of the numbers of patients on treatment j and m for j 6= m and j,m =
1, ..., K is Cov(Lj,n, Lm,n) = −npjpm = −n/K2 after n assignments. We want to
show that Cov(Lj,n, Lm,n) ≥ Cov(nj,n, nm,n) for all n ≥ 1 and j 6= m. Now, if n =
1, the covariance under complete randomization is Cov(Lj,1, Lm,1) = −1/K2. Under
the biased coin design, the assignment rule for the first assignment is just complete
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randomization. Therefore, if n = 1, we have Cov(Lj,1, Lm,1) ≥ Cov(nj,1, nm,1). We
assume that the result holds at stage n, so that
Cov(Lj,n, Lm,n) ≥ Cov(nj,n, nm,n)
for j 6= m and j,m = 1, ..., K.
We can write the covariance after n+ 1 assignments for the biased coin design as
Cov(nj,n+1, nm,n+1) = E[{nj,n+1 − E(nj,n+1)}{nm,n+1 − E(nm,n+1)}]
= E
[{
nj,n+1 − n+ 1
K
}{







nj,n+1 − n+ 1
K
}{
nm,n+1 − n+ 1
K
}] ∣∣∣∣Dn) .
After n + 1 assignments, for any treatment j = 1, ..., K, the number of patients on
treatment j will be nj,n+1 = nj,n or nj,n+1 = nj,n+1. Now consider treatmentm where
m 6= j and m = 1, ..., K. If nj,n+1 = nj,n, we will have either nm,n+1 = nm,n + 1 or
nm,n+1 = nm,n. However, if nj,n+1 = nj,n + 1, then nm,n+1 = nm,n. Let qj(Dn/n) =
1− pj(Dn/n) for any treatment j = 1, ..., K, so that pj(Dn/n) + qj(Dn/n) = 1.
Using the above, the covariance for the biased coin design after n + 1 assignments
can be written as
E
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By combining the three expectations, the covariance of nj,n+1 and nm,n+1 for the













































































































































































Since we know that, for any treatment j, E {pj (Dn/n)} = 1/K and E(nj,n) = n/K,
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Further, we know that Cov(nj,n, nm,n) = E {(nj,n − n/K) (nm,n − n/K)}, and so





































































































We know that, for any treatment j, 0 ≤ pj (Dn/n) ≤ 1. The covariance of Lj,n+1 and
Lm,n+1 is Cov(Lj,n+1, Lm,n+1) = −(n + 1)/K2 = Cov(Lj,n, Lm,n)− 1/K2. It is clear
that, for Wei’s class of biased coin designs, if nj,n−n/K = 0, then pj(Dn/n) = 1/K. If
nj,n−n/K > 0, then pj(Dn/n) < 1/K, and, if nj,n−n/K < 0, then pj(Dn/n) > 1/K.













































Cov(nj,n+1, nm,n+1) ≤ Cov(Lj,n+1, nm,n+1).
4.4 Asymptotic properties of randomization schemes
One of the main aims of randomization schemes in clinical trials is to achieve balance
in the numbers of patients across treatment groups. It is clear that, for any treatment
j = 1, ..., K, Lj,n/n→ 1/K almost surely under complete randomization and nj,n/n→
1/K almost surely under the biased coin design as n→∞.
4.4.1 Complete randomization



















in distribution as n→∞. Here,NK(0,Σc) represents a multivariate normal distribution
with mean vector aK × 1 vector of zeros and theK ×K covariance matrix Σc. For any




















since Lj,n has a binomial distribution with parameters n and 1/K. For any two different


























The covariance matrixΣc hasΣcj,j as its jth diagonal element andΣ
c
j,m as element (j,m).
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4.4.2 Wei’s class of biased coin designs with Smith’s approximation
The approximation for the covariance of the numbers of patients on two different
treatments was obtained by Smith (1984) and is given in Section 4.2.6. We will only look
at a particular stage n. For this class of biased coin designs, we aim to achieve the same
limiting proportion of patients on each treatment. Therefore, the limiting proportion is
ξj = 1/K for j = 1, ..., K and ρ =
∑K


















in distribution as n → ∞. For any stage n, the covariance matrix Σw can be obtained















































The K ×K covariance matrix has Σwj,j as its jth diagonal element and Σwj,m as element
(j,m). It is clear that, with Smith’s approximation, both the variance and the covariance
are one-third of their respective values under complete randomization.
4.4.3 DA-optimum biased coin design
In the case where there are only two treatments, Smith (1984) studied Wei’s (1978)
class of designs when f : [−1, 1] → [0, 1] is the conditional probability that the next
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patient is allocated to treatment 1 given the numbers of patients n1 and n2 on treatments
1 and 2, respectively. This function is differentiable at 0 with special case
p(n1, n2) = ft(x) =
(1− x)t






When t = 1 or 2, this is the same as Atkinson’s (1982) designs. The asymptotic prop-
erties of Smith’s class of designs apply to Atkinson’s designs when there are two treat-
ments.
Smith (1984) showed that, forK ≥ 2, the probabilities pj in Atkinson’sDA-optimum
biased coin design satisfy the two conditions in Section 4.2.6 with ξj = 1/K for all


















in distribution as n→∞.
4.4.4 Efron’s biased coin design
For Efron’s biased coin design, the assignment is made based on the numbers of
patients on the treatments from the previous stage. There is a fixed probability p > 1/K
of allocating the next patient to the treatment that has been chosen least often. This
probability is a fixed constant instead of a continuous function used in Wei’s class of
biased coin designs.
In Hu, Zhang and He (2009), Efron’s biased coin design is a special case of the
efficient randomized-adaptive design which is a family of response-adaptive designs and
asymptotically attains a lower bound for the variance of the allocation proportion. Hu,
Rosenberger and Zhang (2006) state that any procedure that attains the lower bound is
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asymptotically best. For K > 2 treatments, the asymptotic properties of the response-
adaptive design are given. The regularity conditions are as follows.
• The parameter spaceΘj is an open subset of Rd, d ≥ 1, for j = 1, ..., K.
• The limiting proportion of patients on treatment j for j = 1, ..., K is ρj(θ) and
ρ(θ) = (ρ1(θ), ..., ρK(θ))




almost surely as n→∞.









− (ρ1(θ), ..., ρK(θ))T
]
→ NK(0, V (θ))
in distribution as n→∞.
A procedure is said to be asymptotically best if V (θ) attains the lower bound
B(θ) = ∇ρ(θ)I−1(θ)∇ρ(θ)T ,
where I(θ) = diag{ρ1(θ)I1(θ1), ..., ρK(θ)IK(θK)} and Ij(θj) is the information matrix








when the above conditions hold, Σ1(θ) = diag{ρ(θ)} − ρ(θ)ρ(θ)T and γ is some non-
negative integer. When γ = 0, the procedure becomes deterministic. The larger the
value of γ, the greater the randomness in the design. As γ → ∞, 1/(1 + 2γ) → 0 and
2(1 + γ)/(1 + 2γ) → 1, so that V (θ) attains the lower bound B(θ). In other words, as
γ →∞, the response-adaptive design is asymptotically the best.
Under Efron’s biased coin design for K > 2 treatments, the limiting proportion of
patients on treatment j is ρj = 1/K for j = 1, ..., K, so that ρ(θ) = (1/K, ..., 1/K)T .
135


















→ (0, ..., 0)T
in probability as n→∞.
4.5 Imbalance for different randomization schemes
In this section, we will study the imbalance in the numbers of patients on the treat-
ments for four different randomization schemes, complete randomization, Efron’s biased
coin design,DA-optimal randomization and our new class of randomization schemes, the
adjustable biased coin design. It is always most efficient to test for treatment differences
using balanced treatment groups when the variances of patients’ responses on different
treatments are the same. Imbalances reduce the power of the test.
We define the overall imbalance across treatments to be a vector which contains
the imbalances ∆j for j = 1, ..., K, which are the imbalances obtained at stage n. In
other words, we have ∆j = ∆j,n for j = 1, ..., K in the vector. Denote this vector by
∆ = (∆1,∆2, ...,∆K)




in probability as n→∞. This result holds for each of the four randomization schemes.
We are interested in the asymptotic distribution and the properties of the imbalances
under these designs. For any particular treatment j,
√
n(nj,n/n − 1/K) can be written
as
√









in distribution as n → ∞ under complete randomization. As the DA-optimum biased















→ (0, ..., 0)T
in probability as n→∞ for Efron’s biased coin design.
4.5.1 Simulations for the imbalances
We will now study the imbalance properties of the different randomization schemes
by simulation. First, the values for the imbalances under these randomization schemes
are produced. Then the properties of the imbalances will be shown using their quartiles
and the spike plot for one of the K treatments.
In the simulations, assume that there are 60 patients in the trial. They are allocated
to one of the treatments upon arrival according to the assignment rules under complete
randomization, Efron’s biased coin design, theDA- optimum biased coin design and the
new class of designs, the adjustable biased coin design. We took K = 3 and K = 4.
The trial is simulated 10, 000 times under each scheme. When each patient arrives, we
generate a random number for this patient from a uniform distribution between 0 and 1.
Complete randomization
Under complete randomization, each patient is equally likely to be allocated to one
of the K treatments. We divide the real line between 0 and 1 into K equal intervals
and identify the interval in which the simulated values lies. When the simulated value
is greater than or equal to 0 and less than 1/K, we allocate this patient to treatment 1.
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If the value is greater than or equal to 1/K and less than 2/K, the patient is allocated
to treatment 2, and similarly for all other treatments, until an assignment is made. The
imbalances across all treatments will be calculated after each assignment. At the end of a
trial, the imbalance∆ is obtained by computing the imbalances after the last assignment
for all treatments j = 1, ..., K.
Efron’s biased coin design
For Efron’s biased coin design, we fix the probability p > 1/K of allocating the
treatment that has been chosen least often. We considered the values for p which are
8/12, 9/12, 10/12 and 11/12. As p increases, the assignment becomes more determin-
istic. The trial starts off with complete randomization.
The process of treatment assignment of the first patient is the same as that described
for complete randomization. The first patient is assigned to treatment 1 if the simulated
value is greater than or equal to 0 and less than 1/K, to treatment 2 if the simulated value
is greater than or equal to 1/K and less than 2/K, and so on for all other treatments until
an assignment is made. From the second patient onwards, the current numbers of patients
on the treatments are noted. The treatments that have the least number of patients are
identified. Let the number of treatments that have the least number of patients at the
current stage be n∗ for n∗ = 1, ..., K. At any particular stage, if there is only one
treatment that has the least number of patients, we will allocate the next patient to this
treatment if the simulated value is less than p. Otherwise, for all otherK− 1 treatments,
the assignment is to the first of these treatments if the simulated value is greater than or
equal to p and less than p+(1−p)/(K−1), to the second of these treatments if the value
is greater than or equal to p+ (1− p)/(K − 1) and less than p+ 2(1− p)/(K − 1), and
so on. When there are more than two treatments that have the least number of patients,
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the next patient will be allocated to the first of these treatments if the simulated value
is greater than or equal to zero and less than p/n∗, to the second of these if the value is
greater than or equal to p/n∗ and less than 2p/n∗, and so on. If the simulated value is
greater than p, the patient will be allocated to the group of treatments that do not have
the least number of patients at the current stage. The patient will be allocated to the first
of these if the simulated value is greater than or equal to p+ (1− p)/(K − n∗) and less
than p + 2(1 − p)/(K − n∗), to the second of these if the value is greater than or equal
to p + 2(1 − p)/(K − n∗) and less than p + 3(1 − p)/(K − n∗), and similarly for the
rest of the intervals until an assignment is made. After all assignments are made at the
end of the trial, the vector∆ is obtained.
DA-optimum biased coin design
For the DA-optimum biased coin design, the probability pj of assigning the next
patient to treatment j is calculated at each stage based on the current number of patients
on the jth treatment for j = 1, ..., K. For the initial K patients, we will allocate the
first patient to treatment 1, the second patient to treatment 2 and so on. We then have
one patient on each of the K treatments before the assignment rules are applied. For
the (K + 1)st patient onwards, a simulated value is generated for each patient. For the
(K + 1)st patient, we have pj = 1/K for all j = 1, ..., K. The (K + 1)st patient will be
allocated to treatment 1 if its simulated value is greater than or equal to 0 and less than
1/K, to treatment 2 if the simulated value is greater than or equal to 1/K and less than
2/K, and so on for all other treatments until a treatment assignment is made. For the
(K + 2)nd patient onwards, the probabilities pj obtained for each patient are sorted into
ascending order. Some of these probabilities may be the same. The next patient will be
allocated to the treatment with the smallest pj if the simulated value is greater than or
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equal to zero and less than pj . For the next largest pl, treatment l 6= j will be assigned to
the next patient if the simulated value is greater than or equal to pj and less than pj + pl,
and similarly for the other probabilities. At the end of the trial, we will obtain the vector
of imbalances under this scheme.
The adjustable biased coin design
Finally, we will describe the new class of designs proposed, the adjustable biased
coin design. The probability pj of assigning the next patient to treatment j for j =
1, ..., K is calculated at each stage based on the current imbalance across the treatments.
For each trial, the values for the imbalances on the treatments at each stage are needed
to obtain pj for j = 1, ..., K. The first patient under this scheme is equally likely to be
assigned to one of the K treatments with pj = 1/K for all j = 1, ..., K. For the second
patient, we need to obtain ∆j,1, the imbalances on treatment j for j = 1, .., K. Then
values for Fj(z) for all j can be obtained and hence the pj for the treatment assignment
of the second patient. Once the values for pj are known, they are put into ascending
order. The treatment assignment process is then the same as that described for the DA-
optimum biased coin design. The next patient will be allocated to the treatment with the
smallest pj if the simulated value for this patient is greater than or equal to 0 and less
than pj , and to the treatment with the next smallest pl if the simulated value is greater
than or equal to pj and less than pj+pl. The process continues for the other probabilities
until a treatment is assigned. This process of assignment applies to all other patients
until the assignment is made for the last patient. Although the vector of imbalances∆ is
obtained here at each stage, we will only study the vector of imbalances obtained at the
end of the trial.
After 10, 000 trials under each randomization scheme are simulated, the values for
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the 10, 000 vectors of imbalances∆ are recorded and the imbalances obtained for each
of the treatments are plotted. Here, we show the plots for the first treatment under each
randomization scheme when K = 3 and K = 4. The rest of the plots for the other
treatments will be given in Appendix B.
When K = 3, the plots under these four randomization schemes for treatment 1 are
given. Different values of pwhich are 8/12, 9/12, 10/12 and 11/12 are considered under
Efron’s biased coin design. Then, we show the plots of the imbalances for treatment 1
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































We also give the numerical values for the quartiles of the imbalances on treatment 1
under the four randomization schemes for the above two scenarios. Here, CR represents
complete randomization, DA represents the DA-optimum biased coin design, ABCD
represents the adjustable biased coin design and BCD for the Efron’s biased coin design.
Also min denotes the minimum value and max the maximum value. The numerical
values of the quartiles for treatments 2, 3 and 4 for both scenarios are given in Appendix
B.
Table 4.1: Numerical values of the quartiles of imbalance under all schemes for K = 3
for treatment 1
CR DA ABCD BCD
p = 8/12 p = 9/12 p = 10/12 p = 11/12
min -14 -6 -5 -8 -5 -4 -2
Q1 -2 -1 -1 -1 -1 0 0
Q2 0 0 0 -1 0 0 0
mean -0.0067 -0.0112 -0.0027 -0.7298 -0.2821 -0.1041 -0.03632
Q3 2 1 1 0 0 0 0
max 16 8 5 8 6 5 4
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Table 4.2: Numerical values of the quartiles of imbalance under all schemes for K = 4
for treatment 1
CR DA ABCD BCD
p = 8/12 p = 9/12 p = 10/12 p = 11/12
min -14 -7 -6 -8 -8 -6 -4
Q1 -2 -1 -1 -1 -1 0 0
Q2 0 0 0 -1 0 0 0
mean -0.0188 0.0034 0.0018 -0.6709 -0.3430 -0.1295 -0.0316
Q3 2 1 1 0 0 0 0
max 15 8 5 21 14 14 11
From the values of the quartiles and the shapes of the plots above, we can see that
these confirm the theoretical results that we stated in Section 4.4. The range of the im-
balances is largest for complete randomization and smallest for the DA-optimum biased
coin design and the adjustable biased coin design. This means that complete random-
ization is the most variable randomization scheme. For complete randomization, the
DA-optimum biased coin design and the adjustable biased coin design, the imbalances
are approximately normally distributed. The values for the imbalances under these three
randomization schemes for each of the treatments have peaks at 0. These results sug-
gest that each of the vectors of imbalances∆ under these two schemes are multivariate
normal with mean vector (0, ..., 0)T , which confirms the theoretical results for complete
randomization and Wei’s class of designs.
For Efron’s biased coin design, the increase in p from 8/12 to 11/12 means that the
design becomes more deterministic. The plots for this design show that the imbalances
on each of the treatments in both scenarios have sharp peaks at 0 and do not follow a nor-
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mal distribution. These results suggest that∆ for Efron’s biased coin design converges
to (0, ..., 0)T in probability and confirm the theoretical results.
The idea of this design is to give a greater probability of assignment to the treatment
that has been chosen less often. Therefore, we have to choose the appropriate p in order
to balance the numbers of patients across treatments. For example, p = 8/12 may not
be a good choice. For K = 3, when there are two treatments that have the least number
of patients, then we have a probability 1/2 × 8/12 = 1/3 of allocating the next patient
to either of these treatments and 1/3 to the treatment that has the largest number of
patients. The probabilities are the same and the design at this stage becomes complete
randomization. For K = 4, when three of the four treatments have the least number of
patients, the probability p = 8/12 will have to be divided by three to give 2/9 as the
probability of assigning each of these three treatments. The treatment with the largest
number of patients has a probability 1/3 of being allocated to the next patient. Since 1/3
is greater than 2/9, this invalidates the idea of Efron’s biased coin design in balancing
the numbers of patients across the treatments. As a result, there are a few extreme values
for the imbalances. These values are either too large or too small, particularly when p is
small. Although the plots have peaks at zero, the median and mean will be affected by
these few extreme values. We can see that the range of the values is becoming smaller
as p increases. Therefore, the value for p has to be chosen carefully according to the
number of treatments involved in the trial.
For the adjustable biased coin design, the numerical values of the quartiles for dif-
ferent treatments show that the range of the imbalances is the smallest compared to the
other designs for both scenarios. In other words, the variability under this design is
the smallest. The shapes of all of the plots suggest that the imbalances on each of the
treatments have a normal distribution with mean 0. This may indicate that, under the ad-
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justable biased coin design, the vector of imbalances has asymptotically a multivariate
normal distribution with mean vector (0, ..., 0)T .
4.6 Power under different randomization schemes
Let µj be the mean response on treatment j for j = 1, ..., K. We have the null
hypothesis H0 : µ1 = µ2 = ... = µK of no treatment differences and the alternative
hypothesis H1 : at least two of the mean responses are different. We test these hypothe-
ses by constructing the analysis of variance table. It is assumed that the responses on
treatment j are normally distributed with variance σ2, all independent.
With the assignment rules at each stage for different randomization schemes, we will
know the number of patients on each of the treatments at the end of the trial. Let n be
the total number of patients at the end of the trial with nj the number of patients on
treatment j for j = 1, ..., K. Also, let yij be the response of the ith patient on treatment
j, so that we have the treatment total Tj =
∑nj
i=1 yij for the jth treatment. After obtaining
K treatment totals, we calculate the grand total G =
∑K
j=1 Tj and the correction factor




















Finally, the residual sum of squares is
SR = SG − ST .
The analysis of variance table can now be constructed. The degrees of freedom for
the treatment, residual and total sums of squares areK−1, n−K and n−1, respectively.
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Each of their mean squares are then defined as their sums of squares divided by their














Under H0 given the number of patient on treatment j for j = 1, ..., K, F has an F
distribution with K − 1 and n − K degrees of freedom. We reject H0 at the 100α%
level if F > FK−1,n−K,α, where FK−1,n−K,α is the upper 100α% value of the FK−1,n−K
distribution. The power given the nj , or, in other words, the conditional power of the
test, is the probability of rejecting H0 given that there is a genuine treatment difference,
that is, when H1 is true.
We will study the power of the test under the four randomization schemes by sim-
ulation. We will again consider the two scenarios K = 3 and K = 4. Consider a trial
where patients are allocated to treatments according to the assignment rules for the ran-
domization schemes. The numbers of patients on the treatments are then recorded at
the end of the trial. Next we generate the patients responses for the test. In the sim-
ulations, nj responses will be generated from a normal distribution with mean µj and
variance σ2 for j = 1, ...K. We took σ2 = 1. Various values for the mean responses
on different treatments will be considered. The trial is simulated 10, 000 times and the
number of rejections of H0 is counted. The proportion of rejections of H0 will be the
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estimated power for the test for different randomization schemes. This estimated power
is the unconditional power.
For simplicity, we assume that the value for µ1 is always 0. For µ2, we take nine
values from 0 to 2 with increments of 0.25. We take 0 together with eight values from
0.5 to 2.25 with increments of 0.25 for µ3. Finally, we have 0 and eight values from
0.75 to 2.5 with increments of 0.25 for µ4. The values for µ1, µ2 and µ3 are the same in
both scenarios. Let dj = µj − µ1 for j = 2, ..., K. Then the numerical values for the
power will be given under the four randomization schemes for different values of d2 and
d3 when K = 3 and d2, d3 and d4 when K = 4. Let α = 0.05 the significance level of
the test.
Table 4.3: Powers under four randomization schemes for K = 3
d2 = 0 d2 = 0.25 d2 = 0.5 d2 = 0.75 d2 = 1 d2 = 1.25 d2 = 1.5
d3 = 0 d3 = 0.5 d3 = 0.75 d3 = 1 d3 = 1.25 d3 = 1.5 d3 = 1.75
CR 0.050 0.258 0.540 0.815 0.957 0.994 1
BCD(p=8/12) 0.050 0.261 0.544 0.824 0.961 0.995 1
BCD(p=9/12) 0.051 0.262 0.548 0.825 0.962 0.996 1
BCD(p=10/12) 0.050 0.262 0.547 0.824 0.963 0.996 1
BCD(p=11/12) 0.050 0.263 0.547 0.827 0.962 0.996 1
DA 0.050 0.262 0.542 0.824 0.962 0.995 1
ABCD 0.050 0.260 0.545 0.825 0.963 0.996 1
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Table 4.4: Powers under four randomization schemes for K = 4
d2 = 0 d2 = 0.25 d2 = 0.5 d2 = 0.75 d2 = 1 d2 = 1.25 d2 = 1.5
d3 = 0 d3 = 0.5 d3 = 0.75 d3 = 1 d3 = 1.25 d3 = 1.5 d3 = 1.75
d4 = 0 d4 = 0.75 d4 = 1 d4 = 1.25 d4 = 1.5 d4 = 1.75 d4 = 2
CR 0.050 0.384 0.621 0.833 0.950 0.989 0.998
BCD(p=8/12) 0.050 0.393 0.633 0.845 0.957 0.993 0.999
BCD(p=9/12) 0.050 0.393 0.630 0.846 0.958 0.993 0.999
BCD(p=10/12) 0.052 0.391 0.634 0.846 0.960 0.993 1
BCD(p=11/12) 0.051 0.392 0.632 0.849 0.960 0.994 0.999
DA 0.050 0.387 0.629 0.847 0.958 0.993 0.999
ABCD 0.051 0.391 0.629 0.845 0.960 0.993 0.999
The first column in the two tables represents the significance level of the simulated
test. The values are very close to α = 0.05, which is the assumed significance level of the
test. We can see that the values for the powers increase when the differences in the mean
treatment responses increase. The powers obtained under complete randomization are
the lowest among the randomization schemes in both scenarios. The power under Efron’s
biased coin design usually increases as p increases. In addition, for both scenarios, when
Efron’s biased coin design is very deterministic with p = 10/12 or p = 11/12, the
power obtained is higher than that under the adjustable biased coin design. For K = 3,
the DA-optimum biased coin design sometimes achieves a higher power than Efron’s
biased coin design with p = 8/12, and p = 9/12.
For each randomization scheme, the powers achieved when K = 3 are lower than
those obtained when K = 4. When more treatments are involved in the trial, the prob-
ability of detecting a treatment effect under different randomization schemes is higher.
When K = 4, the powers under the DA-optimum biased coin design is lower than that
under Efron’s biased coin design for most values of p. In general, we can say that the
152
adjustable biased coin design is very efficient regardless of the number of treatments
involved and the values for the treatment differences.
4.7 Conclusions
In the literature, randomization schemes for more than two treatments have not
gained great attention over the years and there are only limited theoretical results avail-
able about these randomization schemes. In this chapter, a new class of designs called
the adjustable biased coin design is proposed and the results given show that this design
is generally more efficient at balancing the numbers of patients across the treatments
than complete randomization, Efron’s biased coin design when p = 8/12 and p = 9/12,
and the DA-optimum biased coin design.
The adjustable biased coin design is the only design which uses the imbalances in-
stead of the numbers of patients on the treatments at each stage. The advantage of this
design is that the imbalances are taken into account in the calculation of the assignment
probabilities. Furthermore, under this design, the probability of assigning treatment j to
the next patient not only depends on the current imbalance on treatment j, but also on
all current imbalances on the other treatments.
The results from simulations indicate that the vector of imbalances under the ad-
justable biased coin design has a multivariate normal distribution asymptotically with
mean vector (0, ..., 0)T . The form of the covariance matrix is not known. Further work
can be carried out on the theoretical properties of the imbalance and power under this
design. The rate of convergence of the imbalance and the structure of the covariance






randomization for several treatments in
clinical trials
5.1 Introduction
Randomization schemes used in clinical trials are considered as essential and of great
importance to maintain a balance in the numbers of patients across treatment groups and
to gain some randomness in assigning a treatment to a patient to avoid any selection or
accidental bias. A trial having similar numbers of patients across treatment groups is bet-
ter for comparison purposes. Statistical inference based on an equal number of patients
in each treatment group is the most efficient method to detect a genuine treatment effect
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when the variances of the patients’ responses across treatments are the same. However,
imbalance in assignments will still occur, even in well-defined randomization schemes.
The problem of imbalance in the numbers of patients across treatment groups is more
serious in clinical trials where fewer patients are recruited and involved in the study. An
imbalance in the numbers of patients in the treatment groups will decrease the power,
the probability of correctly detecting a genuine treatment effect (McPherson, Campbell
and Elbourne, 2012).
Under complete randomization for two-treatment assignments, each patient is equally
likely to be assigned to either of the treatments. The number of patients in any of the two
treatment groups will follow a binomial distribution with parameters the sample size and
the probability of 1/2 to assign either treatment to a patient. Complete randomization
is very likely to produce very serious imbalance and have most of the patients assigned
to one treatment group. It is known that imbalance caused by complete randomization
is unlikely to occur in a large trial when the number of patients involved is greater than
200.
Another randomization scheme that is used in clinical trials by pharmaceutical com-
panies is randomly permuted-block randomization. There are two basic schemes: un-
stratified and centre-stratified permuted-block randomization. Given an assigned propor-
tion of patients for each treatment within a block, a sequence of treatment assignments
is generated by randomly listing all of the possibilities for different permuted blocks.
Patients are then assigned to the treatment according to this sequence in order upon their
arrival. Here, unequal allocations are allowed within a block. However, in order to
achieve a balance in the numbers of patients across treatment groups, the treatment al-
location ratio within a block is usually assumed to be the same. Under this assumption,
imbalance will not occur in any of the complete blocks, but it may occur in the incom-
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plete block. In other words, under the permuted-block design, it is sufficient to study the
imbalance in the numbers of patients across treatments by investigating the properties of
the incomplete block.
The treatment imbalance properties for different randomization schemes have been
investigated by Hallstrom and Davis (1988) for stratified block randomization, Lachin
(1988a, 1988b) for complete randomization and urn randomization, and Anisimov (2007,
2010, 2011) for centre-stratified permuted-block randomization. All of the above au-
thors have considered the imbalance in the number of patients for two treatments. This
chapter extends work on the analysis of the imbalance properties to more than two treat-
ment groups. In the previous papers, the expectation and the variance of the imbalance
are obtained. The distribution of the overall imbalance is approximately normal with
the same expectation and variance. In this chapter, the main focus is to investigate the
imbalance properties for two randomization schemes, centre-stratified permuted-block
randomization and complete randomization when more than two treatments are studied
in a clinical trial. The overall imbalance is represented as a vector of imbalances on
different treatments rather than a scalar in the two-treatment case, and asymptotically it
has a multivariate normal distribution with a vector of means and a covariance matrix.
In Section 5.2, we consider centre-stratified permuted-block randomization and com-
plete randomization for cases when there are more than two treatments. In Section 5.3,
the imbalance for both randomization schemes will be defined for a particular treatment
in a particular centre and for all centres. The means, variances and covariances of the im-
balances within a centre or for all centres will be evaluated when the numbers of patients
to recruit in different centres are known.
In Section 5.4, we will consider the case where the numbers of patients recruited
in different centres are random variables. This is based on the Poisson-gamma patient
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recruitment model developed by Anisimov and Fedorov (2007), where the recruitment
process follows a Poisson process with recruitment rates from a gamma distribution.
Therefore, the numbers of patients recruited in different centres have beta-binomial dis-
tributions. The expectations, variances and covariances of the imbalances within a centre
or for all centres will be evaluated. In Section 5.5, the variances of the imbalance for the
two randomization schemes are compared. In Section 5.6, numerical values are simu-
lated for the imbalances on treatments for two particular scenarios. The values for the
expectations and the covariance matrices are given together with histograms of the im-
balances, which confirm the theoretical results produced in Section 5.4. In Section 5.7,
a test will be described for all pairs of treatment differences with the control group and
hence how the power can be obtained from this test. Numerical results for the power
and the sample size are also given by simulation for different scenarios. By fixing a
particular level of power to be achieved for the balanced case, the sample size can be
found. The same sample size will be used to study the power in the imbalanced case.
In addition, the number of patients that need to be added in each scenario to achieve the
same level of power in the balanced case is given. Finally, conclusions will be drawn in
Section 5.8.
5.2 Randomization schemes formore than two treatments
Consider a multi-centre trial study, where in total n patients have to be recruited by
N clinical centres. Patients have to be assigned to one of the K ≥ 3 treatments. Let ni
be the number of patients who have to be recruited in centre i. Then
∑N
i=1 ni = n.
There are two types of permuted-block randomization schemes that are commonly
used in clinical trials: unstratified permuted-block randomization and centre-stratified
permuted-block randomization. Unstratified randomization means that patients are ran-
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domized to treatment according to independent randomly permuted blocks of fixed size
without regard to centres. Centre-stratified permuted-block randomization means that
each of the centres has a separate permuted-block randomization scheme. Patients for
the study are randomized to treatments according to the independent randomly permuted
blocks of fixed size within each centre.
For example, suppose that there are three treatments a, b and c, the size of the block
is 3 and the ratio within blocks is 1 : 1 : 1. Then there will be six possibilities for
the different permuted blocks: {(a, b, c), (a, c, b), (b, a, c), (b, c, a), (c, a, b), (c, b, a)}. A
randomly chosen sequence of blocks forms a sequence of treatments. The patients are
assigned to treatments according to this sequence in the order of their registration.
It is obvious that unstratified permuted-block randomization will minimise the imbal-
ance in the number of patients on different treatments for the whole study and increase
the imbalance in each centre compared to centre-stratified permuted-block randomiza-
tion.
Assume that there are in total K ≥ 3 treatments with the allocation in the block
(k1, k2, ..., kK), where kj is the number of patients within a block that are allocated to
treatment j for j = 1, ..., K. Let K1 =
∑K
j=1 kj be the block size.
Now consider centre-stratified permuted-block randomization. The total number of
patients recruited ni in centre i may not be a multiple of the block size K1. This may
lead to incomplete blocks in some of the centres. These incomplete blocks will, however,
have the chance to contain an unequal number of patients on each treatment and cause
imbalance. In a multi-centre clinical trial, if there exist many incomplete blocks, this will
cause serious imbalance in the total numbers of patients on the treatments. Therefore, we
can study the imbalance properties of a randomization scheme by studying the properties
of these incomplete blocks. The last block can be incomplete. If the size of the last block
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is K1, ni is a multiple of K1 and contains no incomplete block for this study. For some
centre i, let the size of the incomplete block be r such that r = 1, ..., K1 − 1.
Let ξj(r) be the number of patients on treatment j in an incomplete block of size r.
We can see that ξj(r) has a hypergeometric distribution, that is,

















kjr(K1 − kj)(K1 − r)
K21(K1 − 1)
.
If r = 0, we set ξj(r) = 0.
Let the total number of patients in centre i on treatment j be nij . Denote by bzc the






kj + ξj [mod(ni, K1)] .
The centre-stratified permuted-block design will be studied and referred to as permuted-
block randomization in this chapter.
Consider now complete randomization. For ease of comparison, centre-stratified
complete randomization is studied and referred to as complete randomization. Each
patient is assigned to a treatment j with probability pj . The total number of patients in
centre i on treatment j, nij , has a binomial distribution with parameters ni and pj . In
general, pj is the proportion of patients that are allocated to treatment j in a complete
block such that pj = kj/K1. For equal treatment proportions within each complete
block, we have k1 = k2 = ... = kj with block size K1 = Kk1. In this case, we have
pj = 1/K.
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For investigation of the properties of imbalance, we will consider two cases: when
the number of patients recruited in a centre is given or is random. Let {ni} be the
numbers of patients to be recruited in centre i. Define for centre i the imbalance on
treatment j under the permuted block design as
∆ij = nij − ni
K1
kj (5.1)
for j = 1, ..., K and i = 1, ..., N. Similarly, the imbalance on treatment j under complete
randomization is defined as




5.3 The numbers of patients recruited in a centre are
given
5.3.1 Permuted-block design
First, assume that the {ni} are given. By (5.1), the expectation of∆ij given ni under


























































rkj(K1 − kj)(K1 − r)
K21(K1 − 1)
.
We now consider the covariance of the imbalances on two different treatments j and
m in a trial. Let i and l be two different centres. Then, due to the independence of the
numbers of patients on a particular treatment j in different centres, the imbalances on a
particular treatment j in different centres are also independent, so that Cov(∆ij,∆lm) =
0. Therefore, we have to calculate the covariance for two different treatments in the same
centre i, that is,




































+ Cov[ξj(r), ξm(r)] + E[ξj(r)E(ξm(r)],
where Cov[ξj(r), ξm(r)] is the covariance for a multivariate hypergeometric distribution.
161
Lemma 5.3.1 The covariance of ξj(r) and ξm(r) is
Cov[ξj(r), ξm(r)] = −kjkmr(K1 − r)
K21(K1 − 1)
,
and the covariance of ∆ij and ∆im is equal to the covariance of ξj(r) and ξm(r).
Proof. See Appendix C.
Now consider the imbalance on any particular treatment for all centres. The overall




























































































































Now consider another randomization scheme, complete randomization, where the
{ni} for different centres are given. Let nij be the number of patients in centre i assigned
to treatment j. Then nij has a binomial distribution with parameters ni and kj/K1.













The variance is then
Var(∆∗ij) = E(∆
∗2



























The variables ∆∗ij for a particular treatment j in different centres are independent. If
we have two different treatments j andm and two different centres i and l, then∆∗ij and




lm) = 0. The covariance is then calculated
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At centre i, each of the {nij} for j = 1, . . . , K has a binomial distribution. The co-
variance of nij and nim is deduced from the multinomial distribution of nij and nim as






































































































































Assume that the {ni} are given. Then nij has a binomial distribution with parameters
ni and 1/K for equal treatment proportions within each block.
Let ∆∗ij be the imbalance on treatment j in centre i. Then we have






















Since the covariance of nij and nim from the multinomial distribution isCov(nij, nim) =



































































When the number of centres N involved in a clinical trial is large, the imbalance
defined in (5.3) and (5.7) is approximated by a normal distribution with mean 0, and
variance (5.4) and (5.8), respectively, for the permuted-block design and complete ran-
domization. Let the overall imbalance for the permuted-block design and complete ran-
domization be ∆ and ∆∗, respectively. Then each of these is a vector of imbalances









As each of the ∆j and ∆∗j are asymptotically normally distributed, both ∆ and ∆
∗
are asymptotically multivariate normal. Under the permuted-block design, the asymp-
totic multivariate normal distribution of∆ has zero mean vector and covariance matrix
Σ =

σ21 σ12 . . . σ1K
σ21 σ
2
2 . . . σ2K
...
... . . .
...





where σ2j = Var(∆j) in (5.4) and σjm = Cov(∆j,∆m) in (5.5). Similarly, for complete























where σ∗2j = Var(∆
∗






m) in (5.9) or (5.13).
5.4 The numbers of patients recruited in a centre are
random variables
5.4.1 Patient recruitment model
We assume that the {ni} are random and use the Poisson-gamma model of Anisimov
and Fedorov (2007) for the patient recruitment process. Assume that the number of
patients recruited in centre i follows a Poisson process with rate λi. The rates {λi} are
gamma distributed with known parameters (α, β), where these are the shape and the rate
parameters, respectively. For given rates, the number of patients recruited in centre i,
ni, has a binomial distribution with parameters n and pi, where n is the total number of
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Since the {λi} are gamma distributed, pi has a beta distribution with parameters (α, α(N−
1)). Therefore, ni has a beta-binomial distribution with





B(α+ l, α(N − 1) + n− l)
B(α, α(N − 1)) , (5.14)
where B(a, b) =
∫ 1
0







n(N − 1)(αN + n)
N2(αN + 1)
.
5.4.2 Permuted block design
Under the permuted block design with the {ni} random, consider the properties of
the imbalance defined in (5.1). The expectation is
E(∆ij) = E[E(∆ij|ni)] = 0.




























Let Ri = mod(ni, K1) be a random variable which represents the size of the incomplete











































The covariance for two different treatments j and m is calculated in a similar way
using

















































P (n,N, α, r + sK1) (5.18)
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B(α+ r + sK1, α(N − 1) + n− r − sK1)












B(α+ r + sK1, α(N − 1) + n− r − sK1)
B(α, α(N − 1)) .
Note that, if n/N > 2K1, we can assume that the random variableRi has an approxi-
mate discrete uniform distribution on the interval between 0 andK1−1. The probability










Then we can obtain
E(R2i ) = Var(Ri) + [E(Ri)]
2 =
(K1 − 1)(2K1 − 1)
6
.




− kj(K1 − kj)(2K1 − 1)
6K21
=


















































































For n/N > 2K1, the random variable Ri has an approximate discrete uniform distri-
bution. Using the results for E(Ri) and E(R2i ), and (5.19), the variance of ∆j is
Var(∆j) =
Nkj(K1 − kj)(K1 + 1)
6K21
. (5.21)





















Finally, when Ri has an approximate discrete uniform distribution, the covariance of∆j
and ∆m is





Now we study the imbalance of complete randomization when the {ni} are random.
Under complete randomization, the imbalance on treatment j in centre i is defined











































































Since ∆∗ij and ∆
∗
lm are independent variables for two different centres i and l, their
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covariance is zero. The covariance of ∆∗ij and ∆
∗



































For centre i, the conditional covariance of nij and nim can be obtained from the multi-






























































Given the {ni}, the variables {∆∗ij} for a particular treatment j are independent for







































Here, it is clearly seen that, under complete randomization, the variance and covariance
of the imbalance on treatments for all centres are the same as those when ni is given.
Equal Treatment Allocation



















We only consider the covariance of the imbalance on two different treatments in the same
centre. Given the {ni}, ∆∗ij and ∆∗lm, the imbalances on two treatments j and m in two
different centres i and l are independent with covariance equal to zero. The covariance












































































WhenN the number of centres involved in a trial is large, the imbalances∆j and∆∗j
will be asymptotically normally distributed with mean 0 and variance given by (5.20)
and (5.25), respectively. Therefore, the overall imbalances∆ and∆∗ are asymptotically
multivariate normal.
Under the permuted block design, the imbalance∆ has zero mean vector and covari-
ance matrix Σ with entries σ2j in (5.21) and σjm in (5.23). We use the approximation for
the variables {Ri} that they have an approximate discrete uniform distribution. For large
N , the variance of∆j is justN times the variance of∆ij and similarly for the covariance.
The covariance matrix of the overall imbalance is N times the covariance matrix for a
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particular centre. Similarly, for complete randomization, the overall imbalance ∆∗ has
an approximate multivariate normal distribution with zero mean vector. The covariance
matrix Σ∗ has entries σ∗2j in (5.25) or (5.28) and σ
∗
jm in (5.26) or (5.29), or it can be
obtained by multiplying the covariance matrix for a particular centre by N .
Remark 1 For K = 2 when there are only two treatments, a and b, the overall
imbalance was defined by Anisimov (2007) as the difference between the numbers of
patients on treatments a and b. We denote this overall imbalance by ∆˜ = n.a − n.b,
where n.a =
∑N
i=1 nia and n.b =
∑N
i=1 nib. In our case when K = 2, treatment 1 refers
to treatment a and treatment 2 refers to treatment b. The overall imbalance ∆˜ defined by
Anisimov (2007) can be written in terms of our notation as
∆˜ = n.a − n.b









When there is an equal proportion of patients for the two treatments within a complete
block, we have ∆˜ = ∆a − ∆b. Now, the overall imbalance in our notation is ∆ =
(∆a,∆b)
T with expectation E(∆) = (0, 0)T and covariance matrix Σ with entries σ2j in
(5.21) and σjm in (5.23).
Let u = (1,−1)T . Then we can write the overall imbalance ∆˜ in terms of ∆ as
















Remark 2 For equal proportions ka = kb = K1/2 within a complete block, we have
Var(∆˜) = N(K1 + 1)/6.
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For large N , ∆a and ∆b are approximately normal. Therefore, the imbalance ∆˜ as
a linear combination of ∆a and ∆b is also approximately normal. The result calculated
here in terms of our notation for the expectation and variance of ∆˜ matches with the
expectation and variance of the overall imbalance calculated by Anisimov (2007, 2010).
5.5 Comparison of imbalance of complete randomiza-
tion and the permuted block design
5.5.1 The numbers of patients recruited in different centres are given
One of the main aims of a randomization scheme is to balance the numbers of patients
across treatment groups. This ensures that an adequate level of power can be achieved.
The higher the power, the more likely a test will detect a genuine treatment difference.
The variance of the imbalance is always considered to be a good indicator of which
randomization schemes provide better balance. The greater the variance of the imbalance
of a randomization scheme, the less efficient is the design for balancing the numbers of
patients across groups.
By using the calculated variance of the imbalance in (5.3), (5.6), (5.19) and (5.24),
comparisons can be made between the two randomization schemes on their effectiveness
in balancing the numbers of patients across treatment groups. First suppose that ni, the
number of patients in a particular centre i, is given. The ratio of the variances of the











ni(K1 − 1) .
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(sK1 + r)(K1 − 1) .
If s = 0 and r = 0, there will be no patients in the trial and we cannot calculate the
ratio. When s = 0, there is only one incomplete block, so that the ratio becomes
K1 − r
K1 − 1 =

1, r = 1,
< 1, r > 1.
When r = 1, there will be only one patient in centre i and the variance of the imbalance
is the same for complete randomization and the permuted-block design. When r > 1,
there is only one incomplete block in centre i. The variance of that imbalance under
complete randomization is greater than that of the permuted block design for a non-
empty incomplete block, which means that the permuted-block design is more efficient
than complete randomization.
Now consider the case s ≥ 1. When r = 0, centre i contains only complete blocks
and the ratio becomes zero. It is obvious that there is no imbalance in a complete block.
Therefore, there is no imbalance in this centre and hence no variance for the imbalance
can be calculated for both randomization schemes. Now suppose that r ≥ 1, which
implies that K1 − r ≤ K1 − 1, and, for s ≥ 1 and K1 ≥ 1, implies that sK1 + r ≥ r.
Therefore, we have r(K1−r) ≤ (sK1+r)(K1−1). If in centre i, there are more than two
blocks which include at least one complete block and one incomplete block, the variance
of the imbalance for complete randomization is greater than that of the permuted-block
design.
To conclude, the variance of the imbalance in a particular centre i on a particular
treatment j is greater under complete randomization than the permuted-block design in
all cases. In other words, the permuted-block design is more efficient than complete
randomization, except when there is only one patient in each centre.
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We will now study the overall imbalance on treatments under these two randomiza-
tion schemes. We can look at the covariance matrices for the randomization schemes to
see which randomization scheme is better. Therefore, we will study the entries in the





The imbalances on a particular treatment j are independent for different centres. The
variance of the imbalance on a particular treatment j for all centres is just the sum of all
the imbalances on treatment j for each centre i for i = 1, ..., N . Therefore, the variance
of the imbalance on treatment j for all centres under permuted-block randomization will
be less than the variance of the imbalance on treatment j for all centres under complete
randomization. Similarly, consider the covariances for two different treatments j andm












(sK1 + r)(K1 − 1) ,
for ni = sK1 + r.
The covariance ratio of the imbalance is exactly what we obtained for the variance
ratio of the imbalance. Therefore, we can draw the same conclusions here for the covari-
ance ratio of the imbalance. The covariance of the imbalance in a particular centre i on
two different treatments j andm is greater under complete randomization than permuted
block randomization in all cases. Therefore, all the entries in the covariance matrix Σ∗
for complete randomization have values greater than all the entries in the covariance
matrix Σ under permuted-block randomization. For the overall imbalance across treat-
ments, the covariance under permuted-block randomization is less than that under com-
plete randomization, which implies that, under permuted-block randomization, a more
balanced trial can be achieved across treatments for all centres than complete random-
ization.
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5.5.2 The numbers of patients recruited in different centres are ran-
dom
Consider now the case where the numbers of patients {ni} to be recruited are random
variables and the patient recruitment process follows a Poisson-gamma model.
As proved above,
Var(∆ij|ni) = Var(∆∗ij|ni) if ni = 1
and
Var(∆ij|ni) < Var(∆∗ij|ni) if ni > 1.
Now, when the ni are random, if n > 1, then P (ni > 1) > 0. Thus,








Var(∆∗ij|ni = s)P (ni = s)
= Var(∆∗ij).
Therefore, if we have more than one patient in a trial, Var (∆ij) < Var(∆∗ij) and
permuted-block randomization always has lower variability in the imbalance than com-
plete randomization.
Similarly, for the covariance of the imbalance for two different treatments j and m
in centre i,
Cov(∆ij,∆im|ni) = Cov(∆∗ij,∆∗im|ni) if ni = 1
and
Cov(∆ij,∆im|ni) < Cov(∆∗ij,∆∗im|ni) if ni > 1.





For the overall imbalance, we look at the covariance matrices under the two ran-
domization schemes. The conclusion is the same as when ni is fixed. Permuted-block
randomization is better than complete randomization and thus permuted-block random-
ization provides less imbalance in the number of patients on a particular treatment for all
centres than complete randomization. The entries in the covariance matrix for permuted-
block randomization are all less than those for complete randomization. Therefore,
permuted-block randomization gives less overall imbalance than complete randomiza-
tion.
5.6 Simulation for the expectation and covariance ma-
trix of the overall imbalance
Results of simulation support what we have found theoretically in Section 5.4. Con-
sider the centre-stratified randomization process in a study. Assume that the patient
recruitment process is modelled by the Poisson-gamma model, where the number of
patients to be recruited in each centre is simulated from a beta-binomial distribution.
Within each centre, patients are allocated to a treatment according to some randomly
permuted blocks. Assume that an equal proportion of patients is to be allocated to each
treatment within each complete block. Some randomly permuted blocks of size K1 will
be generated in the simulation and the patients will be allocated to treatments accord-
ing to the sequence formed by these randomly permuted blocks. As the imbalance on
treatments is found in the incomplete block for each centre, the treatment allocation to
patients in these incomplete blocks will be simulated from a multivariate hypergeometric
distribution. The imbalance on treatments can be calculated by subtracting the simulated
number of patients allocated to each of the treatments from the expected number of pa-
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tients on each treatment. The imbalance on treatments can be calculated within each
centre and for all centres. Finally, the vector for the overall imbalance on treatments will
be obtained.
The above procedure will be simulated s times. The sample mean vector and the
sample covariance matrix of the overall imbalance can be obtained after s runs. For K
treatments, let ∆̂p be the vector for the overall imbalance obtained in the pth simulation














(∆̂p − ¯̂∆)(∆̂p − ¯̂∆)T .
The values for the sample mean vector and covariance matrix will then be compared
with the theoretical mean and covariance matrix. We consider two particular scenarios.
The first scenario has n = 168, N = 100 K = 4 and K1 = 8, with α = 1.2 and β = 2
for the patient recruitment process. In the second scenario, we have n = 232, N = 100
and the same K,K1, α and β as in the first. The theoretical mean vector and covariance
matrix of the overall imbalance can be calculated by using results in Section 5.4. In both
scenarios, the theoretical expectation of the overall imbalance is the vector of zeros. The
theoretical covariance matrix of the overall imbalance has diagonal entries in (5.20) and
off-diagonal entries in (5.22). If the size of the incomplete block Ri in centre i has an
approximate discrete uniform distribution, the theoretical covariance matrix has entries
(5.21) and (5.23).
For both scenarios, we took s = 100, 000. For the first scenario, the sample mean
vector is
¯̂
∆ = (−0.003,−0.015, 0.025,−0.007)T ,
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18.961 −6.320 −6.320 −6.320
−6.320 18.961 −6.320 −6.320
−6.320 −6.320 18.961 −6.320
−6.320 −6.320 −6.320 18.961

. (5.30)
If the size of the incomplete block Ri in centre i has an approximate discrete uniform
distribution, the theoretical covariance matrix is
Σ =

28.125 −9.375 −9.375 −9.375
−9.375 28.125 −9.375 −9.375
−9.375 −9.375 28.125 −9.375
−9.375 −9.375 −9.375 28.125

. (5.31)
The sample covariance matrix is
Σˆ =

18.863 −6.284 −6.258 −6.320
−6.284 19.095 −6.454 −6.356
−6.258 −6.454 18.962 −6.250
−6.320 −6.356 −6.250 18.926

,
We can see that Σˆ has values close to the theoretical values in (5.30).
Consider the second scenario with n = 232, N = 100, K = 4, K1 = 8, α = 1.2 and
β = 2. The sample mean vector is
¯̂
∆ = (0.002,−0.019, 0.025,−0.008)T ,
which is again close to the theoretical mean vector. The theoretical covariance matrix is
Σ =

21.668 −7.223 −7.223 −7.223
−7.223 21.668 −7.223 −7.223
−7.223 −7.223 21.668 −7.223




When Ri, the size of the incomplete block in centre i, has an approximate discrete uni-
form distribution, we have
Σ =

28.125 −9.375 −9.375 −9.375
−9.375 28.125 −9.375 −9.375
−9.375 −9.375 28.125 −9.375
−9.375 −9.375 −9.375 28.125

. (5.33)
The sample covariance matrix of the overall imbalance is
Σˆ =

21.723 −7.080 −7.404 −7.239
−7.080 21.444 −7.136 −7.228
−7.404 −7.136 21.667 −7.126
−7.239 −7.228 −7.126 21.593

,
which also has values close to the theoretical values in (5.32).
For both scenarios, the results from simulation are consistent with the numerical val-
ues for the theoretical mean vector and covariance matrices in (5.30) and (5.32). When
the size of the incomplete block Ri in centre i has an approximate discrete uniform dis-
tribution, the theoretical covariance matrix is less accurate. In the second scenario, the
value assumed for n, the number of patients recruited, is higher than the corresponding
value assumed in the first scenario. The difference between the two theoretical covari-
ance matrices is larger when we have fewer patients.
The theoretical covariance matrices in (5.30) and (5.32) hold whenN the number of
centres involved in the trial is large. Furthermore, those in (5.31) and (5.33) hold when
n/N > 2K1 such that Ri has an approximate discrete uniform distribution. This is a
good approximation, since for any size of the incomplete block r, P (Ri = r) ≈ 1/K1
when n/N > 2K1. For example, take n = 720, N = 80, K1 = 4 and α = 1.2 such
that n/N = 9 and 2K1 = 8. Using (5.18), P (Ri = r) for r = 0, 1, 2, 3 is 0.2761,
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0.2616, 0.2416 and 0.2207, respectively. We can see that all of these values are close
to 1/K1 = 0.25, and so it will be appropriate for us to use the approximate discrete
uniform for Ri when n/N > 2K1. We have n/N equal to 1.68 for the first scenario and
2.32 for the second scenario, which are both far less than 2K1 = 16. The size of the
incomplete block in any centre i for both scenarios cannot be approximated by a discrete
uniform distribution. Therefore, the values for the sample covariance matrices in the
two scenarios are not close to the theoretical covariance matrices in (5.31) and (5.33).
In general, the discrete uniform approximation is quite good when n/N > K1.
As defined in (5.3) ,∆j the imbalance on a particular treatment j for j = 1, ..., K for
all centres is approximated by a normal distribution with mean 0 and variance (5.20), or
(5.21) if the size of the incomplete block has an approximate discrete uniform distribu-
tion. The results of the simulations support this. For both scenarios, we considerK = 4
treatments with block size K1 = 8. The values of ∆j for j = 1, .., 4 are calculated for
100, 000 simulations. Below are the histograms of the values of ∆j for each treatment















































































































































































































































































































































The curves for the empirical density functions of ∆j/
√
Var(∆j) for j = 1, ..., 4 are
also shown in the two figures below. It is clear that, in both scenarios, the curves for the
empirical density functions coincide with that for the density function of the standard
normal distribution.
Figure 5.3: Empirical density functions of ∆j/
√
Var(∆j) for j = 1, . . . , 4 for the first
scenario











empirical imbalance denisty in all treatments with normal density





The yellow line represents the density function of the standard normal distribu-
tion. The red, blue, pink and green lines represent the values of ∆j/
√
Var(∆j) for
j = 1, 2, 3, 4, respectively.
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Figure 5.4: Empirical density functions of ∆j/
√
Var(∆j) for j = 1, . . . , 4 for the sec-
ond scenario











empirical imbalance denisty in all treatments with normal density





The yellow line represents the density function of the standard normal distribu-
tion. The red, blue, pink and green lines represent the values of ∆j/
√
Var(∆j) for
j = 1, 2, 3, 4, respectively.
5.7 Power and sample size
Here, we will study the impact of imbalance on treatments on the power for centre-
stratified randomization. We will also see in the imbalanced case how an increase in
the sample size can compensate for the loss in power. This will be shown by numerical
results from simulation.
Let n be the total number of patients to be randomized to K > 2 treatments at N
clinical centres. Centre-stratified randomization has blocks of size K1. Let nj be the
number of patients randomized to treatment j for j = 1, ..., K and X¯j be the mean of the
patient responses on treatment j. Assume that the observations are independent normal
with unknown meansmj for j = 1, ..., K and known variance σ2. Suppose that the first
group of patients receive the standard treatment and let this group be the control group.
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We will be carrying out K − 1 tests assuming no centre effect.
Consider testing the null hypothesis H0 : m1 = m2 = ... = mK = m for any non-
negative constant m against H1 : at least one mj −m1 = hj > 0 for any j = 2, ..., K.






for j = 2, ..., K. Under H0, the Sj are dependent standard normal random variables.
Given γ as the significance level of one test, let Φ be the standard normal distribution
function and let zγ satisfy 1 − Φ(zγ) = γ. We will reject H0 if, for at least one j with
j = 2, ..., K, Sj > zγ. Let the significance level of the overall test be γ∗. We can
represent the significance level as
P
{∪Kj=2 (Sj > zγ) |H0} = γ∗.













as a standard normal random variable for each j = 2, ..., K. Let β∗ be the probability of













































































are two independent standard normal random variables. So each ηj can be written as a
linear combination of two independent normal random variables, since
ηj = ζjcj1 − ζ1cj2, (5.34)













The form in (5.34) for ηj can be used to simulate values for ηj and hence simulate
numerical values for the power of the test.
5.7.1 Impact of imbalance on power and sample size
Here, we will study the power of the test by simulation for four scenarios when
γ = 0.05 and γ = 0.05/(K − 1). First, consider the balanced case where we have the
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same number of patients on each of the treatments. We will simulate the test 100, 000
times to find n, the total number of patients to be recruited for each of the scenarios such
that the power is at least 0.95. In each simulation, we will generate nj patient responses
on treatment j from a normal distribution with meanmj and variance σ2 for j = 2, ..., K.
We take the values m1 = 0, m2 = 0.5, m3 = 0.55, m4 = 0.6, m5 = 0.65, m6 = 0.7,
m7 = 0.75 and m8 = 0.8 in each of the scenarios, and σ2 = 1. Then we can obtain the
sample mean of the responses X¯j and hence values of ζj for j = 1, ..., K. Finally, the
values for ηj are obtained from the linear combination of ζj and ζ1 for j = 2, ..., K. The
values for cj1 and cj2 can be calculated in the balanced case, since n1 = n2 = ... = nK .
By (5.35) and (5.36), cj1 = cj2 = 1/
√
2. If at least one of the ηj for j = 2, ..., K is
greater than zγ , we will reject H0 for this simulation. After 100, 000 simulations, the
proportion of rejections of H0 will be the estimated power of the test.
Let K be the total number of treatments involved in the study and let K1 be the size
of a complete block. In the balanced case, the number of patients on each treatment will
be n/K. We will find n for each scenario such that there are at least 95, 000 rejections
of H0 in a total of 100, 000 simulations.
Once n is known for each scenario, we can study the estimated power in the imbal-
anced case to see how much less it is compared to the balanced case and how many extra
patients we need to compensate for the loss. Under centre-stratified permuted-block
randomization when the patient recruitment process is modelled by the Poisson-gamma
model, the number of patients to be recruited in centre i, ni, may not be a multiple of the
block size K1. Incomplete blocks will be formed in centres and the numbers of patients
across treatments will not be equal. For simulation in the imbalanced case, for each sce-
nario, we will use the same n as in the balanced case. We will first model the patient
recruitment process by the Poisson-gamma model. Once the numbers of patients to be
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recruited in different centres are known, the numbers of patients on different treatments
for all centres are known. Then we will simulate again nj responses from a normal dis-
tribution with mean mj and variance σ2. The values for cj1, cj2, ζj and ζ1, and hence
ηj can be obtained. As in the balanced case, in each simulation for all j = 2, ..., K, it
will be checked if at least one of the ηj is greater than zγ . The whole process will be
simulated 100, 000 times and the proportion of rejections of H0 in these 100, 000 runs
will be the estimated power for the imbalanced case. We will also simulate imbalanced
cases when extra patients are added to the trial and study the numerical values of the
estimated power in these cases.
We will consider four scenarios, each with a different number of treatments. We have
N = 5 for the total number of centres. All the numerical results for the estimated overall
significance level and power are summarised in the two tables below.
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Table 5.1: Simulated overall significance levels and powers for four scenarios when
γ = 0.05
K = 4 K = 5 K = 6 K = 8
K1 = 8 K1 = 10 K1 = 12 K1 = 8
Balanced case
n 168 160 168 152
γ∗ 0.121 0.147 0.168 0.205
Power 0.957 0.952 0.961 0.956
Imbalanced case
n 168 160 168 152
γ∗ 0.118 0.143 0.166 0.207
Power 0.956 0.950 0.959 0.953
n 169 161 169 153
γ∗ 0.118 0.144 0.166 0.203
Power 0.956 0.951 0.959 0.956
n 170 162 170 154
γ∗ 0.118 0.144 0.166 0.202
Power 0.958 0.951 0.960 0.956
n 171 163 171 155
γ∗ 0.117 0.143 0.168 0.203
Power 0.958 0.952 0.961 0.957
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Table 5.2: Simulated overall significance levels and powers for four scenarios when
γ = 0.05/(K − 1)
K = 4 K = 5 K = 6 K = 8
K1 = 8 K1 = 10 K1 = 12 K1 = 8
Balanced case
n 232 250 264 280
γ∗ 0.045 0.042 0.041 0.039
Power 0.954 0.952 0.952 0.952
Imbalanced case
n 232 250 264 280
γ∗ 0.043 0.041 0.040 0.037
Power 0.953 0.950 0.951 0.952
n 233 251 265 281
γ∗ 0.044 0.042 0.039 0.038
Power 0.954 0.950 0.950 0.951
n 234 252 266 282
γ∗ 0.042 0.041 0.040 0.037
Power 0.954 0.950 0.952 0.953
n 235 253 267 283
γ∗ 0.043 0.042 0.040 0.037
Power 0.954 0.952 0.951 0.953
We can see from the tables that the test is anticonservative when γ = 0.05 and
slightly conservative when γ = 0.05/(K − 1), becoming more so as K increases, and
that there is a slight loss in power in the imbalanced case compared to the balanced case
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when n is the same. No more than three patients are needed in the imbalanced case in
order to achieve the same level of power as in the balanced case.
5.8 Conclusions
In this chapter, imbalances are defined for complete randomization and the permuted
block design for clinical trials with more than two treatments. Most of the literature
studied previously dealt with imbalance properties for different randomization schemes
for two treatment groups only. The overall imbalance for more than two treatments is
no longer the difference in the numbers of patients on two treatments, but a vector that
contains the imbalance for each treatment group from the expected number of patients
in the group.
The imbalance for each of the treatments is defined here within centres and for all
centres. The calculations of the expectations, variances and covariances of the imbal-
ances in a centre or for all centres are shown for the two randomization schemes. Two
cases are considered: the number of patients recruited in a centre is given and is known;
and the number of patients recruited in a centre follows the Poisson-gamma model of
Anisimov and Fedorov (2007). The overall imbalance is defined and asymptotically it
has a multivariate normal distribution. Furthermore, the variances of the two random-
ization schemes are compared. For trials with several treatments, in general, centre-
stratified permuted-block randomization performs better than complete randomization
in balancing the numbers of patients across treatment groups. In other words, complete
randomization provides more uncertainty in the numbers of patients in different treat-
ment groups. A test is also developed by comparing each treatment to the control group.
The numerical values for the power of the test are given in the balanced and imbalanced
cases. These suggest that we can compensate for the loss in power in the imbalanced
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case by adding no more than three patients.
In real clinical trials, it is common for pharmaceutical companies to have more than
two treatments under investigation at the same time in order to obtain more results for
comparison, and to reduce costs and time to recruit patients in a trial to expedite earlier
availability of an effective treatment to the general public. The imbalance properties for
the several treatments case are of particular importance as they will affect the power of
the test for treatment differences. The more serious the imbalance is in a trial, the less
power it will have to detect a genuine treatment difference. The loss in power due to the





In this thesis, we have studied three types of randomization schemes, restricted ran-
domization schemes, covariate-adaptive randomization schemes and the permuted-block
randomization scheme.
In Chapter 2, the treatment assignment rules under different restricted randomization
schemes are given. In addition, the asymptotic properties are stated under these ran-
domization schemes. The theoretical power of a test for a treatment effect is obtained
for both complete randomization and Efron’s biased coin design for normal and binary
responses. The parameters of interest are the population mean difference for normal re-
sponses and the population difference in probabilities of survival for binary responses.
The test is for a treatment effect represented by a larger value of the population mean
of patients’ responses in the treatment group than in the control group for normal re-
sponses. For binary responses, the test is for a treatment effect represented by a larger
value of the probability of surviving in the treatment group than in the control group.
In particular, for normal responses, we studied the cases where the variances of the pa-
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tients’ responses in the two treatment groups are different when they are either known
or unknown. Efron’s biased coin design is more efficient at balancing the numbers of
patient on the two treatments than complete randomization. We see that the numerical
values obtained for the power are higher for Efron’s biased coin design than for complete
randomization in all cases. Simulation results for the power under the adjustable biased
coin design and Efron’s biased coin design for normal responses are also given, which
show that the adjustable biased coin design is as good as Efron’s biased coin design in
balancing the numbers of patients on the two treatments. Finally, numerical values for
the power obtained by a normal approximation are compared with the exact values un-
der complete randomization and Efron’s biased coin design. For all cases, the power
obtained by the normal approximation is higher than the actual power.
In Chapter 3, covariate-adaptive randomization schemes are introduced. They are
covariate-adaptive simple random sampling, the covariate-adaptive biased coin design
and the covariate-adaptive adjustable biased coin design. A normal linear model for pa-
tients’ responses involving covariates is considered. This model takes into account the
values of the covariates and their interactions. Then the methodologies for global and
marginal balancing the numbers of patients grouped by their prognostic factors are given
for different covariate-adaptive randomization schemes. Next, we detail the theoretical
calculations for the analysis of covariance t test under the fixed-effects linear model. In
addition, normal approximations to the power are given for the two-sample t test and the
analysis of covariance t test when the covariates are considered to be random variables.
Numerical values for the power obtained by normal approximations with one covariate
in the model are compared with the corresponding values obtained by simulation for the
two-sample t test and the analysis of covariance t test. In both tests, the powers obtained
by normal approximations are higher than the simulated values. Furthermore, the nor-
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mal approximation to the power for more than two covariates is given theoretically. We
also simulated the power under the fixed-effects model for either global or marginal bal-
ancing when interactions between the two covariates are both present and absent. They
show that global balancing is better than marginal balancing when there is an interaction
between the covariates under the three covariate-adaptive randomization schemes. When
there is no interaction between the covariates, global balancing is as good as marginal
balancing.
In Chapter 4, restricted randomization schemes for more than two treatments are
considered. The assignment rules under complete randomization, Efron’s biased coin
design, the DA-optimum biased coin design, Wei’s class of biased coin design and a
new class of designs, the adjustable biased coin design, are given. In addition, their
asymptotic properties are provided. In this chapter, the overall imbalance is defined as
a vector which contains the imbalances in the numbers of patients on all treatments.
The properties of the overall imbalance have been studied under different randomization
schemes by simulation. The distributional properties of the imbalances represented by
plots and the values for the quartiles of the imbalances under different designs are also
given for two scenarios. The simulated results show that, except for Efron’s biased coin
design, the overall imbalance has an asymptotically multivariate normal distribution. For
Efron’s bised coin design, the overall imbalance tends to the zero vector in probability
asymptotically. Furthermore, we have studied the simulated power of these randomiza-
tion schemes for the analysis of variance F test. Numerical values for the power are
given for two scenarios. The results showed that, for all schemes, the power increases
when we consider more treatments in the trial. Efron’s biased coin design gives the high-
est power when the design is very deterministic with p = 11/12 and 10/12. Other than
these two situations, the adjustable biased coin design achieves the highest power in all
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cases in the two scenarios.
In Chapter 5, we consider situations for multi-centre trials for more than two treat-
ments. The model for patient recruitment introduced by Anisimov and Fedorov (2007)
is used. The recruitment process is described by a Poisson process with rate following a
gamma distribution. By using this patient recruitment model, the number of patients to
be recruited in each centre follows a beta-binomial distribution. The imbalance on each
treatment is defined both within centres and for all centres under complete randomization
and centre-stratified permuted-block randomization. We studied the imbalance of each
treatment within centres and for all centres when the number of patients recruited in each
centre is fixed or has a beta-binomial distribution. The expectations and the variances
of the imbalances are given theoretically under the two schemes for the two situations.
The overall imbalance which is defined as a vector which contains the imbalance on
each treatment for all centres has a multivariate normal distribution when the number
of centres involved is large. Hence, we have the vectors of expectations and the covari-
ance matrices of these overall imbalances for the two situations. The variances of the
imbalance on a treatment within centres are compared for complete randomization and
centre-stratified permuted-block randomization. We showed that, under centre-stratified
permuted-block randomization, the imbalance is less variable. Furthermore, we studied
the power under centre-stratified permuted-block randomization. We have a test for at
least one treatment difference when we compare the treatment groups with the control
group. We found the sample size for a balanced trial in each scenario for which a certain
level of power is achieved. Then we studied the change in the power in the imbalanced
case when the patient recruitment model is used. The results showed that the loss of
power in the imbalanced case can be compensated for by an increase of no more than
three patients for each scenario.
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6.2 Future work
The results presented in this thesis provide a basis for further study and possible
extensions. Some of the ideas for further work are mentioned throughout the thesis.
In Chapter 2, the theoretical power function is given for binary responses for com-
plete randomization and Efron’s biased coin design. The critical value used to reject
the null hypothesis is chosen so that the significance level is less than or equal to the
assumed level α = 0.05. This is due to the discrete distribution of the test statistics.
Further research can be carried out so that we obtain the critical value corresponding to
the assumed significance level of the test. One possibility is a randomized test.
In Chapter 3, covariate-adaptive randomization schemes are studied. When the co-
variates are considered to be random variables, an expression is given for the normal
approximation to the power when there is more than one covariate. Simulated values for
the power can be compared with numerical values obtained using the normal approxima-
tion in this case. These results can also be compared with those obtained in Section 3.6.2,
when there is only one covariate. Furthermore, under the fixed-effects model, numerical
values for the power are shown by simulation for global and marginal balance with two
covariates when interactions between the covariates are both present and absent. Further
work may be possible for more than two covariates.
In Chapter 4, a new class of designs called the adjustable biased coin design for
more than two treatments has been introduced. The treatment assignment probabilities
under this design are obtained based on all of the current imbalances on the treatments.
Using simulation, the imbalance properties and the power are obtained under this design.
These suggest that this design is as good as Efron’s biased coin design and the DA-
optimum biased coin design in balancing the numbers of patients across treatments.
Further research can be pursued on the asymptotic properties of the adjustable biased
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coin design. In particular, the theoretical power of the test for treatment differences for
Efron’s biased coin design and the adjustable biased coin design is of interest.
In Chapter 5, we studied the imbalance properties of centre-stratified permuted-block
randomization in the case of more than two treatments. We assumed that, within a block,
the number of patients to be allocated to each of the treatments is the same. Thus, we
aim for a balance in the numbers of patients across treatments to maximize the power of
the test for treatment differences. However, it may be more powerful in some cases to
have unequal numbers of patients on the treatments. Therefore, further research in this
direction is possible. Moreover, the test for comparing each of the treatments with the
control does not have the same significance level for all situations. Further work can be
carried out on different tests for treatment differences with a chosen significance level,
and hence the power of these tests. We have only considered the test when the variances
of the patients’ responses are known and are the same. This can be extended to cases





A.1 Uncorrelated µ̂∗ and β̂


















where Var(Y) is the n × n covariance matrix of the patients’ responses with σ2² as the
diagonal elements and zeros elsewhere, denoted by σ2² In. Thus, we have
Cov(µ̂∗, β̂) = σ2² (W
TW)−1WTRWZ(ZTRWZ)−1.
Since WTRWZ gives a null matrix, the covariance of µ̂
∗ and β̂ is the zero matrix.
Hence, µ̂∗ and β̂ are uncorrelated.
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A.2 The independence of Z and β̂ when the covariates
are random variables
Since β̂ is the least squares estimator of β, we have
β̂ = (ZTRWZ)
−1ZTRWY,
where RW = In −W(WTW)−1WT . If Z and β̂ are independent, then E(Zβ̂) =

















ZTZ− ZTW (WTW)−1WTZ}−1 {ZTWµ+ ZTZβ + ZT²













β + ZT (ZZT )−1²
)}
= E(Zβ) = E(Z)β.
Hence, we have E(Zβ̂) = E(Z)β = E(Z)E(β̂).
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A.3 Normal approximation for the power when there
are more than two randomly distributed covariates







for j = 1, 2 conditionally on Z . Further, (∆ik, ²i1, ²i2) are conditionally independent of
I given Z , E(²ij|Z) = 0, E(2Ii−1|Z) = 0 and E(∆ik|Z) = E(∆ik|D(Zik)) = 0. The
asymptotic mean of Y¯2− Y¯1 is calculated by taking the expectation of Y¯2− Y¯1 given Z . It
is also known that E(Zik|D(Zik)), E(Z2ik|D(Zik)) and E(ZikZim|D(Zik)) are discrete,
and that
∑n
i=1(2Ii − 1) = op(n−1/2). When n→∞, E(Y¯2 − Y¯1|Z) = µ2 − µ1.
Now, we can write
Y¯2 − Y¯1 = µ2 − µ1 + 2
n
(A+B + C +D + E + F +G) + op(n
−1/2),
where A, B, C, D, E,F and G are the terms in order in (3.11). We need the variance
of Y¯2 − Y¯1 given Z . From above, this will be a sum of the variances of all the terms
involved and all the covariances of any two different terms. The term G is expressed in
terms of the random errors ²ij . Since (∆ik, ²i1, ²i2) are independent of I given Z and the
expectation of ²ij given Z is zero, the covariance of any term with G will be equal to
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zero. Also, µ2 − µ1 is a constant, so that Var(µ2 − µ1|Z) = 0. Thus, we have
Var(Y¯2 − Y¯1|Z) = 4
n2
{Var(A|Z) + Var(B|Z) + Var(C|Z) + Var(D|Z)
+ Var(E|Z) + Var(F |Z) + Var(G|Z) + 2Cov(A,B|Z)
+ 2Cov(A,C|Z) + 2Cov(A,D|Z) + 2Cov(A,E|Z)
+ 2Cov(A,F |Z) + 2Cov(B,C|Z) + 2Cov(B,D|Z)
+ 2Cov(B,E|Z) + 2Cov(B,F |Z) + 2Cov(C,D|Z)
+ 2Cov(C,E|Z) + 2Cov(C,F |Z) + 2Cov(D,E|Z)
+ 2Cov(D,F |Z) + 2Cov(E,F |Z)}+ op(n−1).
Note that (2Ii − 1)2 = 4I2i − 4Ii + 1 = 1, because I2i = Ii
We can split the above expression into two parts. We have one part that contains all
the variance terms and one that contains all covariance terms. Consider the first part. As






















We have similar results for Var(C|Z) and Var(D|Z). For Var(G|Z), we have nσ2² .
As E{Zik|D(Zik)} , E{Z2ik|D(Zik)} and E{ZikZim|D(Zik)} are constants given Z , the
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For the second part involving the covariances, we takeCov(A,B|Z) andCov(A,C|Z)
as examples. Now, E(AB|Z) = BE(A|Z) and E{A|D(Zik)} = 0, so we have
Cov(A,B|Z) = 0.






































































































































































The variance of Y¯2 − Y¯1 can be written as the sum of (A.1), (A.2), (A.3) and op(n−1).
We now look at its asymptotic properties as n→∞. We know that
Var{∆ik|D(Zik)} = E{∆2ik|D(Zik)} − [E{∆ik|D(Zik)}]2 = E{∆2ik|D(Zik)}.
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E{Zik|D(Zik)} → E[E{Zk|D(Zk)}] = E(Zk)





E(∆2ik|D(Zik))→ E(E(∆2k|D(Zk))) = E(∆2k).





B.1 Plots of imbalances under different randomization
schemes for both scenario
First, the plots of the imbalances on treatments 2 and 3 under each of the randomiza-
tion schemes will be given when K = 3. Then we have the plots of the imbalances in





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































B.2 Tables of quartiles of imbalance
We have the numerical values of the quartiles of the imbalances for all schemes by
simulation when K = 3 for treatments 2 and 3 and when K = 4 for treatments 2, 3 and




















































































































































































































































































































































































































































































































































































































































































C.1 Proof of Lemma 5.3.1
For a multivariate hypergeometric distribution, the joint probability distribution is










for si = 0, 1, . . . ,min(ki, r) and i = 1, . . . , K. As all marginal distributions of the
multivariate hypergeometric distribution are hypergeometric, it is sufficient to consider
the bivariate hypergeometric distribution to obtain the covariance of ξj(r) and ξm(r).
The probability distribution of a bivariate hypergeometric distribution can be written as



























































































































since this is the sum of all the probabilities for a bivariate hypergeometric distribution.
The covariance of ξj(r) and ξm(r) is then
Cov[ξj(r), ξm(r)] =
kjkmr(r − 1)




= −kjkmr(K1 − r)
K21(K1 − 1)
.













Cov[ξj(r), ξm(r)] = Cov(∆ij,∆im).
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